eIF4E-inhibiting 4-oxo-3,4-dihydropyrido[3,4-D]pyrimidine compounds
4-oxo-3,4-dihydropyrido[3,4-D]pyrimidine compounds are developed to inhibit eIF4E activity, addressing the limitations of current inhibitors and offering therapeutic benefits in treating various cancers by reducing eIF4E activity and overcoming drug resistance.
Patent Information
- Application Number
- JP2022500099
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-02
- Filing Date
- 2020-06-30
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2040-06-30
AI Technical Summary
Current pharmacological inhibitors for eukaryotic translation initiation factor 4E (eIF4E) are limited, particularly in addressing the role of eIF4E in regulating cancer pathways and overcoming drug resistance in cancer therapy.
Development of 4-oxo-3,4-dihydropyrido[3,4-D]pyrimidine compounds that inhibit or modulate eIF4E activity, including stereoisomers and pharmaceutically acceptable salts, for use in treating eIF4E-dependent diseases such as various types of cancer.
The compounds effectively reduce eIF4E activity in cancer cells, potentially inhibiting tumor growth and overcoming drug resistance, thereby providing a therapeutic benefit for treating conditions like colon, gastric, thyroid, lung, leukemia, lymphoma, and other cancers.
Smart Images

Figure 0007595055000514 
Figure 0007595055000515 
Figure 0007595055000516
Abstract
Description
[Technical Field]
[0001]
[0001] This invention relates generally to compounds having activity as eukaryotic translation initiation factor 4e (eIF4e) inhibitors, as well as related compositions and methods for utilizing the compounds of the invention as therapeutic agents for treating eIF4e-dependent diseases, including the treatment of cancer. [Background technology]
[0002] Eukaryotic translation initiation factor 4E (eIF4E) is a general translation factor with the potential to preferentially enhance the translation of messenger RNAs (mRNAs), leading to the production of malignancy-associated proteins. This selectivity may be related to the increased requirement of eIF4E and its binding partners for the translation of mRNAs containing extensive secondary structure in their 5'-untranslated regions (5'-UTRs). These mRNAs include those encoding certain proteins that regulate cell cycle progression and tumorigenesis. Under normal cellular conditions, the availability of active eIF4E is limited, resulting in repression of translation of these malignancy-associated mRNAs; however, when eIF4E is overexpressed or hyperactivated, its levels can increase. Elevated eIF4E levels have been observed in many types of tumors and cancer cell lines, including colon cancer, breast cancer, bladder cancer, lung cancer, prostate cancer, gastrointestinal cancer, head and neck cancer, Hodgkin's lymphoma, and neuroblastoma.
[0003]
[0003] Cap-dependent translation initiation is thought to depend on eIF4F assembly, a translation initiation factor complex containing eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A. eIF4E is the only one of these proteins that directly binds to the mRNA cap structure and is therefore a key factor in eIF4F assembly at the 5' cap. The scaffolding protein eIF4G also binds to eIF4B, a protein that recruits 40S ribosomal subunits to mRNA through its interaction with eIF3 and assists the RNA helicase function of eIF4A, thus promoting translation of mRNAs containing structured 5'-UTRs. The availability of eIF4E as part of the eIF4F complex is a limiting factor in controlling translation rate; therefore, eIF4E is a key regulator of mRNA translation.
[0004]
[0004] Regulation of eIF4E activity forms a convergence node of the PI3K / Akt / mTOR and Ras / Raf / MAPK signaling pathways. The PI3K (phosphoinositide 3-kinase) / PTEN (phosphatase and tensin homolog deleted on chromosome 10) / Akt / mTOR (mammalian target of rapamycin) pathway is often involved in tumorigenesis and sensitivity and resistance to cancer therapy. Deregulated signaling through the PI3K / PTEN / Akt / mTOR pathway is often the result of genetic alterations in key components of this pathway and / or mutations in upstream growth factor receptors or signaling components. PI3K initiates a cascade of events when activated, for example, by extracellular growth factors, mitogens, cytokines, and / or receptors. PDK1 activates Akt and phosphorylates and inactivates the tumor suppressor complex containing TSC1 and 2 (tuberous sclerosis complex 1 / 2), leading to activation of mTORC1 (target of rapamycin complex 1) by Rheb-GTP. Activation of PDK1 and Akt by PI3K is negatively regulated by PTEN.
[0005] PTEN is an important tumor suppressor gene that is frequently mutated or silenced in human cancers. Its loss results in the activation of Akt and increased downstream mTORC1 signaling. The involvement of mTOR complex 1 (mTORC1) in neoplastic transformation appears to depend on its regulatory role on the eIF4F complex; overexpression of eIF4E can confer resistance to rapamycin. mTORC1 regulates eIF4F complex assembly, which is important for cell growth, prevention of apoptosis, and translation of mRNAs associated with transformation. mTORC1 accomplishes this by phosphorylating and inactivating 4E-BP and subsequently dissociating 4E-BP from eIF4E. This then allows eIF4E to interact with the scaffolding protein eIF4G, enabling assembly of the eIF4F complex and translation of structured mRNAs. mTORC1 also promotes activation of the translational activator S6K, which phosphorylates other substrates, including the ribosomal protein S6 and eIF4B. mTORC1 signaling is inhibited by rapamycin and its analogues (rapalogs), but these compounds act allosterically rather than directly inhibiting mTOR kinase activity.
[0006] Given the importance of the PI3K / Akt / mTOR pathway in regulating mRNA translation of genes encoding pro-tumor proteins and the high incidence of activated mTORC1 signaling in a high proportion of cancers, these kinases have been actively pursued as oncological drug targets. Numerous pharmacological inhibitors have been identified, some of which have reached advanced clinical stages. However, it has recently become clear that the mTOR pathway engages in a complex feedback loop that can attenuate Akt activation. Long-term treatment of cancer cells or patients with mTOR inhibitors has been shown to increase PI3K activity, leading to phosphorylation of Akt and eIF4E and promoting cancer cell survival. eIF4E acts downstream of Akt and mTOR, recapitulating the role of Akt in tumorigenesis and drug resistance, and eIF4E-mediated Akt signaling is an important mechanism of tumorigenesis and drug resistance in vivo.
[0007] In addition to the PI3K / Akt / mTOR pathway, eIF4E is also a target of the growth factor-activated Ras / Raf / MAP signaling cascade and the stress-activated p38 MAP kinase pathway. Erk1 / 2 and p38 then phosphorylate MAP kinase-interacting kinase 1 (Mnk1) and MAP kinase-interacting kinase 2 (Mnk2). The Erk pathway is also activated in many cancers, reflecting, for example, activating mutations in Ras (found in approximately 20% of tumors) or loss of function of the Ras GTPase activator protein NF1. Mnk1 and Mnk2 are threonine / serine protein kinases that specifically phosphorylate serine 209 (Ser209) of eIF4E within the eIF4F complex, where the interaction between eIF4E and Mnk plays a role in recruiting Mnk to act on eIF4E. Mice carrying mutant eIF4E in which Ser209 is replaced by alanine fail to phosphorylate eIF4E and have significantly reduced tumor growth. Importantly, Mnk activity is required for eIF4E-mediated oncogenic transformation but is dispensable for normal development. Thus, pharmacological inhibition of Mnk represents an attractive therapeutic strategy for cancer.
[0008] Despite an increased understanding of Mnk structure and function, little progress has been made in the discovery of pharmacological Mnk inhibitors, and relatively few Mnk inhibitors have been reported: CGP052088 (Tschopp et al., Mol Cell Biol Res Commun. 3(4):205-211, 2000); CGP57380 (Rowlett et al., Am J Physiol Gastrointest Liver Physiol. 294(2):G452-459, 2008); and Cercosporamide (Konicek et al., Cancer Res. 71(5):1849-1857, 2011). However, these compounds have primarily been used for the purpose of validating Mnk targets. More recently, researchers have proposed additional compounds for treating diseases affected by inhibition of the kinase activity of Mnk1 and / or Mnk2, such as those disclosed in WO 2014 / 044691 and various patent documents cited therein, 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3,-d]pyrimidine disclosed in Yu et al., European Journal of Med. Chem., 95:116-126, 2015, and 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione and various compounds disclosed in WO 2015 / 200481. Summary of the Invention
[0009]
[0009] Thus, despite advances in the field, there remains a significant need in the art for compounds that specifically inhibit eIF4E activity, and related compositions and methods, particularly with respect to the role of eIF4E in regulating cancer pathways. The present invention fulfills this need and provides related advantages.
[0010] overview
[0010] The present invention is directed to compounds that inhibit or modulate eIF4E activity, as well as to stereoisomers, tautomers, and pharmaceutically acceptable salts of such compounds. The invention is also directed to pharmaceutically acceptable compositions comprising such compounds, and related methods for treating conditions that would benefit from eIF4E inhibition, such as cancer.
[0011] In one embodiment, the present invention provides a compound according to formula I
[0012] [ka]
[0013] or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is CR 2 , -CL 1 -Y or N; X 2 , X 5 and X 6 independently, CR 2 or N, where X 5 and X 6 is joined together with three or four carbon or nitrogen atoms to form a 5- or 6-membered cycloalkyl or heterocyclyl, or or X 2 is CR 2 If R 1 and R 2 together with the atoms to which they are attached form a 6-membered aryl or heteroaryl; X 3 is C or X 4 If is a bond, then X 3 is C or N; X 4 is a bond, CR 2 or N, where X 4 and X 5is joined together with three or four carbon or nitrogen atoms to form a five- or six-membered heteroaryl; Q is H or -L 1 -Y; L 1 is -(CH2)-, -(CH2)2-, -(CH2)3-, -CH((C1-C8)alkyl)(CH2)-, -CH((C1-C8)alkyl)(CH2)2-, -(CH2)2-O-, -CH2CH=CH-, -CH2C≡C- or -CH2(cyclopropyl)-; Y is
[0014] [ka]
[0015] where: Ring B is a 6-membered aryl, heteroaryl, or heterocyclyl; R 1 is H, OH, halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl, (C3-C6) cycloalkyl or NR 5 R 5 and; R 2 are independently H, halo, CN, NO, NO2, C≡H, (C1-C8) alkyl, (C1-C8) haloalkyl, CH2SR 5 , OR 5 , NHR 5 , N.R. 5 R 5 [(C1-C8) alkylene] heterocyclyl, [(C1-C8) alkylene] heteroaryl, [(C1-C8) alkylene] NHR 5 , [(C1-C8) alkylene]NR 5 R 5 [(C1-C8) alkylyne]NR 5 R 5 , C(O)R 5 , C(O)OR 5 , C(O)NHR 5 , C(O)NR 5 R 5 , S.R. 5, S(O)R 5 , SO2R 5 , SO2NHR 5 , SO2NR 5 R 5 , NH(CO)R 6 , N.R. 5 (CO)R 6 , aryl, heteroaryl, cycloalkyl, or heterocyclyl; R 3 are independently OH, halo, CN, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, C≡H, or NHR 7 , N.R. 7 R 7 , CO2H, CO2R 7 [(C1-C3) alkylene] (C1-C3) alkoxy, [(C1-C3) alkylene] CO2H, (C3-C5) cycloalkyl, =O. =S, SR 7 , SO2R 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 4 is H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, SR 7 or Z, where Z is
[0016] [ka]
[0017] and Ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; L 2 is -C(R 6 )(R 6 )-, -C(R 6 )(R 6 )C(R 6 )(R 6 )-, -C(R 6 )=C(R 6 )-, -N(R 5 )C(R 6)(R 6 )-, -OC(R 6 )(R 6 )-, -C(=O)-, -C(=O)N(R 5 )C(R 6 )(R 6 )-or bond; R 5 are independently H, (C1-C3)alkyl, (C1-C3)haloalkyl, (C3-C5)cycloalkyl, COH, [(C1-C3)alkylene]heteroaryl, [(C1-C3)alkylene]aryl, [(C1-C3)alkylene]COH, heterocyclyl, aryl, or heteroaryl; or two R's 5 the substituents, together with the nitrogen atom, form a 4-, 5-, 6-, or 7-membered heterocyclyl; R 6 are independently H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, NHR 7 , N.R. 7 R 7 , CO2H, [(C1-C3) alkylene]CO2H, (C3-C5) cycloalkyl, SR 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 7 are independently H, (C1-C8)alkyl, (C1-C8)haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 8 are H, OH, CO2H, and CO2R 7 , CF2C(R 6 )2OH, C(R 6 )2OH, C(CF3)2OH, SO2H, SO3H, CF2SO2C(R 6 )3, CF2SO2N(H)R 5 , SO2N(H)R 5 , SO2N(H)C(O)R 6 , C(O)N(H)SO2R 5 , C(O)haloalkyl, C(O)N(H)OR 5 , C(O)N(R5 )OH, C(O)N(H)R 5 , C(O)NR 5 C(O)N(R 5 )2, P(O)(OR 5 )OH, P(O)(O)N(H)R 5 , P(O)(C(R 6 )3)C(R 6 )3, B(OH)2, heterocyclyl or heteroaryl; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; wherein any alkyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of OH, CN, SH, SCH3, SO2CH 3、 SO2NH2, SO2NH(C1-C4)alkyl, halogen, NH2, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(aryl), C(O)NH2, C(O)NH(alkyl), CH2C(O)NH(alkyl), COOH, COOMe, acetyl, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, O(C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, thioalkyl, cyanomethylene, alkylaminyl, alkylene-C cycloalkyl, heterocyclyl, aryl, or heteroaryl optionally substituted with one, two, or three groups selected from (O)NH, alkylene-C(O)—NH(Me), NHC(O)alkyl, CH—C(O)—(C1-C8)alkyl, C(O)—(C1-C8)alkyl, and alkylcarbonylaminyl, or optionally substituted with OH, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, or O(C1-C8)haloalkyl; where X 4 is a bond, then ring A forms a 5-membered heteroaryl, where X 1 , X 5 and X 6 is a group consisting of NR in addition to the substituents as defined above. 2 and further, X 1 Ha-NL1 - may be Y; where Q is -L 1 -Y or X 1 Ga-CL 1 -Y or -NL 1 -Y).
[0018]
[0012] The present invention also provides pharmaceutical compositions comprising: (i) a therapeutically effective amount of at least one compound according to Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof; in combination with (ii) a pharmaceutically acceptable carrier, diluent, or excipient.
[0019]
[0013] The present invention also provides a method for reducing or inhibiting eIF4E activity in at least one cell overexpressing eIF4E, the method comprising the step of contacting at least one cell with a compound according to formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
[0020]
[0014] According to the method of the present invention, at least one cell is a colon cancer cell, a gastric cancer cell, a thyroid cancer cell, a lung cancer cell, a leukemia cell, a B-cell lymphoma, a T-cell lymphoma, a hairy cell lymphoma, a Hodgkin's lymphoma cell, a non-Hodgkin's lymphoma cell, a Burkitt's lymphoma cell, a pancreatic cancer cell, a melanoma cell, a multiple melanoma cell, a brain cancer cell, a CNS cancer cell, a renal cancer cell, a prostate cancer cell, an ovarian cancer cell, or a breast cancer cell.
[0021]
[0015] According to yet another embodiment, the present invention provides a method for treating an eIF4E-dependent condition in a mammal in need thereof, comprising the step of administering to the mammal (i) a therapeutically effective amount of at least one compound according to Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, or (ii) a pharmaceutical composition according to the present invention.
[0022]
[0016] The compounds and pharmaceutically acceptable formulations according to the present invention are useful for treating eIF4E-dependent conditions, such as colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, pancreatic cancer, melanoma, multiple melanoma, brain cancer, CNS cancer, renal cancer, prostate cancer, ovarian cancer, or breast cancer.
[0023]
[0017] The above embodiments and other aspects of the present invention will become readily apparent in the following detailed description. Various references are set forth herein which further detail certain background information, procedures, compounds and / or compositions, and are hereby incorporated by reference in their entirety. [Brief explanation of the drawings]
[0024] [Figure 1] 1 is a graph showing the results of a cell proliferation assay using compound 1188. [Figure 2] Graph showing the results of a cell proliferation assay using compound 634. [Figure 3] 1 is a graph showing the results of a cell proliferation assay using compound 1141. DETAILED DESCRIPTION OF THE INVENTION
[0025] Detailed Description In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the present invention. However, it will be understood by those skilled in the art that the present invention may be practiced without these details. Unless the context requires otherwise, throughout this specification and claims, the word "comprise" and variations thereof, such as "comprises" and "comprising," should be interpreted in an open and inclusive sense (i.e., as "including, but not limited to").
[0026]
[0022] Throughout this specification, references to "one embodiment" or "embodiment" mean that a particular feature, structure, or feature described in connection with the embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrase "in one embodiment" or "in an embodiment" in various places throughout this specification do not necessarily all refer to the same embodiment. Furthermore, particular features, structures, or features may be combined in any suitable manner in one or more embodiments.
[0027] definition As used herein, unless specifically noted to the contrary, the following terms and phrases have the meanings indicated below.
[0028] "Amino" refers to an -NH2 substituent. "Aminocarbonyl" refers to a -C(O)NH2 substituent. "Carboxyl" refers to a -CO2H substituent.
[0029] "Carbonyl" refers to the group -C(O)-, -(CO)- or -C(=O)-, all designations used interchangeably within the specification. "Cyano" refers to a -C≡N substituent.
[0030] "Cyanoalkylene" refers to a -(alkylene)C≡N substituent. "Acetyl" refers to a -C(O)CH3 substituent.
[0031] "Hydroxy" or "hydroxyl" refers to an --OH substituent.
[0031]
[0032] "Hydroxyalkylene" refers to an -(alkylene)OH substituent.
[0033] "Oxo" refers to the =O substituent.
[0034] "Thio" or "thiol" refers to an --SH substituent.
[0032]
[0035] "Alkyl" refers to an alkyl group containing 1 to 12 carbon atoms (C1-C 12 "Ci-C alkyl" refers to a saturated, straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms having from 1 to 8 carbon atoms (Ci-C alkyl) or from 1 to 6 carbon atoms (Ci-C alkyl) and attached to the rest of the molecule by a single bond. Exemplary alkyl groups include methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like.
[0033]
[0036] "Lower alkyl" has the same meaning as alkyl as defined above, but having from 1 to 4 carbon atoms (C1-C4 alkyl).
[0037] "Alkenyl" refers to an alkyl group having at least one double bond and 2 to 12 carbon atoms (C-C 12 alkenyl), unsaturated alkyl groups having from 2 to 8 carbon atoms (C2-C8 alkenyl) or from 2 to 6 carbon atoms (C2-C6 alkenyl) attached to the rest of the molecule by a single bond, such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, etc.
[0034]
[0038] "Alkynyl" refers to an alkyl group having at least one triple bond and 2 to 12 carbon atoms (C2-C6).12 alkynyl), 2 to 10 carbon atoms (C2-C 10 Alkynyl) refers to unsaturated alkyl groups having from 2 to 8 carbon atoms (C2-C8 alkynyl) or from 2 to 6 carbon atoms (C2-C6 alkynyl) and attached to the rest of the molecule by a single bond, e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc.
[0035]
[0039] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon (alkyl) chain, consisting solely of carbon and hydrogen, respectively, to which the remainder of the molecule is attached via a radical group. Alkylenes, such as methylene, ethylene, propylene, n-butylene, etc., can have from 1 to 12 carbon atoms. The alkylene chain is attached to the rest of the molecule via a single or double bond. The point of attachment of the alkylene chain to the rest of the molecule can be through one carbon or any two carbons within the chain. "Optionally substituted alkylene" refers to an alkylene or substituted alkylene.
[0036]
[0040] "Alkenylene" refers to a divalent alkene. Examples of alkenylene include, but are not limited to, ethenylene (-CH=CH-) and all its stereoisomers and conformational isomers. "Substituted alkenylene" refers to a divalent substituted alkene. "Optionally substituted alkenylene" refers to alkenylene or substituted alkenylene.
[0037]
[0041] "Alkynylene" refers to a divalent alkyne. Examples of alkynylene include, but are not limited to, ethynylene and propynylene. "Substituted alkynylene" refers to a divalent substituted alkyne.
[0038]
[0042] "Alkoxy" is a group of formulas -OR a where R ais alkyl, as defined above, having the indicated number of carbon atoms. Examples of alkoxy groups include, but are not limited to, -O-methyl (methoxy), -O-ethyl (ethoxy), -O-propyl (propoxy), -O-isopropyl (isopropoxy), and the like.
[0039]
[0043] "Alkylaminyl" refers to a group of the formula -NHR a or -NR a R a where each R a are independently alkyl groups having the indicated number of carbon atoms as defined above.
[0040]
[0044] "Cycloalkylaminyl" refers to a group of the formula -NHR a or -NR a R a where R a is a cycloalkyl group as defined herein.
[0045] "Alkylcarbonylaminyl" refers to a group of the formula -NHC(O)R a or -NR a C(O)R a where R a is an alkyl group having the indicated number of carbon atoms as defined herein.
[0041]
[0046] "Cycloalkylcarbonylaminyl" refers to a group of the formula -NHC(O)R a or -NR a C(O)R a where R a is a cycloalkyl group as defined herein.
[0042]
[0047] "Alkylaminocarbonyl" refers to a group of the formula -C(O)NHR a or -C(O)NR a R a where each R a are independently an alkyl group having the indicated number of carbon atoms, as defined herein.
[0043]
[0048] "Cyclolkylaminocarbonyl" is a group of the formula -C(O)NHR a where R a is a cycloalkyl group as defined herein.
[0044]
[0049] "Aryl" refers to a hydrocarbon ring system group containing hydrogen, 6 to 18 carbon atoms, and at least one aromatic ring. Exemplary aryls are hydrocarbon ring systems containing hydrogen, 6 to 9 carbon atoms, and at least one aromatic ring; hydrocarbon ring systems containing hydrogen, 9 to 12 carbon atoms, and at least one aromatic ring; hydrocarbon ring systems containing hydrogen, 12 to 15 carbon atoms, and at least one aromatic ring; or hydrocarbon ring systems containing hydrogen, 15 to 18 carbon atoms, and at least one aromatic ring. For purposes of the present invention, aryl groups may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused or bridged ring systems. Aryl groups include, but are not limited to, aryl groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. "Optionally substituted aryl" refers to an aryl group or a substituted aryl group.
[0045]
[0050] "Arylene" means a divalent aryl, and "substituted arylene" refers to a divalent substituted aryl.
[0051] "Aralkyl" or "araalkylene" may be used interchangeably and refer to a group having the formula -R b -R c where R b is an alkylene chain as defined herein, and R cis one or more aryl groups as defined herein, for example, benzyl, diphenylmethyl, and the like.
[0046]
[0052] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having from 3 to 15 carbon atoms, preferably from 3 to 10 carbon atoms, from 3 to 9 carbon atoms, from 3 to 8 carbon atoms, from 3 to 7 carbon atoms, from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, a ring having 4 carbon atoms, or a ring having 3 carbon atoms, which may include fused or bridged ring systems. The cycloalkyl ring may be saturated or unsaturated and may be attached to the remainder of the molecule by a single bond. Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
[0047]
[0053] "Cycloalkylalkylene" or "cycloalkylalkyl" may be used interchangeably and refer to a group of the formula -R b R e where R b is an alkylene chain as defined herein, and R e is a cycloalkyl group as defined herein. In certain embodiments, R b is further substituted with a cycloalkyl group such that the cycloalkylalkylene contains two cycloalkyl moieties. Cyclopropylalkylene and cyclobutylalkylene are exemplary cycloalkylalkylene groups containing at least one cyclopropyl or at least one cyclobutyl group, respectively.
[0048]
[0054] "Fused" refers to any ring structure described herein that is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom of the existing ring structure that becomes part of the fused heterocyclyl ring or fused heteroaryl ring may be replaced with a nitrogen atom.
[0049]
[0055] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodo.
[0056] "Haloalkyl" refers to an alkyl group having the indicated number of carbon atoms, as defined herein, wherein one or more hydrogen atoms of the alkyl group are replaced with a halogen (halo group), as defined above. The halogen atoms may be the same or different. Exemplary haloalkyls include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
[0050]
[0057] "Heterocyclyl," "heterocycle," or "heterocyclic ring" refers to a stable 3- to 18-membered saturated or unsaturated group consisting of 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. Exemplary heterocycles include, but are not limited to, a stable 3- to 15-membered saturated or unsaturated group, a stable 3- to 12-membered saturated or unsaturated group, a stable 3- to 9-membered saturated or unsaturated group, a stable 8-membered saturated or unsaturated group, a stable 7-membered saturated or unsaturated group, a stable 6-membered saturated or unsaturated group, or a stable 5-membered saturated or unsaturated group.
[0051]
[0058] Unless stated otherwise in the specification, a heterocyclyl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged or spiro ring systems; the nitrogen, carbon or sulfur atoms in the heterocyclyl group can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl group can be partially saturated or fully saturated. Examples of non-aromatic heterocyclyl groups include, but are not limited to, oxirane, oxetane, azetidinyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, thietanyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Heterocyclyl includes heteroaryl as defined herein, and examples of aromatic heterocyclyl are listed below in the definition of heteroaryl.
[0052]
[0059] A "heterocyclylalkyl" or "heterocyclylalkylene" is a group of the formula -R b R f where R b is an alkylene chain as defined herein, and R f is a heterocyclyl group as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl group at the nitrogen atom.
[0053]
[0060] "Heteroaryl" or "heteroarylene" refers to a 5- to 14-membered ring system containing a hydrogen atom, 1 to 13 carbon atoms, 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and at least one aromatic ring. For purposes of this invention, a heteroaryl group may be a stable 5- to 12-membered ring, a stable 5- to 10-membered ring, a stable 5- to 9-membered ring, a stable 5- to 8-membered ring, a stable 5- to 7-membered ring, or a stable 6-membered ring containing at least one heteroatom, at least two heteroatoms, at least three heteroatoms, at least four heteroatoms, at least five heteroatoms, or at least six heteroatoms. Heteroaryls may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused or bridged ring systems; nitrogen, carbon, or sulfur atoms in heteroaryl groups may be optionally oxidized; and nitrogen atoms may be optionally quaternized. The heteroatoms may be members of an aromatic or non-aromatic ring, provided that at least one ring in the heteroaryl is aromatic.Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzoindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, inda Zolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl).
[0054]
[0061] A "heteroarylalkyl" or "heteroarylalkylene" is a heteroaryl group of the formula -R b R g where R b is an alkylene chain as defined above, and R g is a heteroaryl group as defined above.
[0055]
[0062] "Thioalkyl" has the formula -SR a where R ais an alkyl group as defined above containing 1 to 12 carbon atoms, at least 1-10 carbon atoms, at least 1-8 carbon atoms, at least 1-6 carbon atoms, or at least 1-4 carbon atoms.
[0056]
[0063] "Heterocyclylaminyl" has the formula -NHR f where R f is a heterocyclyl group as defined above.
[0064] "Thione" refers to a ═S group attached to a carbon atom of a saturated or unsaturated (C3-C8) cyclic or (C1-C8) acyclic moiety.
[0057]
[0065] "Sulfoxide" refers to the group --S(O)-- in which a sulfur atom is covalently bonded to two carbon atoms.
[0066] "Sulfone" refers to an -S(O)2- or -(SO2)- group in which a hexavalent sulfur is bonded to two oxygen atoms each through double bonds and further bonded to two carbon atoms through single covalent bonds.
[0058]
[0067] The term "oxime" refers to -C(R a )=N-OR a refers to the group, where R a is hydrogen, a lower alkyl, alkylene, or arylene group as defined above.
[0068] The compounds of the present invention may exist in one or more tautomeric forms, including various isomers and both single tautomers and mixtures of tautomers. The term "isomer" is intended to encompass all isomeric forms of the compounds of the present invention, including tautomers of the compounds.
[0059]
[0069] Some compounds described herein may have asymmetric centers, and therefore exist in different enantiomeric and diastereomeric forms.The compounds of the present invention may be in the form of optical isomers or diastereomers.Therefore, the present invention encompasses the compounds of the present invention as described herein and their use in the form of their optical isomers, diastereoisomers, and mixtures thereof, including racemic mixtures.The optical isomers of the compounds of the present invention can be obtained by known techniques, such as asymmetric synthesis, chiral chromatography, or by using optically active resolving agents to chemically separate stereoisomers.
[0060]
[0070] Unless otherwise indicated, "stereoisomer" means one stereoisomer of a compound that is substantially free of the other stereoisomer of the compound. Thus, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound contains more than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of the other stereoisomer, e.g., more than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomer, or more than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomer, or more than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomer.
[0061]
[0071] In the event of a discrepancy between a depicted structure and the name given to that structure, the depicted structure shall prevail. Furthermore, if the stereochemistry of a structure or portion of a structure is not shown, for example, with a bold or dashed line, the structure or portion of the structure should be interpreted as encompassing all stereoisomers thereof. However, in some cases, when more than one chiral center is present, the structure and name may be represented as a single enantiomer to help describe the relative stereochemistry. Those skilled in the art of organic synthesis will know whether a compound will be prepared as a single enantiomer from the method used to prepare it.
[0062]
[0072] In this description, a "pharmaceutically acceptable salt" is a pharmaceutically acceptable organic or inorganic acid or base salt of a compound of the present invention. Representative pharmaceutically acceptable salts include, for example, alkali metal salts, alkaline earth salts, ammonium salts, water soluble and water insoluble salts such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium salt, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothiocyanate, and the like. Salts include ionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyl bromide, methyl nitrate, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, diacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate. A pharmaceutically acceptable salt may have more than one charged atom in its structure. In this case, the pharmaceutically acceptable salt may have multiple counterions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.
[0063]
[0073] The terms "treat", "treating" and "treatment" refer to improving or eradicating a disease or symptoms associated with a disease. In certain embodiments, such terms refer to minimizing the spread or worsening of a disease due to the administration of one or more prophylactic or therapeutic agents to a patient exhibiting such a disease. In the context of the present invention, the terms "treat", "treating" and "treatment" refer to: (i) preventing the occurrence of a disease or condition in a mammal, particularly where such mammal is susceptible to the condition but has not yet been diagnosed as having it; (ii) inhibiting the disease or condition, i.e., arresting its development; (iii) alleviating the disease or condition, i.e., causing regression of the disease or condition; or (iv) It also refers to the alleviation of symptoms resulting from a disease or condition, i.e., the alleviation of pain without addressing the underlying disease or condition. As used herein, the terms "disease" and "condition" may be used interchangeably and may differ in that a particular illness or condition may not have a known causative agent (so that the etiology has not yet been elucidated) and, as a result, is not yet recognized as a disease, but rather an undesirable state or syndrome in which a particular set of symptoms is more or less identified by a clinician.
[0064]
[0074] The term "effective amount" refers to an amount of a compound of the invention or other active ingredient sufficient to provide a therapeutic or prophylactic benefit in treating or preventing a disease, or to delay or minimize symptoms associated with a disease. Furthermore, a therapeutically effective amount with respect to a compound of the invention means an amount of a therapeutic agent alone or in combination with other therapies that provides a therapeutic benefit in treating or preventing a disease. The term used in connection with a compound of the invention can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease, or enhances therapeutic efficacy or synergy with another therapeutic agent.
[0065]
[0075] The term "inhibit" or "inhibitor" refers to a direct or indirect alteration, interference, reduction, down-regulation, blocking, suppression, abrogation, or degradation in the expression, amount, or activity of a target gene, target protein, or signaling pathway compared to (1) a control, endogenous, or reference target or pathway, or (2) the absence of the target or pathway, that is statistically, biologically, or clinically significant. The term "inhibit" or "inhibitor" includes gene "knockout" and gene "knockdown" methods, for example, by chromosome editing.
[0066]
[0076] The terms "modulate", "modulation" and the like refer to the ability of a compound to increase or decrease the function or activity of, for example, eukaryotic translation initiation factor 4E (eIF4E). "Modulation" in its various forms is intended to encompass inhibition, antagonism, partial antagonism, activation, agonism and / or partial agonism of the activity associated with eIF4E. An eIF4E inhibitor is a compound that binds to, partially or completely blocks, reduces, prevents, delays activation, inactivates, desensitizes, or downregulates signal transduction. The ability of a compound to modulate eIF4E activity can be demonstrated by enzyme assay or cell-based assay.
[0067]
[0077] A "patient" or "subject" includes an animal, such as a human, cow, horse, sheep, lamb, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, or guinea pig. The animal may be a mammal, such as a non-primate and a primate (e.g., monkey and human). In one embodiment, the patient is a human, such as a human infant, child, adolescent, or adult.
[0068]
[0078] The term "prodrug" refers to a drug precursor, a compound that, when administered to a patient, must undergo chemical transformation by metabolic processes to become an active pharmacological agent. Exemplary prodrugs of compounds according to Formula I are esters, acetamides, and amides. Compounds of the Invention
[0079] The present invention is generally directed to compounds encompassed by the genus of Formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0069]
[0080] In one embodiment, the present invention provides a compound according to formula II:
[0070] [ka]
[0071] or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 2 and X 5 independently, CR 2 or N, or X 2 is CR 2 If R 1 and R 2 together with the atoms to which they are attached form a 6-membered aryl or heteroaryl; L 1 is -(CH2)-, -(CH2)2-, -(CH2)3-, -CH((C1-C8)alkyl)(CH2)-, -CH((C1-C8)alkyl)(CH2)2-, -(CH2)2-O-, -CH2CH=CH-, -CH2C≡C- or -CH2(cyclopropyl)-; L 2 is -C(R 6 )(R 6 )-, -C(R 6 )(R 6 )C(R 6 )(R 6 )-, -C(R 6 )=C(R 6 )-, -N(R5 )C(R 6 )(R 6 )-, -OC(R 6 )(R 6 )-, -C(=O)-, -C(=O)N(R 5 )C(R 6 )(R 6 )-or bond; Ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 1 is H, OH, halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl, (C3-C6) cycloalkyl or NR 5 R 5 and; R 2 are independently H, halo, CN, NO, NO2, C≡H, (C1-C8) alkyl, (C1-C8) haloalkyl, CH2SR 5 , OR 5 , NHR 5 , N.R. 5 R 5 [(C1-C8) alkylene] heterocyclyl, [(C1-C8) alkylene] heteroaryl, [(C1-C8) alkylene] NHR 5 , [(C1-C8) alkylene]NR 5 R 5 , [(C1-C8) alkyline]NR 5 R 5 , C(O)R 5 , C(O)OR 5 , C(O)NHR 5 , C(O)NR 5 R 5 , S.R. 5 , S(O)R 5 , SO2R 5 , SO2NHR 5 , SO2NR 5 R 5 , NH(CO)R 6 , N.R. 5 (CO)R 6 , aryl, heteroaryl, cycloalkyl, or heterocyclyl; R 3are independently OH, halo, CN, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, C≡H, or NHR 7 , N.R. 7 R 7 , CO2H, CO2R 7 [(C1-C3) alkylene] (C1-C3) alkoxy, [(C1-C3) alkylene] CO2H, (C3-C5) cycloalkyl, =O. =S, SR 7 , SO2R 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 5 are independently H, (C1-C3)alkyl, (C1-C3)haloalkyl, (C3-C5)cycloalkyl, COH, [(C1-C3)alkylene]heteroaryl, [(C1-C3)alkylene]aryl, [(C1-C3)alkylene]COH, heterocyclyl, aryl, or heteroaryl; or two R's 5 the substituents, together with the nitrogen atom, form a 4-, 5-, 6-, or 7-membered heterocyclyl; R 6 are independently H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, NHR 7 , N.R. 7 R 7 , CO2H, [(C1-C3) alkylene]CO2H, (C3-C5) cycloalkyl, SR 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 7 are independently H, (C1-C8)alkyl, (C1-C8)haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 8 are H, OH, CO2H, and CO2R 7 , CF2C(R 6 )2OH, C(R 6)2OH, C(CF3)2OH, SO2H, SO3H, CF2SO2C(R 6 )3, CF2SO2N(H)R 5 , SO2N(H)R 5 , SO2N(H)C(O)R 6 , C(O)N(H)SO2R 5 , C(O)haloalkyl, C(O)N(H)OR 5 , C(O)N(R 5 )OH, C(O)N(H)R 5 , C(O)NR 5 C(O)N(R 5 )2, P(O)(OR 5 )OH, P(O)(O)N(H)R 5 , P(O)(C(R 6 )3)C(R 6 )3, B(OH)2, heterocyclyl or heteroaryl; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; wherein any alkyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of OH, CN, SH, SCH3, SO2CH 3、SO2NH2, SO2NH(C1-C4)alkyl, halogen, NH2, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(aryl), C(O)NH2, C(O)NH(alkyl), CH2C(O)NH(alkyl), COOH, COOMe, acetyl, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, O(C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, thioalkyl, cyanomethylene, alkylaminyl, alkylene-C (O)NH2, alkylene-C(O)-NH(Me), NHC(O)alkyl, CH2-C(O)-(C1-C8)alkyl, C(O)-(C1-C8)alkyl and alkylcarbonylaminyl, or is cycloalkyl, heterocyclyl, aryl or heteroaryl optionally substituted with OH, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl or O(C1-C8)haloalkyl).
[0072]
[0081] In another embodiment, the present invention provides a compound of formula III
[0073] [ka]
[0074] or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: L 1 is -(CH2)-, -(CH2)2-, -(CH2)3-, -CH((C1-C8)alkyl)(CH2)-, -CH((C1-C8)alkyl)(CH2)2-, -(CH2)2-O-, -CH2CH=CH-, -CH2C≡C- or -CH2(cyclopropyl)-; L 2 is -C(R 6 )(R 6 )-, -C(R 6 )(R 6 )C(R 6 )(R 6 )-, -C(R 6)=C(R 6 )-, -N(R 5 )C(R 6 )(R 6 )-, -OC(R 6 )(R 6 )-, -C(=O)-, -C(=O)N(R 5 )C(R 6 )(R 6 )-or bond; Ring C is heteroaryl; R 1 is H, OH, halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl, (C3-C6) cycloalkyl or NR 5 R 5 and; R 2 are independently H, halo, CN, NO, NO2, C≡H, (C1-C8) alkyl, (C1-C8) haloalkyl, CH2SR 5 , OR 5 , NHR 5 , N.R. 5 R 5 [(C1-C8) alkylene] heterocyclyl, [(C1-C8) alkylene] heteroaryl, [(C1-C8) alkylene] NHR 5 , [(C1-C8) alkylene]NR 5 R 5 , [(C1-C8) alkyline]NR 5 R 5 , C(O)R 5 , C(O)OR 5 , C(O)NHR 5 , C(O)NR 5 R 5 , S.R. 5 , S(O)R 5 , SO2R 5 , SO2NHR 5 , SO2NR 5 R 5 , NH(CO)R 6 , N.R. 5 (CO)R 6 , aryl, heteroaryl, cycloalkyl, or heterocyclyl; R 3are independently OH, halo, CN, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, C≡H, or NHR 7 , N.R. 7 R 7 , CO2H, CO2R 7 [(C1-C3) alkylene] (C1-C3) alkoxy, [(C1-C3) alkylene] CO2H, (C3-C5) cycloalkyl, =O. =S, SR 7 , SO2R 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 5 are independently H, (C1-C3) alkyl, (C1-C3) haloalkyl, (C3-C5) cycloalkyl, or heterocyclyl; R 6 are independently H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, NHR 7 , N.R. 7 R 7 , CO2H, [(C1-C3) alkylene]CO2H, (C3-C5) cycloalkyl, SR 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 7 are independently H, (C1-C8)alkyl, (C1-C8)haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 8 are H, OH, CO2H, and CO2R 7 , CF2C(R 6 )2OH, C(R 6 )2OH, C(CF3)2OH, SO2H, SO3H, CF2SO2C(R 6 )3, CF2SO2N(H)R 5 , SO2N(H)R 5 , SO2N(H)C(O)R 6 , C(O)N(H)SO2R 5 , C(O)haloalkyl, C(O)N(H)OR 5, C(O)N(R 5 )OH, C(O)N(H)R 5 , C(O)NR 5 C(O)N(R 5 )2, P(O)(OR 5 )OH, P(O)(O)N(H)R 5 , P(O)(C(R 6 )3)C(R 6 )3, B(OH)2, heterocyclyl or heteroaryl; R 9 is H, (C1-C8) alkyl, (C1-C8) haloalkyl, cycloalkyl, or heterocyclyl; m is 0, 1, or 2; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; wherein any alkyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of OH, CN, SH, SCH3, SO2CH 3、 SO2NH2, SO2NH(C1-C4)alkyl, halogen, NH2, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(aryl), C(O)NH2, C(O)NH(alkyl), CH2C(O)NH(alkyl), COOH, COOMe, acetyl, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, O(C1-C8)haloalkyl, optionally substituted with one, two, or three groups selected from (C2-C8)alkenyl, (C2-C8)alkynyl, thioalkyl, cyanomethylene, alkylaminyl, alkylene-C(O)NH2, alkylene-C(O)—NH(Me), NHC(O)alkyl, CH2—C(O)—(C1-C8)alkyl, C(O)—(C1-C8)alkyl, and alkylcarbonylaminyl).
[0075]
[0082] In one embodiment, the present invention provides a compound according to formula IV
[0076] [ka]
[0077] or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 2 and X 5 independently, CR 2 or N, or X 2 is CR 2 If R 1 and R 2 together with the atoms to which they are attached form a 6-membered aryl or heteroaryl; X 3 is C or X 4 If is a bond, then X 3 is C or N; X 4 is a bond, CR 2 or N, where X 4 and X 5 is joined together with three or four carbon or nitrogen atoms to form a five- or six-membered heteroaryl; L 1 is -(CH2)-, -(CH2)2-, -(CH2)3-, -CH((C1-C8)alkyl)(CH2)-, -CH((C1-C8)alkyl)(CH2)2-, -(CH2)2-O-, -CH2CH=CH-, -CH2C≡C- or -CH2(cyclopropyl)-; L 2 is -C(R 6 )(R 6 )-, -C(R 6 )(R 6 )C(R 6 )(R 6 )-, -C(R 6 )=C(R 6 )-, -N(R 5 )C(R 6 )(R 6 )-, -OC(R 6 )(R 6 )-, -C(=O)-, -C(=O)N(R 5 )C(R 6 )(R 6 )-and; Ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 1 is H, OH, halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl, (C3-C6) cycloalkyl or NR 5 R 5 and; R 2 are independently H, halo, CN, NO, NO2, C≡H, (C1-C8) alkyl, (C1-C8) haloalkyl, CH2SR 5 , OR 5 , NHR 5 , N.R. 5 R 5 [(C1-C8) alkylene] heterocyclyl, [(C1-C8) alkylene] heteroaryl, [(C1-C8) alkylene] NHR 5 , [(C1-C8) alkylene]NR 5 R 5 , [(C1-C8) alkyline]NR 5 R 5 , C(O)R 5 , C(O)OR 5 , C(O)NHR 5 , C(O)NR 5 R 5 , S.R. 5 , S(O)R 5 , SO2R 5 , SO2NHR 5 , SO2NR 5 R 5 , NH(CO)R 6 , N.R. 5 (CO)R 6 , aryl, heteroaryl, cycloalkyl, or heterocyclyl; R 3 are independently OH, halo, CN, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, C≡H, or NHR 7 , N.R. 7 R 7 , CO2H, CO2R 7 [(C1-C3) alkylene] (C1-C3) alkoxy, [(C1-C3) alkylene] CO2H, (C3-C5) cycloalkyl, =O. =S, SR7 , SO2R 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 5 are independently H, (C1-C3)alkyl, (C1-C3)haloalkyl, (C3-C5)cycloalkyl, COH, [(C1-C3)alkylene]heteroaryl, [(C1-C3)alkylene]aryl, [(C1-C3)alkylene]COH, heterocyclyl, aryl, or heteroaryl; or two R's 5 the substituents, together with the nitrogen atom, form a 4-, 5-, 6-, or 7-membered heterocyclyl; R 6 are independently H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, NHR 7 , N.R. 7 R 7 , CO2H, [(C1-C3) alkylene]CO2H, (C3-C5) cycloalkyl, SR 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 7 are independently H, (C1-C8)alkyl, (C1-C8)haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 8 are H, OH, CO2H, and CO2R 7 , CF2C(R 6 )2OH, C(R 6 )2OH, C(CF3)2OH, SO2H, SO3H, CF2SO2C(R 6 )3, CF2SO2N(H)R 5 , SO2N(H)R 5 , SO2N(H)C(O)R 6 , C(O)N(H)SO2R 5 , C(O)haloalkyl, C(O)N(H)OR 5 , C(O)N(R 5 )OH, C(O)N(H)R 5, C(O)NR 5 C(O)N(R 5 )2, P(O)(OR 5 )OH, P(O)(O)N(H)R 5 , P(O)(C(R 6 )3)C(R 6 )3, B(OH)2, heterocyclyl or heteroaryl; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; wherein any alkyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of OH, CN, SH, SCH3, SO2CH 3、 SO2NH2, SO2NH(C1-C4)alkyl, halogen, NH2, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(aryl), C(O)NH2, C(O)NH(alkyl), CH2C(O)NH(alkyl), COOH, COOMe, acetyl, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, O(C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, thioalkyl, cyanomethylene, alkylaminyl, alkylene- cycloalkyl, heterocyclyl, aryl or heteroaryl optionally substituted with one, two or three groups selected from C(O)NH2, alkylene-C(O)-NH(Me), NHC(O)alkyl, CH2-C(O)-(C1-C8)alkyl, C(O)-(C1-C8)alkyl and alkylcarbonylaminyl, or optionally substituted with OH, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl or O(C1-C8)haloalkyl; where X 4 is a bond, ring A forms a 5-membered heteroaryl, and X 1 and X 5 may be N in addition to C).
[0078]
[0083] In another embodiment, the present invention provides a compound of formula V
[0079] [ka]
[0080] or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: Q is -L 1 -Y; L 1 is -(CH2)-, -(CH2)2-, -(CH2)3-, -CH((C1-C8)alkyl)(CH2)-, -CH((C1-C8)alkyl)(CH2)2-, -(CH2)2-O-, -CH2CH=CH-, -CH2C≡C- or -CH2(cyclopropyl)-; Y is
[0081] [ka]
[0082] where: Ring B is a 6-membered aryl, heteroaryl, or heterocyclyl; R 1 is H, OH, halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl, (C3-C6) cycloalkyl or NR 5 R 5 and; R 2 are independently H, halo, CN, NO, NO2, C≡H, (C1-C8) alkyl, (C1-C8) haloalkyl, CH2SR 5 , OR 5 , NHR 5 , N.R. 5 R 5 [(C1-C8) alkylene] heterocyclyl, [(C1-C8) alkylene] heteroaryl, [(C1-C8) alkylene] NHR 5 , [(C1-C8) alkylene]NR 5 R 5 , [(C1-C8) alkyline]NR 5 R 5 , C(O)R 5 , C(O)OR 5 , C(O)NHR 5 , C(O)NR5 R 5 , S.R. 5 , S(O)R 5 , SO2R 5 , SO2NHR 5 , SO2NR 5 R 5 , NH(CO)R 6 , N.R. 5 (CO)R 6 , aryl, heteroaryl, cycloalkyl, or heterocyclyl; R 3 are independently OH, halo, CN, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, C≡H, or NHR 7 , N.R. 7 R 7 , CO2H, CO2R 7 [(C1-C3) alkylene] (C1-C3) alkoxy, [(C1-C3) alkylene] CO2H, (C3-C5) cycloalkyl, =O. =S, SR 7 , SO2R 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 4 is H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, SR 7 or Z, where Z is
[0083] [ka]
[0084] and Ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; L 2 is -C(R 6 )(R 6 )-, -C(R 6 )(R 6 )C(R 6 )(R 6 )-, -C(R 6 )=C(R 6)-, -N(R 5 )C(R 6 )(R 6 )-, -OC(R 6 )(R 6 )-, -C(=O)-, -C(=O)N(R 5 )C(R 6 )(R 6 )-or bond; R 5 are independently H, (C1-C3)alkyl, (C1-C3)haloalkyl, (C3-C5)cycloalkyl, COH, [(C1-C3)alkylene]heteroaryl, [(C1-C3)alkylene]aryl, [(C1-C3)alkylene]COH, heterocyclyl, aryl, or heteroaryl; or two R's 5 the substituents, together with the nitrogen atom, form a 4-, 5-, or 6-membered heterocyclyl; R 6 are independently H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, NHR 7 , N.R. 7 R 7 , CO2H, [(C1-C3) alkylene]CO2H, (C3-C5) cycloalkyl, SR 7 , NH(CO)R 7 or NR 7 (CO)R 7 can be; R 7 are independently H, (C1-C8)alkyl, (C1-C8)haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 8 are H, OH, CO2H, and CO2R 7 , CF2C(R 6 )2OH, C(R 6 )2OH, C(CF3)2OH, SO2H, SO3H, CF2SO2C(R 6 )3, CF2SO2N(H)R 5 , SO2N(H)R 5 , SO2N(H)C(O)R 6 , C(O)N(H)SO2R 5, C(O)haloalkyl, C(O)N(H)OR 5 , C(O)N(R 5 )OH, C(O)N(H)R 5 , P(O)(OR 5 )OH, P(O)(O)N(H)R 5 , P(O)(C(R 6 )3)C(R 6 )3, B(OH)2, heterocyclyl or heteroaryl; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; q is 0, 1, 2, 3 or 4; wherein any alkyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of OH, CN, SH, SCH3, SO2CH 3、 SO2NH2, SO2NH(C1-C4)alkyl, halogen, NH2, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(aryl), C(O)NH2, C(O)NH(alkyl), CH2C(O)NH(alkyl), COOH, COOMe, acetyl, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, O(C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, thioalkyl, cyanomethylene, alkylaminyl, alkylene-C (O)NH2, alkylene-C(O)-NH(Me), NHC(O)alkyl, CH2-C(O)-(C1-C8)alkyl, C(O)-(C1-C8)alkyl and alkylcarbonylaminyl, or is cycloalkyl, heterocyclyl, aryl or heteroaryl optionally substituted with OH, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl or O(C1-C8)haloalkyl).
[0085] In another embodiment, the present invention provides a compound of formula VI
[0086] [ka]
[0087] or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: Q is -L 1 -Y; L 1 is -(CH2)-, -(CH2)2-, -(CH2)3-, -CH((C1-C8)alkyl)(CH2)-, -CH((C1-C8)alkyl)(CH2)2-, -(CH2)2-O-, -CH2CH=CH-, -CH2C≡C- or -CH2(cyclopropyl)-; Y is
[0088] [ka]
[0089] where: Ring B is a 6-membered aryl, heteroaryl, or heterocyclyl; R 1 is H, OH, halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl, (C3-C6) cycloalkyl or NR 5 R 5 and; R 2 are independently H, halo, CN, NO, NO2, C≡H, (C1-C8) alkyl, (C1-C8) haloalkyl, CH2SR 5 , OR 5 , NHR 5 , N.R. 5 R 5 [(C1-C8) alkylene] heterocyclyl, [(C1-C8) alkylene] heteroaryl, [(C1-C8) alkylene] NHR 5 , [(C1-C8) alkylene]NR 5 R 5 , [(C1-C8) alkyline]NR 5 R 5 , C(O)R 5 , C(O)OR 5 , C(O)NHR 5 , C(O)NR5 R 5 , S.R. 5 , S(O)R 5 , SO2R 5 , SO2NHR 5 , SO2NR 5 R 5 , NH(CO)R 6 , N.R. 5 (CO)R 6 , aryl, heteroaryl, cycloalkyl, or heterocyclyl; R 3 are independently OH, halo, CN, NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, C≡H, or NHR 7 , N.R. 7 R 7 , CO2H, CO2R 7 [(C1-C3) alkylene] (C1-C3) alkoxy, [(C1-C3) alkylene] CO2H, (C3-C5) cycloalkyl, =O. =S, SR 7 , SO2R 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 4 is H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, SR 7 or Z, where Z is
[0090] [ka]
[0091] and; Ring C is cycloalkyl, heterocyclyl, aryl, or heteroaryl; L 2 is -C(R 6 )(R 6 )-, -C(R 6 )(R 6 )C(R 6 )(R 6 )-, -C(R 6 )=C(R6 )-, -N(R 5 )C(R 6 )(R 6 )-, -OC(R 6 )(R 6 )-, -C(=O)-, -C(=O)N(R 5 )C(R 6 )(R 6 )-or bond; R 5 are independently H, (C1-C3)alkyl, (C1-C3)haloalkyl, (C3-C5)cycloalkyl, COH, [(C1-C3)alkylene]heteroaryl, [(C1-C3)alkylene]aryl, [(C1-C3)alkylene]COH, heterocyclyl, aryl, or heteroaryl; or two R's 5 the substituents, together with the nitrogen atom, form a 4-, 5-, or 6-membered heterocyclyl; R 6 are independently H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, NHR 7 , N.R. 7 R 7 , CO2H, [(C1-C3) alkylene]CO2H, (C3-C5) cycloalkyl, SR 7 , NH(CO)R 7 or NR 7 (CO)R 7 and; R 7 are independently H, (C1-C8)alkyl, (C1-C8)haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 8 are H, OH, CO2H, and CO2R 7 , CF2C(R 6 )2OH, C(R 6 )2OH, C(CF3)2OH, SO2H, SO3H, CF2SO2C(R 6 )3, CF2SO2N(H)R 5 , SO2N(H)R 5 , SO2N(H)C(O)R 6 , C(O)N(H)SO2R 5, C(O)haloalkyl, C(O)N(H)OR 5 , C(O)N(R 5 )OH, C(O)N(H)R 5 , C(O)NR 5 C(O)N(R 5 )2, P(O)(OR 5 )OH, P(O)(O)N(H)R 5 , P(O)(C(R 6 )3)C(R 6 )3, B(OH)2, heterocyclyl or heteroaryl; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; q is 0, 1, 2, 3 or 4; wherein any alkyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of OH, CN, SH, SCH3, SO2CH 3、 SO2NH2, SO2NH(C1-C4)alkyl, halogen, NH2, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(aryl), C(O)NH2, C(O)NH(alkyl), CH2C(O)NH(alkyl), COOH, COOMe, acetyl, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, O(C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, thioalkyl, cyanomethylene, alkylaminyl, alkylene- optionally substituted with one, two or three groups selected from C(O)NH, alkylene-C(O)—NH(Me), NHC(O)alkyl, CH—C(O)—(C1-C8)alkyl, C(O)—(C1-C8)alkyl and alkylcarbonylaminyl, or is cycloalkyl, heterocyclyl, aryl or heteroaryl optionally substituted with OH, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl or O(C1-C8)haloalkyl).
[0092] In one embodiment, X in Formulas I, II, and IV 2 is N. In one embodiment, X in formula I and IV 3 is C. In one embodiment, X in formula I and IV 4 is CR 2 Or N.
[0093] In one embodiment, X in formula I and IV 5 is CR 2 is. In one embodiment, L of Formulas I, II, III, IV, V and VI 1 is —(CH)—O—, —CHCH═CH—, or —CHC≡C—. In another embodiment, L 1 is -(CH2)2-O-.
[0094] In one embodiment, L of Formulas I, II, III, IV, V and VI 2 is a bond. In one embodiment, ring B of formulas I, V and VI is aryl.
[0095] In one embodiment, ring C of formulas I, II, III, IV, V and VI is heteroaryl. In one embodiment, ring C of formulas I, II, III, IV, V and VI is
[0096] [ka]
[0097] is. In one embodiment, ring C of formula III is
[0098] [ka]
[0099] is. In one embodiment, R of Formulas I, II, III, IV, V and VI 1is H, (C1-C8) alkyl or (C1-C8) haloalkyl.
[0100] In one embodiment, R of formula IV 1 is NHR 5 or N[(C1-C3) alkyl](R 5 ) In one embodiment, R of Formulas I, II, III, IV, V and VI 2 is halo, CN, (C1-C8) alkyl, (C1-C8) haloalkyl or OR 5 In another embodiment, R 2 is halo, CN, or (C1-C8)haloalkyl.
[0101] In one embodiment, R of Formulas I, II, III, IV, V and VI 3 is halo, CN, (C1-C3) alkyl or (C1-C3) haloalkyl. In one embodiment, R of Formulas I, V, and VI 4 is Z, where Z is
[0102] [ka]
[0103] is. In one embodiment, R of Formulas I, II, III, V and VI 5 is H, (C1-C3) alkyl, or (C1-C3) haloalkyl. In another embodiment, R 5 In another embodiment, R of Formulas I, II, III, IV, V, and VI is aryl. 5 is H, (C1-C3) alkyl or (C1-C3) haloalkyl.
[0104] In one embodiment, R of Formulas I, II, III, IV, V, and VI 6is H, OH, halo, CN, (C1-C3) alkyl, (C1-C3) haloalkyl or (C1-C3) alkoxy.
[0105] In one embodiment, R of Formulas I, II, III, IV, V and VI 7 is H, (C1-C8) alkyl or (C1-C8) haloalkyl. In one embodiment, R of Formulas I, II, III, IV, V, and VI 8 is CO2H or C(O)N(H)SO2R 5 is.
[0106] In one embodiment, R of Formula III 9 is (C1-C8) alkyl or (C1-C8) haloalkyl. In one embodiment, R of Formula III 9 is cycloalkyl or heterocyclyl.
[0107] In one embodiment, "m" in Formulas I and II = 2 or 3. In another embodiment, "n" in Formulas I, II, IV, V and VI = 1 or 2. In yet another embodiment, "p" in Formulas I, II, III, IV, V and VI = 0 or 1.
[0108] In one embodiment, any substituent on alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is OH, CN, halogen, (C1-C8)alkyl, O(C1-C8)alkyl, haloalkyl, alkylene-C(O)NH2, or alkylene-C(O)-NH(Me).
[0109] In one embodiment, the optional substituents on alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl are cycloalkyl, heterocyclyl, aryl, or heteroaryl optionally substituted with OH, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, O(C1-C8)alkyl, or O(C1-C8)haloalkyl.
[0110] In one embodiment, the compound according to Formula I, II, III, IV, V, and VI is selected from compounds 1-1250. The compounds of the invention according to Formulas I, II, III, IV, V and VI may be isotopically labeled by replacing one or more atoms with atoms having a different atomic mass or mass number. Examples of isotopes that may be incorporated into the compounds according to Formulas I, II, III, IV, V and VI include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, or iodine. Examples of such isotopes are, respectively: 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. These radiolabeled compounds may be used to measure biodistribution, tissue concentration, and transport and excretion kinetics from biological tissues, including subjects to which such labeled compounds are administered. The labeled compounds are also used to determine therapeutic efficacy, site or mode of action, and binding affinity of candidate therapeutic agents to pharmacologically important targets. Thus, certain radiolabeled compounds according to Formulas I, II, III, IV, V, and VI are useful in drug and / or tissue distribution studies. The radioisotope tritium, i.e., 3 H, and carbon-14, i.e., 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
[0111]
[0111] Heavy isotopes, such as deuterium, i.e., 2Substitution with H provides certain therapeutic advantages due to superior metabolic stability, e.g., increased half-life of deuterium-containing compounds in vivo. Substitution of hydrogen with deuterium may reduce the dose required for therapeutic effect and therefore may be preferred in discovery or clinical settings.
[0112] Positron-emitting isotopes, such as 11 C. 18 F, 15 O and 13 Substitution at N provides labeled analogs of the compounds of the invention, which are useful, for example, in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds according to Formulas I, II, III, IV, V, and VI may generally be prepared using suitable isotopically labeling reagents by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparation and Examples sections below.
[0113]
[0113] Embodiments of the invention disclosed herein are also intended to encompass in vivo metabolic products of compounds according to Formulas I, II, III, IV, V, and VI. Such products may result, for example, from processes such as oxidation, reduction, hydrolysis, amidation, esterification, and the like, primarily resulting from enzymatic activity upon administration of a compound of the invention. Accordingly, the invention includes compounds produced as by-products of enzymatic or non-enzymatic activity on a compound of the invention after administration of such compound to a mammal for a period sufficient to yield the metabolic product. Metabolites, particularly pharmaceutically active metabolites, are typically identified by administering a detectable dose of a radiolabeled compound of the invention to a subject, e.g., a rat, mouse, guinea pig, monkey, or human, for a period sufficient for metabolism to occur, and isolating the metabolites from urine, blood, or other biological samples obtained from the subject receiving the radiolabeled compound.
[0114] The present invention also provides pharmaceutically acceptable salt forms of the compounds in Formulas I, II, III, IV, V, and VI. Included within the scope of the invention are both acid addition and base addition salts, which are formed by contacting a compound of the invention with a pharmaceutically suitable acid or a pharmaceutically suitable base.
[0115] For this purpose, "pharmaceutically acceptable acid addition salts" are those which retain the biological effectiveness and properties of the free base, which are not biologically or otherwise undesirable, and which are not salts of inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyl sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, It refers to salts formed with galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
[0116] Similarly, a "pharmaceutically acceptable base addition salt" refers to a salt that retains the biological effectiveness and properties of the free acid and is not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as ammonia resin, isopropylamine resin, trimethylamine resin, diethylamine resin, triethylamine resin, tripropylamine resin, diethanolamine resin, ethanolamine resin, deanol resin, 2-dimethylaminoethanol resin, 2-diethylaminoethanol resin, dicyclohexylamine resin, lysine resin, arginine resin, histidine resin, caffeine resin, procaine resin, hydrabamine resin, choline resin, betaine resin, benetamine resin, benzathine resin, ethylenediamine resin, glucosamine resin, methylglucamine resin, theobromine resin, triethanolamine resin, tromethamine resin, purine resin, piperazine resin, piperidine resin, N-ethylpiperidine resin, polyamine resin, and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
[0117] Solvates of the compounds of the present invention are often produced by crystallization. As used herein, the term "solvate" refers to an aggregate comprising one or more molecules of a compound of the present invention and one or more molecules of a solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, and the like, as well as corresponding solvated forms. The compounds of the present invention may be true solvates, while in other cases the compounds of the present invention may merely retain incidental water or may be mixtures of water and some incidental solvent.
[0118]
[0118] "Stereoisomer" refers to a compound composed of the same atoms joined by the same bonds but having different, irreplaceable three-dimensional structures. The present invention contemplates various stereoisomers, including "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another, and mixtures thereof.
[0119] The compounds of the present invention, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and thus may give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined in terms of absolute stereochemistry as (R)- or (S)- with respect to amino acids, or as (D)- or (L)-. The present invention is intended to encompass all such possible isomers, as well as their racemic and optically pure forms. Optically active (+)- and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise specified, the compounds are intended to include both E and Z geometric isomers, as well as all tautomers.
[0120] The term "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule, e.g.:
[0121] [ka]
[0122] Refers to...
[0121] The compounds provided in this disclosure may be depicted as different tautomers, and where a compound has tautomers, all tautomers are intended to be within the scope of the invention, and the naming of a compound does not exclude any tautomer of that compound.
[0123] The compounds of the present invention are synthesized using conventional synthetic methods, more specifically using the general methods described below. Pharmaceutical preparations In one embodiment, the compounds according to Formulas I, II, III, IV, V, and VI are formulated as pharmaceutically acceptable compositions comprising the compounds of Formulas I, II, III, IV, V, and VI in an amount effective to treat the particular disease or condition of interest when the pharmaceutical composition is administered to a mammal. Pharmaceutical compositions according to the invention may comprise the compounds of Formulas I, II, III, IV, V, and VI in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
[0124]
[0124] In this regard, a "pharmaceutically acceptable carrier, diluent, or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the U.S. Food and Drug Administration as acceptable for use in humans or domestic animals.
[0125]
[0125] Furthermore, "mammal" includes both humans and domestic animals, such as laboratory animals and household pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits), and non-domestic animals, such as wildlife.
[0126] Pharmaceutical compositions of the present invention may be prepared by combining a compound of the present invention with a suitable pharmaceutically acceptable carrier, diluent, or excipient, and may be formulated into solid, semi-solid, liquid, or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosol preparations. Typical routes of administration of such pharmaceutical compositions include, but are not limited to, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term parenteral, as used herein, includes subcutaneous injection, intravenous, intramuscular, intrasternal injection, or infusion techniques. Pharmaceutical compositions of the present invention are formulated so that the active ingredients contained therein are bioavailable upon administration of the composition to a patient. The compositions to be administered to a subject or patient may take the form of one or more dosage units; for example, a tablet may be a single dosage unit, and a container of a compound of the present invention in aerosol form may hold multiple dosage units. Actual methods for preparing such dosage forms are known or will be apparent to those skilled in the art; see, for example, Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). In any event, the composition to be administered will contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, to treat the disease or condition of interest in accordance with the teachings of this invention.
[0127]
[0127] The pharmaceutical compositions of the present invention may be in solid or liquid form. In one embodiment, the carrier is particulate, so that the composition is, for example, in tablet or powder form. The carrier may also be liquid, so that the composition is, for example, an oral syrup, an injectable liquid, or an aerosol, which is useful, for example, in inhalation administration. When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, with semi-solid, semi-liquid, suspension, and gel forms being included within the scope of forms considered herein to be either solid or liquid.
[0128]
[0128] As a solid composition for oral administration, the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer, or similar form. Such solid compositions will typically contain one or more inert diluents or edible carriers. Additionally, one or more of the following may be present: a binder, such as carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, tragacanth, or gelatin; an excipient, such as starch, lactose, or dextrin; a disintegrant, such as alginic acid, sodium alginate, Primogel, corn starch, or the like; a lubricant, such as magnesium stearate or Sterotex; a glidant, such as colloidal silicon dioxide; a sweetener, such as sucrose or saccharin; a flavoring, such as peppermint, methyl salicylate, or orange flavoring; and a coloring agent.
[0129]
[0129] When the pharmaceutical composition is in the form of a capsule, such as a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.
[0130]
[0130] The pharmaceutical composition may be in the form of a liquid, such as an elixir, syrup, solution, emulsion, or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred compositions contain, in addition to the compound, one or more of a sweetener, a preservative, a dye / colorant, and a flavoring agent. In compositions intended to be administered by injection, one or more of a surfactant, a preservative, a wetting agent, a dispersing agent, a suspending agent, a buffer, a stabilizer, and an isotonic agent may be included.
[0131] Liquid pharmaceutical compositions of the present invention, whether in solution, suspension, or other similar form, may include one or more of the following adjuvants: sterile diluents, such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils, such as synthetic mono- or diglycerides, polyethylene glycol, glycerin, propylene glycol, or other solvents that may serve as solvents or suspending media; antibacterial agents, such as benzyl alcohol or methylparabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetate, citrate, or phosphate, and agents for adjusting tonicity, such as sodium chloride or dextrose. Parenteral preparations may be enclosed in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. Injectable pharmaceutical compositions are preferably sterile.
[0132] A liquid pharmaceutical composition of the present invention intended for either parenteral or oral administration should contain an amount of a compound of the present invention such that a suitable dosage will be obtained.
[0133] The pharmaceutical composition of the present invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base.The base may comprise, for example, one or more of the following: petrolatum, lanolin, polyethylene glycol, beeswax, mineral oil, diluent, such as water and alcohol, and emulsifier and stabilizer.A thickener may be present in the pharmaceutical composition for topical administration.When intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device.
[0133]
[0134] The pharmaceutical composition of the present invention may be intended for rectal administration, for example, in the form of suppositories, which will melt in the rectum and release the drug.The composition for rectal administration may contain an oily base as a suitable non-irritating excipient.Such bases include but are not limited to lanolin, cocoa butter and polyethylene glycol.
[0134]
[0135] The pharmaceutical composition of the present invention can include various materials that modify the physical form of solid or liquid dosage unit.For example, the composition can include materials that form a coating shell around active ingredient.The material that forms the coating shell is usually inert, and can be selected from, for example, sugar, shellac and other enteric coating agents.Alternatively, the active ingredient can be encapsulated in gelatin capsules.
[0135]
[0136] Pharmaceutical compositions of the invention, in solid or liquid form, may include an agent that binds to the compounds of the invention and thereby aids in the delivery of the compounds. Suitable agents that may act in this capacity include monoclonal or polyclonal antibodies, proteins, or liposomes.
[0136]
[0137] The pharmaceutical compositions of the present invention may be comprised of dosage units that can be administered as an aerosol. The term aerosol is used to refer to a variety of systems, ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by liquefied or compressed gas or by a suitable pump system for dispensing the active ingredient. Aerosols of the compounds of the present invention may be delivered in single-phase, two-phase, or three-phase systems to deliver the active ingredient. Aerosol delivery may include the necessary container, activator, valve, subcontainer, etc., which can be combined to form a kit. Those skilled in the art will be able to determine a preferred aerosol without undue experimentation.
[0137]
[0138] The pharmaceutical composition of the present invention can be prepared by any methodology known in the pharmaceutical field.For example, the pharmaceutical composition intended to be administered by injection can be prepared by combining the compound of the present invention with sterile distilled water to form a solution.Surfactant can be added to promote the formation of a homogeneous solution or suspension.Surfactant is a compound that interacts non-covalently with the compound of the present invention, thereby promoting the dissolution or homogeneous suspension of the compound in an aqueous delivery system.
[0138]
[0139] In certain embodiments, pharmaceutical compositions comprising compounds of formula I, II, III, IV, V and VI are administered to mammals in an amount sufficient to inhibit eIF4E activity upon administration, preferably with acceptable toxicity to the mammal. The eIF4E activity of compounds of formula I, II, III, IV, V and VI may be determined by those skilled in the art, for example, as described in the examples below. Appropriate concentrations and dosages can be easily determined by those skilled in the art.
[0139] therapeutic use
[0140] The compounds of the present invention, or pharmaceutically acceptable salts thereof, are administered in therapeutically effective amounts, which will vary depending on a variety of factors, including the activity of the particular compound employed; the metabolic stability and length of action of the compound; the age, weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject for whom therapy is being administered.
[0140]
[0141] An "effective amount" or "therapeutically effective amount" refers to the amount of a compound of the present invention that, when administered to a mammal, preferably a human, is sufficient to effect treatment of an eIF4E-associated condition or disease in the mammal, preferably a human, as defined below. The amount of a compound of the present invention that constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, the mode of administration, and the age of the mammal to be treated, but may be determined routinely by one of ordinary skill in the art having regard to their own knowledge and this disclosure.
[0141]
[0142] The compound of the present invention or its pharmaceutically acceptable salts may also be administered simultaneously with, before, or after the administration of one or more other therapeutic agents.Such combined therapy includes the administration of a single pharmaceutical dosage formulation comprising the compound of the present invention and one or more additional active agents, and the administration of the compound of the present invention and each active agent as separate pharmaceutical dosage formulations.For example, the compound of the present invention and other active agents may be administered to patients together in a single oral dosage composition, for example, a tablet or capsule, or each agent may be administered in separate oral dosage formulations.When separate dosage formulations are used, the compound of the present invention and one or more additional active agents may be administered substantially simultaneously, i.e., together, or separately, staggered, i.e., sequentially; combined therapy is understood to include all these regimens.
[0142]
[0143] In certain embodiments, the disclosed compounds may be useful in inhibiting the activity of eIF4E and / or may be useful in analyzing eIF4E signaling activity in model systems and / or may be useful in preventing, treating, or ameliorating symptoms associated with diseases, disorders, or pathological conditions involving eIF4E, preferably those that afflict humans. Compounds that inhibit the activity of eIF4E will be useful in preventing, treating, ameliorating, or reducing the symptoms or progression of diseases of uncontrolled cell growth, proliferation, and / or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly diseases in which eIF4E is involved. Intervening tumors include, for example, leukemias and myelodysplastic syndromes, hematological tumors, including malignant lymphomas, such as B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Burkitt's lymphoma, solid tumors, and / or metastases thereof, head and neck tumors, including brain tumors and brain metastases, non-small cell and small cell lung tumors, gastrointestinal tumors, endocrine tumors, thoracic tumors, including breast and other gynecological tumors, urinary tumors, including kidney, bladder, and prostate tumors, skin tumors, and sarcomas, and / or metastases thereof.
[0143]
[0144] Furthermore, the compounds of the present invention and pharmaceutical compositions thereof are candidate therapeutic agents for preventing and / or treating cytokine-associated diseases, such as inflammatory diseases, allergies, or other conditions associated with pro-inflammatory cytokines.Exemplary inflammatory diseases include, but are not limited to, chronic or acute inflammation, inflammation of the joints, such as chronic inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, juvenile rheumatoid arthritis, Reiter's syndrome, rheumatoid traumatic arthritis, rubella arthritis, acute synovitis, and gouty arthritis; inflammatory skin diseases, such as sunburn, psoriasis, erythrodermic psoriasis, pustular psoriasis, eczema, dermatitis, acute or chronic graft formation, atopic dermatitis, contact dermatitis, urticaria, and scleroderma; inflammation of the gastrointestinal tract, such as inflammatory bowel disease, Crohn's disease and related conditions, ulcerative colitis, and ulcerative colitis. enteritis, colitis, and diverticulitis; nephritis, urethritis, salpingitis, oophoritis, endometritis, spondylitis, systemic lupus erythematosus and related disorders, multiple sclerosis, asthma, meningitis, myelitis, encephalomyelitis, encephalitis, phlebitis, thrombophlebitis, respiratory diseases such as asthma, bronchitis, chronic obstructive pulmonary disease (COPD), inflammatory lung disease and adult respiratory distress syndrome, and allergic rhinitis; endocarditis, osteomyelitis, rheumatic fever, rheumatic pericarditis, rheumatic endocarditis, rheumatic myocarditis, rheumatic mitral valve disease, rheumatic aortic valve disease, prostatitis, prostatic cystitis, spinal joint disease Inflammatory diseases of the thyroid gland selected from the group consisting of spondoarthropathies, ankylosing spondylitis, synovitis, tenosynovitis, myositis, pharyngitis, polymyalgia rheumatica, shoulder tendinitis or bursitis, gout, pseudogout, vasculitis, granulomatous thyroiditis, lymphocytic thyroiditis, aggressive fibrosing thyroiditis, and acute thyroiditis; Hashimoto's thyroiditis, Kawasaki disease, Raynaud's phenomenon, Sjogren's syndrome, neuroinflammatory diseases, sepsis, conjunctivitis, keratitis, iridocyclitis, optic neuritis, otitis, lymphadenitis, and nasopharyngitis. haringitis), sinusitis, pharyngitis, tonsillitis, laryngitis, epiglottitis, bronchitis, pneumonia, stomatitis, gingivitis, esophagitis, gastritis, peritonitis, hepatitis, cholelithiasis, cholecystitis, glomerulonephritis, Goodpasture's disease, crescentic glomerulonephritis, pancreatitis, endometritis, metritis, cervicitis, endocervicitis, exocervicitis, parametritis, tuberculosis, vaginitis, vulvitis, silicosis, sarcoidosis, pneumoconiosis, pyresis, inflammatory polyarthropathy, psoriatic arthropathy, intestinal fibrosis, bronchiectasis and enteropathic arthropathy.
[0144]
[0145] Furthermore, the compounds of the present invention and pharmaceutical compositions thereof are candidate therapeutic agents for the prevention and / or treatment of fibrotic diseases, such as any disease that results in various forms of fibrosis, fibromas, or fibrosis, whether as a primary or secondary symptom. Exemplary fibrotic diseases include, but are not limited to, viral hepatitis, liver fibrosis, schistosomiasis, steatohepatitis (alcoholic or non-alcoholic), cirrhosis, idiopathic pulmonary fibrosis (IPF), systemic sclerosis (scleroderma), nephrogenic systemic fibrosis (NSF), diabetes, untreated hypertension, heart attack, high blood pressure, atherosclerosis, restenosis, macular degeneration, retinal and vitreoretinopathy, keloids, hypertrophic scars, Crohn's disease, and Alzheimer's disease.
[0145]
[0146] Although inflammation is a unifying pathogenic process of these diseases, current therapies only treat the symptoms of the disease, not the underlying cause of the inflammation. The compositions of the present invention are useful for the treatment and / or prevention of inflammatory diseases and associated complications and disorders.
[0146]
[0147] Accordingly, certain embodiments are directed to a method for treating an eIF4E-dependent condition in a mammal in need thereof, comprising administering to the mammal an effective amount of a pharmaceutical composition as described above (i.e., a pharmaceutical composition comprising one or more compounds of Formulas I, II, III, IV, V and VI).
[0147]
[0148] The above-mentioned deregulation of protein synthesis is a common event in human cancer.The key regulator of translational control is eIF4E, and its activity is a key determinant of tumorigenicity.eIF4E inhibitors are suitable candidate therapeutic agents for treating cell proliferation disorders, such as cancer.Various cancers, including solid tumors, lymphomas and leukemias, can be applied to the compositions and methods disclosed herein. Types of cancer that can be treated include, but are not limited to: adenocarcinoma of the breast, prostate, and colon; all forms of bronchogenic carcinoma of the lung; myeloid; melanoma; hepatocarcinoma; neuroblastoma; papilloma; apodoma; choristoma; branchiomas; malignant carcinoid syndrome; carcinoid heart disease; and carcinomas (e.g., Walker, basal cell, basosquamous cell, Brown-Pierce, ductal, Ehrlich tumor, Krebs 2, Merkel cell, mucinous, non-small cell lung, oat cell, papillary, sclerotic, bronchiolar, bronchogenic, squamous cell, and transitional cell). Additional cancer types that can be treated include: histiocytic disorders; leukemia; malignant histiocytosis; Hodgkin's disease; immunoproliferative small intestinal disease; non-Hodgkin's lymphoma; T-cell lymphoma, B-cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, plasmacytoma; reticuloendotheliosis; melanoma; chondroblastoma; chondroma; chondrosarcoma; fibroma; fibrosarcoma; giant cell tumor; histiocytoma; lipoma; liposarcoma; mesothelioma; myxoma; myxosarcoma; osteoma; osteosarcoma; chordoma; craniopharyngioma; dysgerminoma; hamartoma; mesenchymoma; mesonephroma; sarcoma; ameloblastoma; cementoma; odontoma; teratoma; thymoma; trophoblastic tumor.
[0148]
[0149] Other cancers that can be treated using the compounds of the present invention include, but are not limited to, adenoma; cholangiocarcinoma; cholesteatoma; cystinoma; cystadenoma; granulosa cell tumor; hemispheric ovarian tumor; hepatocarcinoma; hidradenoma; islet cell tumor; Leydig cell tumor; papilloma; Sertoli cell tumor; theca cell tumor; leiomyoma; leiomyosarcoma; myoblastoma; myoma; myosarcoma; rhabdomyoma; rhabdomyosarcoma; ependymoma; ganglioneuroma; glioma; medulloblastoma; meningioma; neurilemmoma; neuroblastoma; neuroepithelioma; neurofibroma; neuroma; paraganglioma; nonchromaffin paraganglioma.
[0149]
[0150] In one embodiment, the compounds of the invention are candidate therapeutic agents for treating cancer, such as angiokeratoma; angiolymphocytosis with eosinophilia; angiosclerosis; angiomatosis; glomus angiomatosis; hemangioendothelioma; hemangioma; hemangiopericytoma; angiosarcoma; lymphangioma; lymphangioleiomyoma; lymphangiosarcoma; pinealoma; carcinosarcoma; chondrosarcoma; cystosarcoma phyllodes; fibrosarcoma; angiosarcoma; leiomyosarcoma; leukemia; liposarcoma; lymphangiosarcoma; myxosarcoma; ovarian cancer; rhabdomyosarcoma; sarcoma; neoplasms; neurofibromatosis; and cervical dysplasia.
[0150]
[0151] In certain embodiments, the present disclosure provides methods for treating solid tumors, colon cancer, rectal cancer, colorectal cancer, bladder cancer, gastric cancer, esophageal cancer, head and neck cancer, myelodysplastic syndrome, brain cancer, CNS cancer, malignant glioma, glioblastoma, hepatocellular carcinoma, hepatocellular carcinoma, thyroid cancer, lung cancer, non-small cell lung cancer, blood cancer, acute and chronic leukemia, B-cell lymphoma, Waldenstrom's macroglobulinemia, T-cell lymphoma, hairy cell lymphoma, diffuse large B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, pancreatic cancer, melanoma, myeloma, multiple myeloma, pancreatic cancer, renal cell carcinoma, renal cancer, cervical cancer, urothelial cancer, prostate cancer, castration-resistant prostate cancer, ovarian cancer, breast cancer, triple-negative breast cancer, hormone receptor-positive breast cancer, or HER2+ breast cancer. According to such methods, a therapeutically effective amount of at least one compound according to Formula I, II, III, IV, V, and VI, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, may be administered to a subject diagnosed with a cell proliferative disorder, such as cancer. Alternatively, a pharmaceutical composition comprising at least one compound according to Formula I, II, III, IV, V, and VI, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, may be administered to a subject diagnosed with cancer.
[0151]
[0152] In certain embodiments, the compounds according to the present invention are administered to a subject with cancer in combination with other conventional cancer therapies, such as radiation therapy or surgery. Radiation therapy is well known in the art and includes X-ray therapy, e.g., gamma irradiation, and radiopharmaceutical therapy.
[0152]
[0153] In certain embodiments, the eIF4E inhibitor compound of the present invention is used together with at least one anti-cancer drug.Anticancer drugs include chemotherapeutic drugs.Chemotherapeutic drugs include but are not limited to chromatin function inhibitors, topoisomerase inhibitors, microtubule inhibitors, DNA damage agents, metabolic antagonists (for example, folic acid antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs), DNA synthesis inhibitors, DNA interaction agents (for example, intercalating agents), and DNA repair inhibitors.
[0153]
[0154] Exemplary chemotherapeutic agents include, but are not limited to, the following groups: metabolite antagonists / anticancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine, and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin, and 2-chlorodeoxyadenosine (cladribine)); antiproliferative / antimitotic agents, including natural products, such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disrupting agents, such as tachycardia, thiazolinone ... San (paclitaxel, docetaxel), vincristine, vinblastine, nocodazole, epothilon and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamine, oxaliplatin, ifosfamide, melphalan, mercury) etamine, mitomycin, mitoxantrone, nitrosoureas, plicamycin, procarbazine, taxol, taxotere, temozolamide, teniposide, triethylenethiophosphoramide, and etoposide (VP16); antibiotics, such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycin, plicamycin (mithramycin), and mitomycin; enzymes (which metabolize L-asparagine systemically) , L-asparaginase, which deprives cells of the ability to synthesize asparagine on their own; antiplatelet agents; antiproliferative / antimitotic alkylating agents, such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkylsulfonates-busulfans, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC);Antiproliferative / antimitotic antimetabolites, e.g., folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotein, aminoglutethimide; hormones, hormone analogs (estrogens, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinogenolytic agents (e.g., tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (vleveldin); immunosuppressants (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); antiangiogenic compounds (TNP470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FG) inhibitors) F) inhibitors); angiotensin receptor blockers; nitric oxide donors; antisense oligonucleotides; antibodies (trastuzumab, rituximab); chimeric antigen receptors; cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-11) and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prenisolone); growth factor signaling kinase inhibitors; mitochondrial dysfunction inducers, toxins such as cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase activators; and chromatin disrupting agents.
[0154]
[0155] In certain embodiments, additional therapeutic agents that may be used in combination with eIF4E inhibitors are inhibitors of immune suppressive components, such as immune checkpoint molecules or genes, metabolic enzymes, immune suppressive cytokines, T reg The term "immunosuppressive component" as used herein refers to one or more cells, proteins, molecules, compounds, or complexes that provide inhibitory signals to assist in regulating or suppressing immune responses. For example, immunosuppressive components include molecules that partially or completely block immune stimulation; reduce, prevent, or delay immune activation; or increase, activate, or upregulate immune suppression. "Regulating or suppressing an immune response" as used herein refers to reducing any one or more of antigen presentation, T cell activation, T cell proliferation, T cell effector function, cytokine secretion or production, and target cell lysis. Such modulation, regulation, or suppression may promote or enable the persistence of hyperproliferative diseases or disorders (e.g., cancer, chronic infectious diseases).
[0155]
[0156] Immune checkpoint molecules include immune checkpoint ligands such as PD-L1, PD-L2, CD80, CD86, B7-H3, B7-H4, HVEM, adenosine, GAL9, VISTA, CEACAM-1, CEACAM-3, CEACAM-5, and PVRL2, and immune checkpoint receptors such as PD-1, CTLA-4, BTLA, KIR, LAG3, TIM3, A2aR, CD244 / 2B4, CD160, TIGIT, LAIR-1, and PVRIG / CD112R. Metabolic enzymes include arginase and indoleamine 2,3-dioxygenase (IDO). Immunosuppressive cytokines include IL-10, IL-4, IL-1RA, and IL-35. In certain embodiments, the inhibitor of the immunosuppressive component is a small molecule, an antisense molecule, a ribozyme, an RNAi molecule (e.g., siRNA), an antibody or antigen-binding fragment thereof, or a fusion polypeptide (e.g., an Fc fusion protein).
[0156]
[0157] The antibody specific for PD-1 may be pidilizumab, nivolumab, pembrolizumab, MEDI0680 (formerly AMP-514), AMP-224, or BMS-936558.
[0157]
[0158] The PD-L1-specific antibody may be MDX-1105 (BMS-936559), durvalumab (formerly MEDI4736), atezolizumab (formerly MPDL3280A), or avelumab (formerly MSB0010718C). The PD-L1-specific compound may be BMS-1001 or BMS-1166.
[0158]
[0159] The CTLA4 inhibitor may be a CTLA4-specific antibody, such as tremelimumab or ipilimumab, or a CTLA4-Ig fusion protein (eg, abatacept, belatacept).
[0159]
[0160] The LAG3 inhibitor may be LAG525, IMP321, IMP701, 9H12, or BMS-986016.
[0161] The IDO inhibitor may be levo-1-methyltryptophan, epacadostat (INCB024360; Liu et al., Blood 115:3520-30, 2010), ebselen (Terentis et al., Biochem. 49:591-600, 2010), indoximod, NLG919 (Mautino et al., American Association for Cancer Research 104th Annual Meeting 2013; Apr 6-10, 2013), 1-methyl-tryptophan (1-MT)-tirapazamine, or any combination thereof.
[0160]
[0162] In certain embodiments, an eIF4E inhibitor according to the present invention is used together with an additional agent as part of a combination therapy regimen, either simultaneously, in the same formulation or in separate formulations, or sequentially.
[0161]
[0163] The eIF4E inhibitors according to Formula I, II, III, IV, V, and VI, including their corresponding salts, and pharmaceutically acceptable compositions of the compounds of Formula I, II, III, IV, V, and VI, are also effective as therapeutic agents for treating or preventing cytokine-mediated disorders, such as inflammation, in patients, preferably humans. In one embodiment, a compound or composition according to the invention is particularly useful for treating or preventing a disease selected from chronic or acute inflammation, chronic inflammatory arthritis, rheumatoid arthritis, psoriasis, COPD, inflammatory bowel disease, septic shock, Crohn's disease, ulcerative colitis, multiple sclerosis, and asthma.
[0162]
[0164] The compounds of the present invention, their corresponding salts, and pharmaceutically acceptable compositions are candidate therapeutic agents for treating brain-related disorders, including, but not limited to, autism, fragile X syndrome, Parkinson's disease, and Alzheimer's disease. Treatment is achieved by administering to a subject in need of treatment a compound of Formula I, II, III, IV, V, or VI, a pharmaceutically acceptable salt form thereof, or a pharmaceutically acceptable composition of a compound of Formula I, II, III, IV, V, or VI or a salt thereof.
[0163]
[0165] The present invention also supports the use of the compounds of the present invention or pharmaceutically acceptable formulations of the compounds of the present invention as inhibitors of eIF4E activity, such inhibition being achieved by contacting a cell expressing eIF4E with the compound or a pharmaceutically acceptable formulation to reduce or inhibit eIF4E activity and provide therapeutic benefit for an eIF4E-dependent condition in a mammal in need thereof.
[0164]
[0166] A therapeutically effective dosage of a compound according to Formula I, II, III, IV, V, and VI, or a composition comprising a compound of Formula I, II, III, IV, V, and VI, will generally be in the range of about 1 to 2000 mg / day, about 10 to about 1000 mg / day, about 10 to about 500 mg / day, about 10 to about 250 mg / day, about 10 to about 100 mg / day, or about 10 to about 50 mg / day. A therapeutically effective dosage may be administered in one or more doses. However, it will be understood that the specific dose of a compound of the present invention for any particular patient will depend on a variety of factors, such as age, sex, weight, general health, diet, the individual response of the patient being treated, the time of administration, the severity of the disease being treated, the activity of the particular compound being applied, the dosage form, the mode of application, and any concomitant medications. The therapeutically effective amount for a given situation will be readily determined by routine experimentation and is within the skill and judgment of an ordinary clinician or physician. In any event, the compound or composition will be administered in a dosage and manner that allows for delivery of a therapeutically effective amount based on the patient's unique condition.
[0165] General methods for synthesizing compounds
[0167] The compounds described in this disclosure have the left and right sides shown below with respect to formula (II):
[0166] [ka]
[0167]
[0168] In general, the compounds described in this disclosure may be synthesized by constructing a left side and a right side and coupling them together, as described in the general method below. Many of the reactions performed on the left side prior to coupling, such as cyanation, may be postponed until after coupling is complete. Similarly, some of the reactions listed in the post-coupling protocol may be performed prior to the coupling reaction to achieve the same results. [Example]
[0168] Example 1. General Method for the Synthesis of 7-Aza-thienylpyridine and Derivative Compounds
[0169] The 7-aza-thienylpyridine compounds in Table 1 can be synthesized using the methods described in Example 1. For some compounds, the compounds can be prepared using some of the reactions described in Example 2 and / or Example 3 below.
[0169] Example 1A. Method for synthesizing the left side Example 1A.1
[0170] [ka]
[0171] To dry N-isopropylpropan-2-amine (1.2 equivalents) in THF (0.3 M) is slowly added n-butyllithium (2.5 M in hexane) (1.2 equivalents) at 0° C., and the mixture is stirred for 10 minutes. The LDA solution in THF is used directly. To a solution of 3-bromo-2-chloro-5-fluoro-pyridine (A, 1 equivalent) in THF (0.3 M) is added the LDA solution at −78° C., and the resulting dark mixture is stirred for 45 minutes. Chloro(trimethyl)silane (1.7 equivalents) is added, and the mixture is allowed to warm to room temperature within approximately 15 hours. The reaction mixture is quenched with water, the layers are separated, and the aqueous layer is extracted with ethyl acetate. The organic layers are combined, evaporated onto silica gel, and loaded onto a column of mobile silica gel. (3-bromo-2-chloro-5-fluoro-6-methyl-4-pyridyl)-trimethyl-silane (B) is purified by silica gel chromatography.
[0172] To a solution of (3-bromo-2-chloro-5-fluoro-4-pyridyl)-trimethyl-silane (B, 1 equivalent) in THF (0.25 M) at −78° C., the LDA solution (1.2 equivalents) prepared above is added, and the resulting dark mixture is stirred for 45 minutes. Iodomethane (10 equivalents) is added, and the mixture is allowed to warm to room temperature within approximately 15 hours. The reaction mixture is quenched with water, the layers are separated, and the aqueous layer is further extracted with ethyl acetate. The organic layers are combined, evaporated onto silica gel, and the mobile silica gel is loaded into a column, and (3-bromo-2-chloro-5-fluoro-6-methyl-4-pyridyl)-trimethyl-silane (C) is purified via silica gel chromatography.
[0173] (3-Bromo-2-chloro-5-fluoro-6-methyl-4-pyridyl)-trimethyl-silane (C, 1 eq.) is dissolved in THF (0.67 M) and cooled to 0° C. Tetrabutylammonium fluoride (in THF) (1.2 eq.) is added and the mixture is stirred at 0° C. After 10 min, the reaction is quenched with NH4Cl(aq) and diluted with EtOAc. The organic layer is washed twice with water, dried, filtered, concentrated, loaded onto a column, and 3-bromo-2-chloro-5-fluoro-6-methylpyridine (D) is purified via silica gel chromatography.
[0174] Example 1A.2
[0175] [ka]
[0176] To a solution of 3-bromo-2-chloro-5-fluoro-6-methylpyridine (A, 1 equivalent) in tetrahydrofuran (0.40 M) at −96° C. (internal temperature), lithium diisopropylamide solution (1.2 equivalents; 2 M in tetrahydrofuran) is added over a period of 60 minutes, maintaining an internal temperature of −96 to −84° C. The reaction mixture is then heated at −96 to −90° C. for 2 hours. Carbon dioxide gas is purged into the reaction mixture for 35 minutes, maintaining an internal temperature of −95 to −78° C. The progress of the reaction is monitored by TLC, and the reaction mixture is warmed to −50 to −45° C., quenched with saturated aqueous ammonium chloride, and stirred for 10 minutes. The solution is acidified to pH 2.0-1.5 with 6 N hydrochloric acid, diluted with ethyl acetate, and the organic layer is washed with water. The aqueous layer is extracted with ethyl acetate, and the combined organic layers are concentrated under reduced pressure, stirred in dichloromethane, and the precipitated solid is filtered, washed with dichloromethane, and dried under vacuum to give 3-bromo-2-chloro-5-fluoro-6-methylisonicotinic acid (B).
[0177] To a solution of 3-bromo-2-chloro-5-fluoro-6-methylisonicotinic acid (B, 1 equivalent) in N,N-dimethylformamide (0.32 M) is added acetamidine hydrochloride (C, 1.4 equivalents), and the reaction mixture is cooled to 0° C. N,N-diisopropylethylamine (5 equivalents) and HATU (1.1 equivalents) are added, and the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is diluted with water, extracted with ethyl acetate, and the combined organic layers are dried over anhydrous sodium sulfate, filtered, and concentrated to give 3-bromo-2-chloro-5-fluoro-N-(1-iminoethyl)-6-methylisonicotinamide (D).
[0178] To a stirred solution of 3-bromo-2-chloro-5-fluoro-N-(1-iminoethyl)-6-methylisonicotinamide (D, 1 equivalent) in tetrahydrofuran (2 M) is added sodium hydride (60%) (1 equivalent) at 0° C. and stirred at 0° C. for 1 hour. The reaction is allowed to warm slowly to room temperature and stirred for 16 hours. The reaction is cooled to 0° C., acidified with 2 N hydrochloric acid (pH ∼2), and the resulting solid is filtered, washed with 10% methanol in diethyl ether, and dried to give 5-bromo-6-chloro-2,8-dimethylpyrido[3,4-d]pyrimidin-4(3H)-one (E).
[0179] To a stirred solution of 5-bromo-6-chloro-2,8-dimethylpyrido[3,4-d]pyrimidin-4(3H)-one (E, 1 equivalent) in N,N-dimethylformamide (0.056 M) is added copper(I) cyanide (1.2 equivalents) at room temperature. The reaction is heated to 100° C. and stirred for 16 hours. The reaction is quenched with 1N hydrochloric acid, and the solid is filtered, washed with diethyl ether, and purified by chromatography to give 6-chloro-2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (F).
[0180] 5-Bromo-6-chloro-2,8-dimethylpyrido[3,4-d]pyrimidin-4(3H)-one (E, 1 equivalent), copper(I) cyanide (1.2 equivalents), and NMP (0.072 M) are combined in a sealable vessel equipped with a stir bar. The resulting mixture is sealed, stirred, and heated at 90° C. for 20 hours. Upon cooling to room temperature, the reaction mixture is diluted with 1% TFA in acetonitrile, filtered, and purified via chromatography to give 6-chloro-2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (F).
[0181] To a solution of 5-bromo-6-chloro-2,8-dimethylpyrido[3,4-d]pyrimidin-4(3H)-one (E, 1 equivalent) in N,N-dimethylacetamide (0.07 M) is added dicyanozinc (1.4 equivalents) and tetrakis(triphenylphosphine)palladium (2.0 equivalents) at room temperature. The mixture is degassed with argon for 5 minutes and stirred at 130°C for 5 hours. After cooling to room temperature, the mixture is diluted with dimethyl sulfoxide and acetonitrile and purified by chromatography to give 6-chloro-2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (F).
[0182] Example 1A.3
[0183] [ka]
[0184] A solution of 6-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (A, 1 equivalent) in dimethyl sulfoxide (0.23 M) is purged with argon gas for 10 minutes. 18-Crown-6 ether (1.5 equivalents) and potassium fluoride (5 equivalents) are added to the reaction mixture, purging is continued for 5 minutes, and the mixture is stirred in a preheated oil bath at 160° C. for 2 hours. The reaction mixture is cooled, poured onto ice water, extracted with ethyl acetate, and the ethyl acetate layer is washed with brine, dried over anhydrous sodium sulfate, concentrated, and triturated with diethyl ether to give 6-fluoro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (B).
[0185] Example 1A.4
[0186] [ka]
[0187] To a solution of tert-butyl methyl(piperidin-4-yl)carbamate (A, 1 equivalent) and N,N-diisopropylethylamine (10 equivalents) in acetonitrile (0.35 M), 2,2,2-trifluoroethyl trifluoromethanesulfonate (2, 1.25 equivalents) is added dropwise, and the mixture is stirred at room temperature for 16 hours. The reaction mixture is diluted with water and extracted with dichloromethane, and the organic layer is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography to give tert-butyl methyl(1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbamate (C).
[0188] A solution of tert-butylmethyl(1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbamate (C, 1 equivalent) in hydrochloride (4M solution in 1,4-dioxane, 0.34 M) is stirred at room temperature for 4 hours. The reaction mixture is concentrated to give N-methyl-1-(2,2,2-trifluoroethyl)piperidin-4-amine hydrochloride (D).
[0189] To a solution of 6-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (E, 1 equivalent) and N-methyl-1-(2,2,2-trifluoroethyl)piperidin-4-amine hydrochloride (D, 3 equivalents) in N,N-dimethylacetamide (0.24 M) was added potassium fluoride (8 equivalents) and 18-crown-6 (1 equivalent), and the reaction mixture was heated at 130° C. for 16 hours. The reaction mixture was cooled, diluted with water, extracted with ethyl acetate, and the organic layer was washed with water, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography to give 2-methyl-6-(methyl(1-(2,2,2-trifluoroethyl)piperidin-4-yl)amino)-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (F).
[0190] Example 1A.5
[0191] [ka]
[0192] 1,4-Dioxane (24 mL) and water (8 mL) are added to a mixture of 2,3-dibromo-5-fluoropyridine (A, 3000 mg, 11.8 mmol), cyclopropylboronic acid (1112 mg, 12.9 mmol), and cesium carbonate (8436 mg, 25.9 mmol). The mixture is bubbled with argon for 5 minutes. Tetrakis(triphenylphosphine)palladium (680 mg, 0.590 mmol) is added to the mixture, and the mixture is evacuated and refilled with argon three times. The resulting clear yellow reaction mixture is stirred at 110° C. for 72 hours. The mixture is diluted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (0 to 5% ethyl acetate in hexane) affords 3-bromo-2-cyclopropyl-5-fluoropyridine (B).
[0193] n-Butyllithium (2.5 M in hexanes, 2.1 mL, 5.30 mmol) is added to a stirred solution of diisopropylamine (0.81 mL, 5.80 mmol) in THF (5 mL) under argon at 0° C. The resulting pale yellow solution is stirred at 0° C. for 10 minutes and then slowly added to a stirred solution of 3-bromo-2-cyclopropyl-5-fluoropyridine (B, 1000 mg, 4.60 mmol) in tetrahydrofuran (20 mL) at −78° C. under argon. The resulting yellow reaction mixture is stirred at −78° C. for 30 minutes under argon, then carbon dioxide gas is bubbled through for 2 minutes. The mixture is stirred at −78° C. for 10 minutes and then allowed to warm to room temperature over 5 minutes. The reaction is diluted with 0.1 N sodium hydroxide and extracted with diethyl ether. The aqueous layer is acidified with 3M hydrogen chloride, extracted twice with ethyl acetate, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to give 3-bromo-2-cyclopropyl-5-fluoroisonicotinic acid (C).
[0194] To a solution of 3-bromo-2-cyclopropyl-5-fluoroisonicotinic acid (C, 730 mg, 2.81 mmol) in N,N-dimethylformamide (14 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (1387 mg, 3.60 mmol) and N,N-diisopropylethylamine (2 mL, 11.2 mmol) at 0° C. The mixture was stirred at room temperature for 5 minutes, and acetamidine hydrochloride (D, 345 mg, 3.60 mmol) was added to the mixture. After stirring the mixture at room temperature for 17 hours, ice-cold water was added to the mixture, and the mixture was extracted twice with ethyl acetate. The combined extracts were washed with aqueous ammonium chloride, aqueous sodium bicarbonate, and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue is dissolved in tetrahydrofuran (18 mL), and sodium hydride (60% in mineral oil, 225 mg, 5.60 mmol) is added to the mixture at 0° C. After stirring the mixture for 18 hours, ice-cold water is added to the mixture, and the mixture is extracted three times with ethyl acetate, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue is triturated with dichloromethane and filtered to give 5-bromo-6-cyclopropyl-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (E).
[0195] Example 1A.6
[0196] [ka]
[0197] To a solution of ethyl 3-amino-6-chloro-5-cyano-2-methylisonicotinate (A, 0.90 g, 3.75 mmol) in 1,4-dioxane and water (4:1, 10.0 mL) was added phenylboronic acid (B, 0.68 g, 5.62 mmol) and potassium carbonate (1.53 g, 11.25 mmol). The reaction mixture was purged with argon for 5 minutes. [1,1-bis(diphenylphospino)ferrocene]dichloropalladium(II) (dichloromethane complex, 0.031 g, 0.037 mmol) was then added, and the reaction mixture was heated at 90° C. for 5 hours. After this time, the reaction mixture was cooled, diluted with water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. This is purified by silica gel (100-200 mesh) column chromatography using 30-40% ethyl acetate in hexane to give ethyl 3-amino-5-cyano-2-methyl-6-phenylisonicotinate (C).
[0198] To a solution of ethyl 3-amino-5-cyano-2-methyl-6-phenylisonicotinate (C, 0.6 g, 2.13 mmol) in tetrahydrofuran and water (4:1, 6 mL) at room temperature, lithium hydroxide (0.44 g, 10.67 mmol) is added. The reaction mixture is stirred at room temperature for 2 hours. After this time, the reaction mixture is diluted with water, acidified with 1N hydrochloric acid, and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which is washed with diethyl ether to give 3-amino-5-cyano-2-methyl-6-phenylisonicotinic acid (D).
[0199] To a solution of 3-amino-5-cyano-2-methyl-6-phenylisonicotinic acid (D, 0.5 g, 1.97 mmol) in N,N-dimethylformamide (5.0 mL) was added ammonium chloride (0.31 g, 5.92 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.840 g, 2.21 mmol). The reaction mixture was cooled to 0° C., N,N-diisopropylethylamine (2.7 mL, 14.70 mmol) was added, and the reaction mixture was stirred at 0° C. for 10 minutes. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. This is purified by silica gel (100-200 mesh) column chromatography using 30-40% ethyl acetate in hexane to give 3-amino-5-cyano-2-methyl-6-phenylisonicotinamide (E).
[0200] A solution of 3-amino-5-cyano-2-methyl-6-phenylisonicotinamide (E, 0.4 g, 1.19 mmol) in triethyl orthoacetate and acetic acid (4:1, 4 mL) is heated in a microwave at 130° C. for 2 hours. After this time, the reaction mixture is cooled, diluted with hexane, and filtered to give 2,8-dimethyl-4-oxo-6-phenyl-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (F).
[0201] Example 1A.7
[0202] [ka]
[0203] To a stirred mixture of 3-chloro-5-fluoroisonicotinic acid (A, 1 equivalent) in diethyl carbonate (0.29 M) and water (0.44 M) under argon, sodium 4,4-difluorocyclohexane-1-sulfinate (B, 3 equivalents) is added and the mixture is cooled to 0° C. tert-Butyl hydroperoxide (70% by weight in water) (10 equivalents) is added, and the mixture is stirred for 5 minutes, then heated under argon using an oil bath at 90° C. for 3 hours. Volatiles are removed on a rotary evaporator. The residue is dissolved in a mixture of water, acetonitrile, and TFA, filtered, and purified via preparative HPLC to give a mixture of 3-chloro-2-(4,4-difluorocyclohexyl)-5-fluoroisonicotinic acid (C) and 5-chloro-2-(4,4-difluorocyclohexyl)-3-fluoroisonicotinic acid (D).
[0204] HATU (1.1 equivalents) is added to a stirred solution of 3-chloro-2-(4,4-difluorocyclohexyl)-5-fluoroisonicotinic acid (C) and 5-chloro-2-(4,4-difluorocyclohexyl)-3-fluoroisonicotinic acid (D, 1 equivalent) in DMF (0.46 M) at room temperature under argon. After 2 minutes, N,N-diisopropylethylamine (1.1 equivalents) is added. After stirring for 35 minutes at room temperature, a solution of acetamidine hydrochloride (2 equivalents) and N,N-diisopropylethylamine (2.2 equivalents) in DMF (5.6 M) is added (heated with a heat gun and sonicated to dissolve all of the acetamidine). The resulting solution is stirred vigorously at room temperature under argon for 1.5 hours. The reaction mixture is diluted with ethyl acetate and washed three times with brine. The organics are dried over magnesium sulfate, filtered, concentrated on a rotary evaporator, and dried under high vacuum to give an amber viscous oil. The oil is dissolved in THF (0.046 M) with stirring under argon. Sodium hydride (2.2 equiv.) is added, and the reaction mixture is stirred vigorously at room temperature under argon for 21 hours. A solution of ammonium chloride (5 equiv.) in water (0.14 M) is added with vigorous stirring. The resulting mixture is partitioned between ethyl acetate and brine. The organics are dried over magnesium sulfate, filtered, and concentrated on a rotary evaporator. The residue is dissolved in NMP, acetonitrile, and TFA, filtered, and purified via preparative HPLC to give 5-chloro-6-(4,4-difluorocyclohexyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (E) and 5-chloro-8-(4,4-difluorocyclohexyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (F).
[0205] Example 1A.8
[0206] [ka]
[0207] 4-Methoxybenzyl chloride (1.27 mL, 9.38 mmol) is added to a stirred mixture of 5-bromo-6-chloro-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (A, 1.98 g, 7.21 mmol) and cesium carbonate (3.29 g, 10.1 mmol) in DMA (14 mL) at room temperature under argon. The resulting mixture is stirred vigorously and heated at 50° C. under argon for 2 hours. The reaction mixture is diluted with ethyl acetate (1.5 L) and washed once with water and twice with brine. Dry the organics over magnesium sulfate, filter, concentrate on silica gel and rotary evaporator, and purify via silica gel chromatography (0-40% ethyl acetate in dichloromethane) to obtain 5-bromo-6-chloro-3-(4-methoxybenzyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (B).
[0208] 5-Bromo-6-chloro-3-(4-methoxybenzyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (B, 1.24 g, 3.14 mmol) is dissolved in DMF (20 mL) with stirring at 90° C. under argon. Copper(I) cyanide (338 mg, 3.77 mmol) is added, and the resulting clear red solution is stirred and heated at 90° C. under argon for 1 hour and 40 minutes. The hot reaction mixture is diluted with ethyl acetate and filtered through Celite into ethyl acetate (600 mL). The filter cake is washed with ethyl acetate. The filtrate is shaken with water to give an emulsion, which is filtered. The filtrate is partitioned between ethyl acetate and brine. Wash the organics twice with brine, dry over magnesium sulfate, filter, concentrate on silica gel and rotary evaporator, and purify via silica gel chromatography (0 to 100% ethyl acetate in dichloromethane) to obtain 6-chloro-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (C).
[0209] 6-Chloro-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (C, 100 mg, 0.293 mmol), 1-(2-fluoroethyl)piperazine bisHCl salt (D, 120 mg, 0.587 mmol), potassium carbonate (183 mg, 1.32 mmol), and NMP (1.5 mL) were combined in a sealable container with a stir bar. The resulting mixture was sealed, stirred vigorously, and heated to 70° C. in an oil bath for 40 minutes. N,N-Diisopropylethylamine (0.26 mL, 1.47 mmol) was added, and the resulting mixture was sealed, stirred vigorously, and heated to 100° C. in an oil bath for 1 hour. After cooling to room temperature, the reaction mixture was diluted with methanol and acetic acid (0.34 mL, 5.87 mmol). The resulting mixture is filtered and purified via preparative HPLC (10–45% acetonitrile in water with 0.1% TFA). Fractions containing the desired product are combined, concentrated to approximately 20 mL on a rotary evaporator, and then lyophilized to yield a yellow oil. The oil is dissolved in acetonitrile and loaded onto a 2-gram Strata XC ion-exchange column from Phenomenex. The column is washed sequentially with water, acetonitrile, methanol, and then 5% ammonium hydroxide in methanol. The eluate containing the desired product is concentrated on a rotary evaporator and dried under high vacuum to yield 6-(4-(2-fluoroethyl)piperazin-1-yl)-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (E).
[0210] To a stirred mixture of 6-(4-(2-fluoroethyl)piperazin-1-yl)-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (E, 28.2 mg, 0.065 mmol) in diethyl carbonate (0.4 mL) and water (0.2 mL), bis((isopropylsulfinyl)oxy)zinc (F, 54.2 mg, 0.194 mmol) was added, followed by tert-butyl hydroperoxide (70 wt % in water) (0.092 mL, 0.666 mmol) under argon. The mixture was stirred and heated under argon at 90°C using an oil bath for 10 min. The reaction mixture was diluted with NMP, acetic acid, and methanol, filtered, and purified via preparative HPLC (15-65% acetonitrile in water with 0.1% TFA). The fractions containing the desired product are loaded onto a Phenomenex Strata XC ion exchange column. The column is washed sequentially with water, acetonitrile, methanol, and then 5% ammonium hydroxide in methanol. The eluate containing the desired product is concentrated on a rotary evaporator and dried under high vacuum to give 6-(4-(2-fluoroethyl)piperazin-1-yl)-8-isopropyl-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (G).
[0211] 6-(4-(2-Fluoroethyl)piperazin-1-yl)-8-isopropyl-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (G, 23.8 mg, 0.050 mmol), TFA (2 mL), and water (0.1 mL) are combined in a sealable container with a stir bar, sealed, stirred, and heated at 70 °C for 1 h. Volatiles are removed on a rotary evaporator. The residue is dissolved in NMP and methanol, filtered, and purified via preparative HPLC (10–40% acetonitrile in water with 0.1% TFA). Fractions containing the desired product are loaded onto a Phenomenex Strata XC ion-exchange column. The column is washed sequentially with water, acetonitrile, methanol, and then 5% ammonium hydroxide in methanol. The eluate containing the desired product is concentrated on a rotary evaporator and dried under high vacuum to give 6-(4-(2-fluoroethyl)piperazin-1-yl)-8-isopropyl-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (H).
[0212] Example 1A.9
[0213] [ka]
[0214] To a solution of 6-chloro-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (A, 192 mg, 0.560 mmol) in 1,4-dioxane (5.6 mL), 1-(2,2,2-trifluoroethyl)piperidin-4-ol (B, 206 mg, 1.13 mmol), cesium carbonate (367 mg, 1.13 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (105 mg, 0.169 mmol), and tris(dibenzylideneacetone)dipalladium (103 mg, 0.113 mmol) were added at room temperature. Argon was bubbled through the mixture for 5 minutes and the mixture was stirred at 100°C for 2 hours. The mixture is diluted with ethyl acetate and filtered through a Celite pad. The filtrate is concentrated in vacuo. Purification by silica gel column chromatography (0 to 80% ethyl acetate in hexanes) gives crude 3-(4-methoxybenzyl)-2-methyl-4-oxo-6-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)oxy)-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (C).
[0215] Example 1A.10
[0216] [ka]
[0217] To a solution of 6-chloro-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (1, 134 mg, 0.390 mmol) in 1,4-dioxane (3.9 mL) was added phenylmethanethiol (1a, 0.09 mL, 0.790 mmol), cesium carbonate (256 mg, 0.790 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (73 mg, 0.118 mmol), and tris(dibenzylideneacetone)dipalladium (72 mg, 0.0790 mmol) at room temperature. Argon was bubbled through the mixture for 5 minutes and the mixture was stirred at 100°C for 2 hours. The mixture is diluted with ethyl acetate, washed with 5% bleach in water, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. 18 Purification by column chromatography (15-85% acetonitrile in water + 0.1% trifluoroacetic acid) affords 6-(benzylthio)-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (2).
[0218] To a solution of 6-(benzylthio)-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (2, 74 mg, 0.173 mmol) in dichloromethane (2 mL) and water (0.4 mL) was added sulfuryl chloride (0.1 mL, 1.21 mmol) at 0° C. The mixture was stirred at room temperature for 1 hour. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give crude 5-cyano-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-6-sulfonyl chloride (3).
[0219] To a solution of 5-cyano-3-(4-methoxybenzyl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-6-sulfonyl chloride (3, 70 mg, 0.173 mmol) in dichloromethane (1.7 mL) was added 1-methylpiperazine (0.06 mL, 0.520 mmol) and diisopropylethylamine (0.09 mL, 0.520 mmol) at 0° C. After stirring the mixture at room temperature for 1 hour, the mixture was diluted with aqueous sodium bicarbonate. The organic material was extracted twice with ethyl acetate, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Preparative HPLC (C 18 Purification by column chromatography (15-60% acetonitrile in water + 0.1% trifluoroacetic acid) affords 3-(4-methoxybenzyl)-2-methyl-6-((4-methylpiperazin-1-yl)sulfonyl)-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (4).
[0220] Example 1A.11
[0221] [ka]
[0222] A solution of 5-bromo-2-chloro-3-fluoropyridine (1, 30.0 g, 143.6 mmol) in tetrahydrofuran (300 mL) is cooled to −78° C., and lithium diisopropylamide (2 M in THF, 78.9 mL, 157.9 mmol) is added dropwise. The reaction mixture is stirred at −78° C. for 1 hour. The reaction mixture is then purged with carbon dioxide gas for 15 minutes and allowed to warm to room temperature. The reaction mixture is quenched with ammonium chloride solution and diluted with water. The aqueous layer is washed with ethyl acetate, acidified with 6N hydrochloric acid solution, and extracted with 15% methanol in dichloromethane. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give 5-bromo-2-chloro-3-fluoroisonicotinic acid (2).
[0223] To a solution of 5-bromo-2-chloro-3-fluoroisonicotinic acid (2, 18.0 g, 71.1 mmol) in N,N-dimethylformamide (30 mL) was added acetamidine hydrochloride (2a, 13.4 g, 142.3 mmol) at 0° C. N,N-diisopropylethylamine (110 mL, 711.0 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (40.5 g, 106.6 mmol) were then added, and the reaction mixture was stirred at room temperature for 2 hours. After this time, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give crude 5-bromo-2-chloro-3-fluoro-N-(1-iminoethyl)isonicotinamide (3).
[0224] A solution of crude 5-bromo-2-chloro-3-fluoro-N-(1-iminoethyl)isonicotinamide (3, 18.0 g) in tetrahydrofuran (200 mL) is cooled to 0° C., and then 60% sodium hydride in mineral oil (7.30 g, NaH, 184.3 mmol) is added portionwise, and the reaction mixture is stirred at room temperature for 12 hours. After this time, the reaction mixture is poured into ice-cold water. The aqueous layer is washed with 5% methanol in dichloromethane, acidified with 6N hydrochloric acid solution, and extracted with 10% methanol in dichloromethane. The organic layer from this extraction is dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which is washed with diethyl ether to give 5-bromo-8-chloro-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (4).
[0225] To a solution of 5-bromo-8-chloro-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (4, 8.0 g, 29.3 mmol) in N,N-dimethylformamide (80.0 mL) is added copper(I) cyanide (4.1 g, 46.8 mmol). The reaction mixture is heated at 90°C for 3 hours. After this time, the reaction mixture is cooled, diluted with water, acidified with 6N hydrochloric acid solution, and extracted with ethyl acetate. The organic layer is concentrated to give the crude product, which is purified by silica gel (100-200 mesh) column chromatography using 40-50% ethyl acetate in hexane as the eluent to give 8-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (5).
[0226] To a solution of 8-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (5, 1.0 g, 4.55 mmol) in 1,4-dioxane (15.0 mL) was added 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (5a, 1.0 mL, 7.5 mmol), potassium carbonate (2.0 g, 15.0 mmol), and water (2 mL) at room temperature. The reaction mixture was degassed with nitrogen for 10 minutes. Then, [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane complex (0.183 g, 0.225 mmol) was added, and the reaction mixture was heated at 95° C. for 12 hours. After this time, the reaction mixture is cooled and concentrated under reduced pressure to give the crude product, which is purified by silica gel (100-200 mesh) column chromatography using 10% methanol in dichloromethane as the eluent to give 2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (6).
[0227] Example 1A.12
[0228] [ka]
[0229] Diethylaminosulfur trifluoride (1.44 mL, 10.4 mmol) is added to a stirred solution of 5-bromo-3-fluoropicolinaldehyde (1, 0.97 g, 4.75 mmol) in DCM (20 mL) at -78 °C under argon. The cooling bath is removed, and the reaction mixture is allowed to warm to room temperature under argon for 1.5 h. The reaction mixture is poured into a stirred mixture of saturated aqueous sodium bicarbonate and ice. The resulting mixture is stirred vigorously at room temperature for 1 h to fully quench the reaction mixture. The phases are separated, and the aqueous layer is extracted with dichloromethane. The combined organics are dried over sodium sulfate, filtered, concentrated on a rotary evaporator, and purified via silica gel chromatography (0–10% ethyl acetate in hexanes). Fractions containing the desired product are combined and concentrated on a rotary evaporator at room temperature. The residue is diluted with dry THF (5 mL) and concentrated on a rotary evaporator. The residue is dried under high vacuum for 2 minutes to give 5-bromo-2-(difluoromethyl)-3-fluoropyridine (2).
[0230] Example 1A.13
[0231] [ka]
[0232] A solution of 3-fluoropyridin-2-ol (1, 20.0 g, 176.9 mmol) in N,N-dimethylformamide (220.0 mL) is cooled to 0° C., bromine (10.30 mL, 194.6 mmol) is added dropwise, and the reaction mixture is stirred at 0° C. for 2 hours. Upon completion, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic layer is washed with sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound. The crude compound is purified by column chromatography using silica gel (100-200 mesh) and 2-3% methanol in dichloromethane to give 5-bromo-3-fluoropyridin-2-ol (2).
[0233] To a solution of 5-bromo-3-fluoropyridin-2-ol (2, 11.0 g, 57.29 mmol) in N,N-dimethylformamide (110 mL) is added cesium carbonate (24.59 g, 74.47 mmol) and sodium 2-bromo-2,2-difluoroacetate (17.04 g, 85.93 mmol), and the reaction mixture is heated at 55° C. After completion, the reaction mixture is diluted with water and extracted with diethyl ether. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound. The resulting crude compound is concentrated under reduced pressure to give the crude product, which is purified by column chromatography using silica gel (100-200 mesh) and 1-2% ethyl acetate in hexane to give 5-bromo-2-(difluoromethoxy)-3-fluoropyridine (3).
[0234] Example 1A.14
[0235] [ka]
[0236] To a solution of 2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (1, 0.16 g, 0.8 mmol) and zinc difluoromethanesulfinate (0.472 g, 1.6 mmol) in a mixture of dichloromethane and water (4:1, 2 mL) was added trifluoroacetic acid (0.06 mL, 0.8 mmol) and tert-butyl hydroperoxide (0.23 mL, 2.4 mmol). The mixture was stirred at room temperature for 16 hours. After this time, the reaction mixture was concentrated under reduced pressure, diluted with water, and extracted with dichloromethane. The combined organic layers were washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel (100-200 mesh) using 40% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 6-(difluoromethyl)-2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (2).
[0237] Example 1A.15
[0238] [ka]
[0239] A solution of 2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (1, 0.200 g, 0.99 mmol) and bis(((trifluoromethyl)sulfinyl)oxy)zinc (1a, 0.662 g, 1.99 mmol) was stirred in chloroform (2.0 mL) and water (2.0 mL), and tert-butyl hydrogen peroxide (70%) (0.38 mL, 2.99 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 15 hours. After this time, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. The crude product was purified by silica gel (100-200 mesh) column chromatography using 70-80% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 2,8-dimethyl-4-oxo-6-(trifluoromethyl)-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (2).
[0240] Example 1A.16
[0241] [ka]
[0242] To a solution of 6-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (1, 1.0 g, 4.54 mmol) in dichloromethane:water (1:1) (20.0 mL) was added 2,2,2-trifluoroacetic acid (10.4 mL, 13.63 mmol). The reaction mixture was stirred at room temperature for 15 minutes, followed by the addition of phenylboronic acid (1a, 1.65 g, 13.63 mmol) and stirring for 40 minutes. Silver nitrate (0.154 g, 0.90 mmol) and potassium persulfate (2.45 g, 9.09 mmol) were added, and the reaction mixture was stirred at room temperature for 24 hours. Upon completion, the reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound. The crude material is washed with 30% diethyl ether in pentane to give 6-chloro-2-methyl-4-oxo-8-phenyl-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (2).
[0243] Example 1A.17
[0244] [ka]
[0245] Zinc powder (<10 microns) (37.7 mg, 0.58 mmol) is weighed into one dry drum vial and placed under argon. DMA (0.4 mL) is added, followed by iodine (3.6 mg, 0.014 mmol). The resulting mixture is stirred vigorously at room temperature under argon until the red color of the iodine disappears (5 min). 4-(Bromomethyl)tetrahydro-2H-pyran (2a, 0.072 mL, 0.56 mmol) is added, and the resulting mixture is sealed, stirred vigorously, and heated at 80° C. for 23 h. After cooling to room temperature, the reaction mixture was placed under argon and 6-chloro-3-(4-methoxybenzyl)-2,8-dimethyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (2, 49.9 mg, 0.14 mmol) and bis(triphenylphosphine)nickel(II) dichloride (9.2 mg, 0.014 mmol) were added. The resulting mixture was vigorously stirred under argon at room temperature for 2.5 h and then at 50 °C for 2 h. The reaction mixture was diluted with NMP and methanol, filtered, and purified via preparative HPLC (15-70% acetonitrile in water with 0.1% TFA). Fractions containing the desired product are combined, lyophilized, and dried to give 3-(4-methoxybenzyl)-2,8-dimethyl-4-oxo-6-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (3).
[0246] Example 1A.18
[0247] [ka]
[0248] 2,3-Dibromo-5-fluoropyridine (1, 3.15 g, 12.4 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1a, 1.93 mL, 13.6 mmol), cesium carbonate (8.86 g, 27.2 mmol), 1,4-dioxane (24 mL), and water (6 mL) are combined in a 100 mL round-bottom flask equipped with a stir bar. The atmosphere in the flask is removed under vacuum and replaced twice with argon. Tetrakis(triphenylphosphine)palladium(0) (0.71 g, 0.62 mmol) is added, and the atmosphere in the flask is removed under vacuum and replaced twice with argon. The resulting clear yellow reaction mixture is vigorously stirred and heated under argon at 100° C. for 12 hours. After cooling to room temperature, the reaction mixture is partitioned between brine and ethyl acetate. Dry the organics over magnesium sulfate, filter, concentrate on a rotary evaporator, and purify via silica gel chromatography (2-15% ethyl acetate in hexanes) to obtain 3-bromo-5-fluoro-2-vinylpyridine (2).
[0249] Dimethylamine (40% by weight in water) (34.1 mL, 108 mmol) is added to a stirred solution of 3-bromo-5-fluoro-2-vinylpyridine (2, 2.18 g, 10.8 mmol) in acetic acid (14.2 mL, 248 mmol). The resulting mixture is sealed, stirred vigorously, and heated at 110° C. for 68 hours. After cooling to room temperature, the reaction mixture is poured onto a stirred mixture of sodium hydroxide (9.93 g, 248 mmol) and sodium bicarbonate (4.53 g, 54.0 mmol) in ice water. The resulting mixture is extracted three times with dichloromethane. The combined organics are dried over magnesium sulfate, filtered, concentrated on a rotary evaporator, and purified via silica gel chromatography (0-20% methanol in dichloromethane). Fractions containing the desired product are combined and concentrated on a rotary evaporator. The residue is concentrated twice from THF and dried under high vacuum to give 2-(3-bromo-5-fluoropyridin-2-yl)-N,N-dimethylethan-1-amine (3).
[0250] Example 1A.19
[0251] [ka]
[0252] A solution of 2,3-dibromo-5-fluoropyridine (1, 10.0 g, 39.2 mmol), tributyl(1-ethoxyvinyl)stannane (1a, 15.5 mL, 43.1 mmol), and lithium chloride (4.9 g, 117.6 mmol) in N,N-dimethylformamide (100 mL) is degassed under nitrogen for 10 minutes. Bis(triphenylphosphine)palladium(II) dichloride (1.3 g, 1.9 mmol) is then added, and the mixture is heated at 100°C for 4 hours. The reaction mixture is cooled, diluted with water, and extracted with diethyl ether. The combined organic layers are washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by column chromatography using silica gel (100-200 mesh) and 0-2% ethyl acetate in hexane to give 3-bromo-2-(1-ethoxyvinyl)-5-fluoropyridine (2).
[0253] A solution of 3-bromo-2-(1-ethoxyvinyl)-5-fluoropyridine (2, 5.7 g, 23.1 mmol) in dichloromethane (60 mL) is cooled to 0° C. Hydrochloric acid in 1,4-dioxane (4 m, 10 mL) is added, and the mixture is stirred at room temperature for 3 hours. The reaction mixture is poured into ice-cold water, neutralized with sodium bicarbonate, and extracted with dichloromethane. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by column chromatography using silica gel (100-200 mesh) and 0-5% ethyl acetate in hexane to give 1-(3-bromo-5-fluoropyridin-2-yl)ethan-1-one (3).
[0254] A solution of 1-(3-bromo-5-fluoropyridin-2-yl)ethan-1-one (3, 3.8 g, 17.4 mmol) in dichloromethane (40 mL) is cooled to 0° C., diethylaminosulfur trifluoride (23.3 mL, 174.0 mmol) is added, and the mixture is stirred at room temperature for 48 hours, then heated at 40° C. for 72 hours. The reaction mixture is cooled, poured into crushed ice (very slowly, in small portions), neutralized with sodium bicarbonate, and extracted with dichloromethane. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by column chromatography using silica gel (100-200 mesh) and 0-1% ethyl acetate in hexane to give 3-bromo-2-(1,1-difluoroethyl)-5-fluoropyridine (4).
[0255] Example 1A.20
[0256] [ka]
[0257] (Trimethylsilyl)diazomethane (2 M in diethyl ether) (19.5 mL, 39.1 mmol) is slowly added to a stirred mixture (not all dissolved) of 3,5-difluoroisonicotinic acid (1, 5.18 g, 32.6 mmol) in wet methanol (200 mL) at 0° C. The resulting cloudy mixture is vigorously stirred under air at 0° C. Effervescence is observed during the addition and is continued for 45 min. Dichloromethane (100 mL) is added, followed by additional (trimethylsilyl)diazomethane (2 M in diethyl ether) (19.5 mL, 39.1 mmol). The resulting clear solution is vigorously stirred under air at 0° C. for 30 min. Add additional (trimethylsilyl)diazomethane (2 M in diethyl ether) (19.5 mL, 39.1 mmol), then add additional (trimethylsilyl)diazomethane (2 M in diethyl ether) (19.5 mL, 39.1 mmol) again until LCMS indicates complete conversion of the starting material. Remove volatiles on a rotary evaporator. Dissolve the residue in dichloromethane and purify via silica gel chromatography (0-50% ethyl acetate in hexanes) (after drying under high vacuum for only a few seconds) to give methyl 3,5-difluoroisonicotinate (2).
[0258] A solution of piperidine-4-carboxylic acid (2a, 1.20 g, 9.27 mmol), ammonium persulfate (2.33 g, 10.2 mmol), and silver nitrate (590 mg, 3.47 mmol) in water (8 mL) is added to a stirred mixture of methyl 3,5-difluoroisonicotinate (2, 802 mg, 4.63 mmol) in 3% sulfuric acid in water (8 mL) at 70° C. The resulting brown mixture is heated at 70° C. with vigorous stirring for 10 minutes (observe bubbling), then cooled to room temperature. The reaction mixture is heated at 70° C., and additional piperidine-4-carboxylic acid (1.20 g, 9.27 mmol), ammonium persulfate (2.33 g, 10.2 mmol), and silver nitrate (590 mg, 3.47 mmol) in water (8 mL) is added. The reaction mixture is heated at 70° C. for 10 minutes, then cooled to room temperature. This is repeated a total of four times. The reaction mixture is basified with potassium carbonate. All volatiles are removed on a rotary evaporator. The residue is slurried in 20% methanol in dichloromethane and filtered through Celite. The filter cake is thoroughly washed with 20% methanol in dichloromethane. The filtrate is concentrated on silica gel on a rotary evaporator and purified via silica gel chromatography (0-20% methanol in dichloromethane) to give methyl 3,5-difluoro-2-(piperidin-4-yl)isonicotinate (3).
[0259] 2,2,2-Trifluoroethyl trifluoromethanesulfonate (3a, 1.05 mL, 7.32 mmol) is added to a stirred solution of methyl 3,5-difluoro-2-(piperidin-4-yl)isonicotinate (3, 625 mg, 2.44 mmol) and N,N-diisopropylethylamine (3.40 mL, 19.5 mmol) in NMP (10 mL) at room temperature under argon. The resulting mixture is stirred at room temperature under argon for 3 hours. The reaction mixture is diluted with ethyl acetate, washed three times with brine, dried over magnesium sulfate, filtered, concentrated on a rotary evaporator, and purified via silica gel chromatography (0-50% ethyl acetate in hexanes) to give methyl 3,5-difluoro-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)isonicotinate (4).
[0260] Methyl 3,5-difluoro-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)isonicotinate (4, 505 mg, 1.49 mmol), trimethyltin hydroxide (1.08 g, 5.97 mmol), and DCE (10 mL) are combined in a 100 mL round-bottom flask equipped with a stir bar. The resulting mixture is stirred vigorously and heated under a reflux condenser under argon at 80° C. for 1 h and then at 85° C. for 3 h. The volatiles are removed on a rotary evaporator. The residue is dissolved in 20% methanol in dichloromethane and purified via silica gel chromatography (0 to 20% methanol in dichloromethane) to give 3,5-difluoro-2-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)isonicotinic acid (5).
[0261] Example 1A.21
[0262] [ka]
[0263] Lithium bis(trimethylsilyl)amide (1 M in toluene) (2.23 mL, 2.23 mmol) is slowly added to a stirred solution of tert-butyl 4-cyanopiperidine-1-carboxylate (1, 469 mg, 2.23 mmol) and 3-bromo-2,5-difluoropyridine (2, 433 mg, 2.23 mmol) in toluene (5 mL) at −78° C. under argon. The cooling bath is removed, and the resulting orange solution is allowed to warm to room temperature with stirring under argon and stirred at room temperature for 2 hours. 0.2 M HCl in water (22.3 mL, 4.46 mmol) is added with vigorous stirring. The resulting mixture is extracted with ethyl acetate. The organics are washed with brine, dried over magnesium sulfate, filtered, concentrated on a rotary evaporator, and purified via silica gel chromatography (0 to 50% ethyl acetate in hexanes) to give tert-butyl 4-(3-bromo-5-fluoropyridin-2-yl)-4-cyanopiperidine-1-carboxylate (3).
[0264] n-Butyllithium (2.5 M in hexanes) (0.48 mL, 1.20 mmol) is added to a stirred solution of diisopropylamine (0.18 mL, 1.30 mmol) in THF (4 mL) under argon at 0° C. The resulting pale yellow solution is stirred at 0° C. for 10 minutes and then slowly added to a stirred solution of tert-butyl 4-(3-bromo-5-fluoropyridin-2-yl)-4-cyanopiperidine-1-carboxylate (3, 401 mg, 1.04 mmol) in THF (7 mL) at −78° C. under argon. The resulting orange reaction mixture is stirred at −78° C. for 30 minutes under argon, and then carbon dioxide gas is bubbled through for approximately 1 minute (the orange color disappears). After 10 minutes, the reaction mixture is quenched by the addition of 0.1 N sodium hydroxide in water (1 mL). The resulting mixture is partitioned between 0.1 N sodium hydroxide in water (20 mL) and diethyl ether. The organics are extracted twice more with 0.1 N sodium hydroxide in water (5 mL). The organics are discarded. The aqueous layer is acidified with 1 N HCl in water and then extracted four times with ethyl acetate. The organics are washed with brine, dried over magnesium sulfate, filtered, concentrated on a rotary evaporator, and dried under high vacuum to give 3-bromo-2-(1-(tert-butoxycarbonyl)-4-cyanopiperidin-4-yl)-5-fluoroisonicotinic acid (4).
[0265] HATU (366 mg, 0.964 mmol) is added to a stirred solution of 3-bromo-2-(1-(tert-butoxycarbonyl)-4-cyanopiperidin-4-yl)-5-fluoroisonicotinic acid (4, 393 mg, 0.918 mmol) in DMF (6 mL) at room temperature under argon. After 2 minutes, N,N-diisopropylethylamine (0.19 mL, 1.10 mmol) is added. The resulting orange mixture is stirred at room temperature under argon for 20 minutes. A solution of acetamidine hydrochloride (174 mg, 1.84 mmol) and N,N-diisopropylethylamine (0.80 mL, 4.59 mmol) in DMF (3 mL) is added, which is heated with a heat gun and sonicated to dissolve all of the acetamidine. The resulting orange mixture is vigorously stirred under argon at room temperature for 2 hours. The reaction mixture is diluted with ethyl acetate, washed four times with brine, dried over magnesium sulfate, filtered, and concentrated on a rotary evaporator. Dry THF (10 mL) is added, and the volatiles are again removed on a rotary evaporator. The residue is dried under high vacuum for 10 minutes. The residue is dissolved in THF (15 mL) with stirring and cooled to 0°C under argon. Sodium hydride (44.1 mg, 1.84 mmol) is added. The cooling bath is removed, and the resulting cloudy orange mixture is vigorously stirred under argon at room temperature for 2.5 hours. A solution of ammonium chloride (147 mg, 2.75 mmol) in water (2 mL) is added, and the resulting mixture is then partitioned between ethyl acetate and brine. Dry the organics over magnesium sulfate, filter, concentrate on a rotary evaporator, and purify via silica gel chromatography (20 to 100% ethyl acetate in hexanes) to obtain tert-butyl 4-(5-bromo-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-6-yl)-4-cyanopiperidine-1-carboxylate (5).
[0266] tert-Butyl 4-(5-bromo-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-6-yl)-4-cyanopiperidine-1-carboxylate (5, 313 mg, 0.698 mmol), ethanol (17 mL), and lithium hydroxide (1 M in water) (6.98 mL, 6.98 mmol) are combined in a sealable vessel with a stir bar. The resulting mixture is sealed, stirred vigorously, and heated to 120°C using an oil bath for 44 hours. After cooling to room temperature, the reaction mixture is diluted with methanol and concentrated on a rotary evaporator. The residue is dissolved in NMP, methanol, and acetic acid (0.60 mL, 10.5 mmol), filtered, and purified via preparative HPLC (15-60% acetonitrile in water with 0.1% TFA). Fractions containing the desired product are combined and lyophilized to give tert-butyl 4-(5-bromo-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-6-yl)-4-carbamoylpiperidine-1-carboxylate (6).
[0267] A stirred mixture of tert-butyl 4-(5-bromo-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-6-yl)-4-carbamoylpiperidine-1-carboxylate TFA salt (6, 186 mg, 0.321 mmol) in 6 M HCl in water (7 mL) was heated to 140° C. using an oil bath for 2 min, then sealed, vigorously stirred, and heated to 140° C. using an oil bath for 2 h. Additional 6 M HCl in water (3 mL) was added, and heating at 140° C. using an oil bath was continued for an additional 21 h. After cooling to room temperature, the reaction mixture was diluted with methanol, filtered, and purified via preparative HPLC (5-18% acetonitrile in water with 0.1% TFA). Fractions containing the desired product were loaded onto a Phenomenex Strata XC ion-exchange column. The column is washed sequentially with water, acetonitrile, methanol, and then 5% ammonium hydroxide in methanol. The eluate containing the desired product is concentrated on a rotary evaporator and dried under high vacuum to give 5-bromo-2-methyl-6-(piperidin-4-yl)pyrido[3,4-d]pyrimidin-4(3H)-one (7).
[0268] Example 1A.22
[0269] [ka]
[0270] To a solution of 5-fluoropyridin-2-ol (1, 9.00 g, 0.079 mol) in tetrahydrofuran (290 mL) at 0° C., trimethylphenylammonium tribromide (29.9 g, 0.079 mol) is slowly added, and the reaction mixture is stirred at room temperature for 16 hours. After 16 hours, the reaction mixture is partitioned between ethyl acetate and water. The aqueous layer is separated and re-extracted with ethyl acetate. The combined organic layers are washed with 5% sodium metabisulfite solution, saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. The crude product is purified by column chromatography using silica gel (100-200 mesh) and 0-30% ethyl acetate in hexane to give 3-bromo-5-fluoropyridin-2-ol (2) as an off-white solid. Yield: 4.90 g, 27%; MS (ESI) m / z 189.99 [M-1] - .
[0271] To a solution of 3-bromo-5-fluoropyridin-2-ol (2, 4.10 g, 0.021 mol) in N,N-dimethylformamide (40 mL) was added cesium carbonate (3.48 g, 0.031 mol) and sodium 2-bromo-2,2-difluoroacetate (2a, 5.05 g, 0.025 mmol), and the reaction mixture was heated at 70° C. for 4 h. Upon completion, the reaction mixture was cooled and partitioned between diethyl ether and water. The aqueous layer was separated and re-extracted with diethyl ether. The combined organic layers were washed with water, saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. The crude product was purified by column chromatography using silica gel (100-200 mesh) and hexane as the eluent to give 3-bromo-2-(difluoromethoxy)-5-fluoropyridine (3).
[0272] Example 1B. Method for synthesizing the right side Example 1B.1
[0273] [ka]
[0274] A solution of 2,2-dimethyl-1,3-dioxane-4,6-dione (B, 1.1 equivalents) and 1,1,1-triethoxyethane (C, 0.7 M) is stirred and heated at 90° C. for 2 hours. Methyl 4-aminothiophene-3-carboxylate (A, 1 equivalent) is added portionwise at 90° C. under an argon atmosphere, and heating is continued at 90° C. for 6 hours. The reaction mixture is cooled to room temperature, water is added, and the mixture is extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product is triturated with diethyl ether to give methyl 4-((1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)ethyl)amino)thiophene-3-carboxylate (D).
[0275] A solution of methyl 4-((1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)ethyl)amino)thiophene-3-carboxylate (D, 1 equivalent) in Dowtherm A (0.5 M) is heated at 235° C. for 4 hours. Upon completion, the reaction is cooled to room temperature and the precipitated solid is isolated by filtration and dried in vacuo. The resulting solid is washed with diethyl ether to give methyl 7-hydroxy-5-methylthieno[3,2-b]pyridine-3-carboxylate (E).
[0276] To a solution of methyl 7-hydroxy-5-methylthieno[3,2-b]pyridine-3-carboxylate (E, 1 equivalent) in 1,2-dichloroethane (0.22 M) is added phosphoryl trichloride (3 equivalents) and a catalytic amount of N,N-dimethylformamide at room temperature, and the reaction mixture is heated at 90°C for 6 hours. The reaction mixture is concentrated under reduced pressure, diluted with ice-cold water, and the solution is basified to a pH of about 7-8 with 10% aqueous sodium hydroxide, followed by extraction with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give methyl 7-chloro-5-methylthieno[3,2-b]pyridine-3-carboxylate (F1).
[0277] To a solution of methyl 7-chloro-5-methylthieno[3,2-b]pyridine-3-carboxylate (F1, 1 equivalent) in a mixture of methanol (1.7 M), water (1.7 M), and tetrahydrofuran (0.64 M) is added lithium hydroxide monohydrate (2 equivalents) at room temperature, and the resulting mixture is stirred for 2 hours. The solid is filtered, and the filtrate is concentrated and combined with the solid. The combined solid is acidified with saturated citric acid solution (to pH = 1) and filtered. The resulting solid is washed with methanol, followed by diethyl ether, and dried under high vacuum to give 7-chloro-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (F2).
[0278] To a solution of 7-chloro-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (F2, 1 equivalent) in tert-butyl alcohol (0.4 M) is added 4-dimethylaminopyridine (1 equivalent) and Boc-anhydride (3 equivalents) at room temperature. The mixture is stirred at 90° C. for 48 hours, and the reaction mixture is concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel to give tert-butyl 7-chloro-5-methylthieno[3,2-b]pyridine-3-carboxylate (F3).
[0279] To a solution of tert-butyl 7-chloro-5-methylthieno[3,2-b]pyridine-3-carboxylate (F3, 1 equivalent) and (5-chloro-2-hydroxyphenyl)boronic acid (G, 1.2 equivalents) in 1,4-dioxane (0.5 M) and water (1.2 M) was added potassium carbonate solution (2 equivalents) at room temperature, and the reaction mixture was degassed with argon for 20 minutes. [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.05 equivalents) was added, and the mixture was heated at 90°C for 2 hours. The reaction mixture was cooled to room temperature, and the solid was filtered, washed with water, then methanol, and dried under vacuum to give tert-butyl 7-(5-chloro-2-hydroxyphenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (H).
[0280] To a solution of tert-butyl 7-(5-chloro-2-hydroxyphenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (H, 1 equivalent) in acetone (0.28 M) are added potassium carbonate (3.5 equivalents) and 1,2-dibromoethane (I, 5.0 equivalents) at room temperature, and the reaction mixture is heated at 40° C. for 12 hours. An additional 5.0 equivalents of 1,2-dibromoethane are then added at room temperature, and the mixture is heated to 45° C. The reaction mixture is filtered through a sintered funnel, washed with acetone, and the filtrate is concentrated and purified by column chromatography to give tert-butyl 7-(2-(2-bromoethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (J).
[0281] Example 1B.2
[0282] [ka]
[0283] A solution of 2-bromo-4-chloro-1-iodobenzene (A, 1 equivalent) and prop-2-yn-1-ol (B, 1.3 equivalents) in triethylamine (0.3 M) is degassed with argon for 10 minutes. Copper(I) iodide (0.15 equivalents) and bis(triphenylphosphine)palladium chloride (0.08 equivalents) are added, and the reaction mixture is stirred at room temperature for 16 hours. The reaction is concentrated under reduced pressure, and the crude compound is purified by Combi-flash to give 3-(2-bromo-4-chlorophenyl)prop-2-yn-1-ol (C).
[0284] To a solution of 3-(2-bromo-4-chlorophenyl)prop-2-yn-1-ol (C, 1 equivalent) in tetrahydrofuran (0.8 M) is added imidazole (3 equivalents), 4-dimethylaminopyridine (0.045 equivalents), and tert-butyldimethylchlorosilane (1.2 equivalents) at room temperature, and the reaction mixture is stirred for 24 hours. The reaction is diluted with water, extracted with ethyl acetate, and the organic layer is separated, dried over anhydrous sodium sulfate, and purified by Combi-flash to give ((3-(2-bromo-4-chlorophenyl)prop-2-yn-1-yl)oxy)(tert-butyl)dimethylsilane (D).
[0285] To a solution of ((3-(2-bromo-4-chlorophenyl)prop-2-yn-1-yl)oxy)(tert-butyl)dimethylsilane (D, 1 eq.) in tetrahydrofuran (0.14 M) is added n-butyllithium (1.23 M in hexane, 1.3 eq.) dropwise at −78° C. and the mixture is stirred at −78° C. for 1 hour. 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (E, 1.2 eq.) is added dropwise at −78° C. and stirring is continued for 1 hour. The reaction is quenched with chilled water, extracted with ethyl acetate, and the organic layer is separated, dried over anhydrous sodium sulfate, concentrated, and purified by Combi-flash to give tert-butyl((3-(4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)prop-2-yn-1-yl)oxy)dimethylsilane (F).
[0286] Example 1B.3
[0287] [ka]
[0288] To a solution of methyl 7-(2-(3-((tert-butyldimethylsilyl)oxy)prop-1-yn-1-yl)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) in tetrahydrofuran (0.21 M) is added tetra-n-butylammonium fluoride (1.2 equivalents) at room temperature and the mixture is stirred for 2 hours. The reaction is diluted with ethyl acetate and washed with cold water, and the organic layer is separated, dried over anhydrous sodium sulfate, concentrated, and triturated with diethyl ether to give methyl 7-(5-chloro-2-(3-hydroxyprop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (B).
[0289] To a solution of methyl 7-(5-chloro-2-(3-hydroxyprop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (B, 1 equivalent) in dichloromethane (10.0 mL) is added triphenylphosphine (1.5 equivalents) at room temperature and the reaction mixture is cooled to 0° C. Carbon tetrabromide (1.5 equivalents) is added and the reaction mixture is stirred at room temperature for 3 hours. The reaction is concentrated and purified by Combi-flash to give methyl 7-(2-(3-bromoprop-1-yn-1-yl)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (C).
[0290] Example 1B.4
[0291] [ka]
[0292] A solution of methyl 7-hydroxy-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) and phosphorus oxybromide (10 equivalents) in 1,2 dichloroethane (0.45 M) is heated at 80° C. for 16 hours. The reaction mixture is cooled to room temperature, quenched with aqueous sodium bicarbonate, extracted with dichloromethane, and the combined organic layers are washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give methyl 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylate (B).
[0293] A solution of methyl 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylate (B, 1 equivalent) and lithium hydroxide (3 equivalents) in a solvent mixture of methanol:tetrahydrofuran:water (1:2:1, 0.25 M) is stirred at room temperature for 16 hours. The reaction is diluted with water, cooled to 0° C., and acidified with 1N hydrochloric acid to a pH of approximately 5. The precipitate is filtered, washed with pentane, and dried to give 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C).
[0294] To a solution of 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C, 1 equivalent) and methanesulfonamide (D, 1.5 equivalents) in dichloromethane (0.16 M) is added N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (2 equivalents) and N,N-dimethylpyridin-4-amine (2.5 equivalents) at room temperature, and the mixture is stirred for 16 hours. The reaction is diluted with water, cooled to 0°C, acidified to pH ∼2 with 1N hydrochloric acid, and extracted with dichloromethane. The combined organic layers are dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give 7-bromo-5-methyl-N-(methylsulfonyl)thieno[3,2-b]pyridine-3-carboxamide (E).
[0295] Example 1B.5
[0296] [ka]
[0297] To a solution of tert-butyl 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylate (1, 1.50 g, 4.5 mmol) in 1,4-dioxane, selenium dioxide (0.55 g, 5.02 mmol) is added and the reaction mixture is heated at 95° C. for 8 hours. After completion, the reaction mixture is filtered over a Celite bed and washed with ethyl acetate. The filtrate obtained is concentrated under reduced pressure to give the crude product. The crude product obtained is purified by column chromatography using silica gel (100-200 mesh) and 10% ethyl acetate in hexane to give tert-butyl 7-bromo-5-formylthieno[3,2-b]pyridine-3-carboxylate (2).
[0298] To a solution of tert-butyl 7-bromo-5-formylthieno[3,2-b]pyridine-3-carboxylate (2, 0.55 g, 1.62 mmol) in methanol (6 mL) was added sodium borohydride (0.12 g, 3.25 mmol) at 0 °C, and the reaction mixture was stirred at the same temperature for 1 hour. After completion, the reaction mixture was quenched with ice water and concentrated under reduced pressure. The crude material was dissolved in ethyl acetate, washed with water, brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound. The resulting crude compound was purified by column chromatography using silica gel (100-200 mesh) and 20% ethyl acetate in hexane to give tert-butyl 7-bromo-5-(hydroxymethyl)thieno[3,2-b]pyridine-3-carboxylate (3).
[0299] To a solution of tert-butyl 7-bromo-5-(hydroxymethyl)thieno[3,2-b]pyridine-3-carboxylate (3, 0.325 g, 0.94 mmol) in dichloromethane (5 mL) at −78° C., DAST (0.18 mL, 1.41 mmol) is added, and the reaction mixture is stirred at −78° C. for 1 hour. After completion, the reaction mixture is quenched with ice-cold water and extracted with dichloromethane. The organic layer is washed with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound. The resulting crude compound is purified by column chromatography using silica gel (100-200 mesh) and 10% ethyl acetate in hexane to give tert-butyl 7-bromo-5-(fluoromethyl)thieno[3,2-b]pyridine-3-carboxylate (4).
[0300] Example 1B.6
[0301] [ka]
[0302] A solution of tert-butyl 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylate (1, 500.0 mg, 1.523 mmol), azobisisobutyronitrile (24.98 mg, 0.152 mmol), and N-bromosuccinimide (271.13 mg, 1.523 mmol) in carbon tetrachloride (10 mL) was stirred at 90 °C for 5 h. Upon completion, the reaction mixture was concentrated under reduced pressure, diluted with dichloromethane, and silica gel was added. The solvent was evaporated. The crude silica mixture was purified by Isco column chromatography using 0-10% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to give tert-butyl 7-bromo-5-(bromomethyl)thieno[3,2-b]pyridine-3-carboxylate (2).
[0303] To a stirred solution of tert-butyl 7-bromo-5-(bromomethyl)thieno[3,2-b]pyridine-3-carboxylate (2, 0.200 g, 0.491 mmol) in methanol (0.2 mL) and N-methylpyrrolidone (2.0 mL), cesium carbonate (0.480 g, 1.474 mmol) is added at room temperature, and the reaction mixture is stirred at room temperature for 8 hours. Upon completion, the reaction mixture is diluted with dichloromethane, and then silica gel is added. The solvent is then evaporated, and the free-flowing silica gel is then loaded onto a column and purified via silica gel chromatography eluting with methanol in dichloromethane to give tert-butyl 7-bromo-5-(methoxymethyl)thieno[3,2-b]pyridine-3-carboxylate (3).
[0304] Example 1B.7
[0305] [ka]
[0306] To a stirred solution of 4-methoxybenzyl alcohol (8.1 g, 59.1 mmol) in N,N-dimethylformamide (100 mL) at 0° C. is added sodium hydride (3.1 g, 65.0 mmol). The reaction mixture is stirred at 0° C. for 30 minutes. 7-Chlorothieno[3,2-b]pyridine (1, 10 g, 59.1 mmol) is then added at 0° C., and the reaction mixture is stirred at room temperature for 16 hours. After this time, the mixture is poured into ice. The resulting precipitate is collected by filtration and dried under reduced pressure to give 7-((4-methoxybenzyl)oxy)thieno[3,2-b]pyridine (2).
[0307] To a stirred solution of 7-((4-methoxybenzyl)oxy)thieno[3,2-b]pyridine (2, 8.0 g, 29.5 mmol) in dry tetrahydrofuran (250 mL), n-butyllithium (2.3 M in hexane, 38.0 mL, 64.9 mmol) is added dropwise at −78° C. The reaction mixture is stirred at the same temperature for 45 minutes. Carbon tetrabromide (9.7 g, 29.5 mmol) is then added at −78° C., and the mixture is stirred at the same temperature for 1 hour. After this time, the reaction is quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer is washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by silica gel (100-200 mesh) column chromatography using 15% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 2-bromo-7-((4-methoxybenzyl)oxy)thieno[3,2-b]pyridine (3).
[0308] A solution of 2-bromo-7-((4-methoxybenzyl)oxy)thieno[3,2-b]pyridine (3, 6.5 g, 18.62 mmol) in a mixture of trifluoroacetic acid and dichloromethane (1:1, 40 mL) is stirred at room temperature for 8 hours. After this time, the reaction mixture is concentrated under reduced pressure. The crude product is recrystallized from ether and pentane to give 2-bromothieno[3,2-b]pyridin-7-ol (4).
[0309] To a solution of 2-bromothieno[3,2-b]pyridin-7-ol (4, 3.5 g, 15.28 mmol) in methanol (30 mL) was added 30% sodium methoxide in methanol (14.0 g, 76.4 mmol) and copper(I) bromide (0.200 g, 1.5 mmol). The reaction mixture was stirred at 120° C. for 30 hours. After this time, the reaction mixture was concentrated under reduced pressure, acidified with 2 N hydrochloric acid to a pH of about 6, and extracted with 10% methanol in dichloromethane. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give 2-methoxythieno[3,2-b]pyridin-7-ol (5).
[0310] A mixture of 2-methoxythieno[3,2-b]pyridin-7-ol (5, 1.7 g, 9.39 mmol) and phosphoryl chloride (10 mL) is heated and stirred at 90° C. for 6 hours. After this time, the reaction mixture is quenched with ice, treated with 50% aqueous sodium hydroxide, and extracted with ethyl acetate. The organic layer is washed with water, then saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product is purified by Combiflash using 30% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 7-chloro-2-methoxythieno[3,2-b]pyridine (6).
[0311] To a solution of 3-bromo-7-chloro-2-methoxythieno[3,2-b]pyridine (6, 0.8 g, 4.02 mmol) in N,N-dimethylformamide (10 mL) at room temperature, N-bromosuccinimide (1.4 g, 8.04 mmol) is added. The reaction mixture is stirred for 30 minutes. The reaction mixture is then poured into ice and extracted with ethyl acetate. The organic layer is washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product is purified by Combiflash (12 g, RediSep column) using 10% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 3-bromo-7-chloro-2-methoxythieno[3,2-b]pyridine (7).
[0312] To a stirred solution of 3-bromo-7-chloro-2-methoxythieno[3,2-b]pyridine (7, 0.7 g, 2.52 mmol) in dry tetrahydrofuran (10 mL) is added n-butyllithium (2.3 M in hexane, 1.97 mL, 4.54 mmol) dropwise at −78° C. The reaction mixture is stirred at the same temperature for 45 minutes. Dry carbon dioxide gas is bubbled into the reaction mixture, which is slowly warmed to room temperature and stirred for 16 hours. The reaction mixture is quenched with 10% aqueous citric acid and extracted with 10% methanol in dichloromethane. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give 7-chloro-2-methoxythieno[3,2-b]pyridine-3-carboxylic acid (8).
[0313] To a solution of 7-chloro-2-methoxythieno[3,2-b]pyridine-3-carboxylic acid (8, 0.5 g, 2.05 mmol) in N,N-dimethylformamide (5.0 mL) at room temperature, potassium carbonate (0.85 g, 6.17 mmol) and methyl iodide (0.32 g, 2.26 mmol) are added. The reaction mixture is stirred for 16 hours. After this time, the reaction mixture is poured into ice and extracted with ethyl acetate. The organic layer is washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product is purified by Combiflash (12 g, RediSep column) using 2% methanol in dichloromethane as the eluent. The desired fractions are concentrated under reduced pressure to give methyl 7-chloro-2-methoxythieno[3,2-b]pyridine-3-carboxylate (9).
[0314] Example 1B.8
[0315] [ka]
[0316] To a stirred solution of 3-bromobenzoic acid (1, 100.0 g, 497.5 mmol) in N,N-dimethylformamide (800 mL) is added carbonyldiimidazole (112.9 gm, 696.5 mmol) at room temperature, and the reaction mixture is heated and stirred at 50° C. for 1 hour. 1,8-Diazabicyclo[5.4.0]undec-7-ene (105.8 gm, 696.5 mmol) and tert-butanol (184.37 gm, 2487.5 mmol) are added at 50° C., and the reaction mixture is continued to stir at 50° C. for 16 hours. Upon completion, the reaction is quenched with water and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product obtained is purified by column chromatography using 100-200 silica gel and 2% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 3-bromobenzoate (2).
[0317] A stirred solution of tert-butyl 3-bromobenzoate (2, 113.0 g, 439.4 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (3, 167.43 g, 659.1 mmol), and potassium acetate (107.65 g, 1098.5 mmol) in dioxane (600 mL) is degassed with argon for 30 minutes. [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) is then added, and the reaction mixture is heated and stirred at 85°C for 16 hours. After completion, the reaction is quenched with water and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude mass. The crude compound is purified by column chromatography using 100-200 silica gel and 3% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (4).
[0318] A stirred solution of 4-chloro-2-iodophenol (5, 60.0 g, 235.8 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (4, 100.37 g, 330.1 mmol), and potassium carbonate (97.76 g, 707.4 mmol) in a mixture of dioxane and water (4:1, 1.0 L) is degassed with argon for 30 minutes. Palladium(II) bis(triphenylphosphine) dichloride is added at room temperature, and the reaction mixture is stirred at 100°C for 6 hours. Upon completion, the reaction is quenched with water and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting crude compound is purified by column chromatography using 100-200 silica gel and 4% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate (6).
[0319] To a stirred solution of tert-butyl 5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate (6, 55.0 g, 180.5 mmol) in a 1N aqueous solution of sodium hydroxide (1.1 L), tetrabutylammonium bromide (8.72 g, 27.07 mmol) and potassium iodide (4.49 g, 27.07 mmol) are added at room temperature, and the reaction mixture is heated to 90°C. 1,2-Dibromoethane (7, 57.82 mL, 667.89 mmol) is added slowly at 90°C, and the reaction mixture is stirred at 90°C for 16 hours. Upon completion, the reaction mixture is extracted with dichloromethane. The organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude mass. The crude compound is purified by column chromatography using 100-200 silica gel and 2% ethyl acetate in hexane to give tert-butyl 2'-(2-bromoethoxy)-5'-chloro-[1,1'-biphenyl]-3-carboxylate (8).
[0320] Example 1B.9
[0321] [ka]
[0322] To a stirred solution of ethyl 2-(diethoxyphosphoryl)acetate (2, 23.01 g, 102.7 mmol) in tetrahydrofuran (100 mL) at 0° C., sodium hydride (60%) (5.47 g, 136.9 mmol) is added and the reaction mixture is stirred at 0° C. for 1 hour. 2-Bromo-4-chlorobenzaldehyde (1, 15.0 g, 68.4 mmol) in tetrahydrofuran (3 mL) is slowly added and the reaction mixture is stirred at 0° C. for 2 hours. After completion, the reaction is quenched with water and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude mass. The crude material is purified by Combi-flash using 3% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give ethyl (E)-3-(2-bromo-4-chlorophenyl)acrylate (3).
[0323] To a stirred solution of ethyl (E)-3-(2-bromo-4-chlorophenyl)acrylate (3, 2.0 g, 17.3 mmol) in dichloromethane (15.0 mL), diisobutylaluminum hydride (1 M in toluene) (31.1 mL, 31.1 mmol) is added and stirred at −78° C. for 1 hour. The reaction mixture is slowly brought to room temperature and stirred for 1 hour. After completion, the reaction is quenched with aqueous ammonium chloride solution and extracted with dichloromethane. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude mass, which is purified by Combi-flash using 13% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give (E)-3-(2-bromo-4-chlorophenyl)prop-2-en-1-ol (4).
[0324] A stirred solution of (E)-3-(2-bromo-4-chlorophenyl)prop-2-en-1-ol (4, 1.5 g, 6.07 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (5, 2.03 g, 6.68 mmol), and potassium carbonate (2.51 g, 18.2 mmol) in a mixture of dioxane and water (4:1) (24.0 mL) was degassed with argon for 30 minutes. [1,1'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.222 g, 0.3 mmol) was added, and the reaction mixture was heated at 90°C for 12 hours. Upon completion, the reaction was quenched with water and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude mass. The crude compound is purified by Combi-flash using 15% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to obtain tert-butyl (E)-5'-chloro-2'-(3-hydroxyprop-1-en-1-yl)-[1,1'-biphenyl]-3-carboxylate (6).
[0325] To a stirred solution of tert-butyl (E)-5'-chloro-2'-(3-hydroxyprop-1-en-1-yl)-[1,1'-biphenyl]-3-carboxylate (6, 1.5 g, 4.34 mmol) and triethylamine (1.82 mL, 13.04 mmol) in dichloromethane at 0°C, methanesulfonyl chloride (0.67 mL, 8.69 mmol) is added, and the reaction mixture is slowly brought to room temperature and stirred for 16 hours. Upon completion, the reaction is quenched with water and extracted with dichloromethane. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude material. The crude compound is purified by Combi-flash using 10% ethyl acetate in hexane as the eluent to give tert-butyl (E)-5'-chloro-2'-(3-chloroprop-1-en-1-yl)-[1,1'-biphenyl]-3-carboxylate (7).
[0326] Example 1B.10
[0327] [ka]
[0328] A stirred solution of 2-bromo-4-chloro-1-iodobenzene (1, 1.0 g, 3.15 mmol), prop-2-yn-1-ol (2, 0.2 mL, 3.47 mmol) and copper(I) iodide (0.024 g, 0.126 mmol) in triethylamine (30 mL) is degassed with argon for 20 minutes. Dichlorobis(triphenylphosphine)palladium(II) (0.110 g, 0.15 mmol) is added and the reaction mixture is stirred at room temperature for 16 hours. Upon completion, the reaction is quenched with water and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude material. The crude compound is purified by Combi-flash using 10% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 3-(2-bromo-4-chlorophenyl)prop-2-yn-1-ol (3) as a yellow solid. Yield: 0.725 g, 93%, MS ionization not observed.
[0329] To a stirred solution of 3-(2-bromo-4-chlorophenyl)prop-2-yn-1-ol (3, 0.72 g, 2.93 mmol) in dichloromethane (10 mL) is added thionyl chloride (0.85 mL, 11.75 mmol) at 0° C., and the reaction mixture is heated and stirred at 50° C. for 16 h. Upon completion, the reaction is concentrated under reduced pressure to give the crude product, which is purified by Combi-flash using 3% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 2-bromo-4-chloro-1-(3-chloroprop-1-yn-1-yl)benzene (4).
[0330] Example 1C. General Coupling Methods Example 1C1
[0331] [ka]
[0332] To a solution of 6-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (A, 1 equivalent) in N,N-dimethylformamide (0.2 M solution) is added potassium carbonate (3 equivalents) and tert-butyl 7-(2-(2-bromoethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (B, 1 equivalent), and the reaction mixture is heated at 60° C. for 16 hours. The reaction mixture is then cooled, diluted with water, and extracted twice with ethyl acetate. The combined organic layers are washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel column chromatography gives tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (C).
[0333] Example 1C2 To a solution of 6-chloro-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (A, 1 equivalent) in N,N-dimethylformamide (0.14 M) is added tert-butyl 7-(2-(2-bromoethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (B, 1.3 equivalents), potassium iodide (0.2 equivalents), and ground potassium carbonate (3 equivalents) at room temperature. The mixture is stirred at 50° C. for 16 hours, diluted with water, and extracted twice with ethyl acetate. The combined organic layers are washed with water, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Purification by silica gel column chromatography gives tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (C).
[0334] Example 1C.3. Alternative Coupling Method
[0335] [ka]
[0336] To a solution of 3-bromo-5-fluoroisonicotinic acid (A, 5.0 g, 21.92 mmol) in dimethylformamide (15 mL) is added potassium carbonate (6.07 g, 43.84 mmol) and iodomethane (2.05 mL, 32.88 mmol) at room temperature, and the reaction mixture is stirred at room temperature for 2 hours. Upon completion, the reaction is diluted with ethyl acetate and washed with cold water. The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. The crude product is purified by flash chromatography, eluting the compound with ethyl acetate (1-10%) in hexane. The desired fractions are concentrated under reduced pressure to give methyl 3-bromo-5-fluoroisonicotinate (B).
[0337] To a solution of methyl 3-bromo-5-fluoroisonicotinate (B, 4.0 g, 17.17 mmol) in dimethylformamide (15 mL) is added potassium carbonate (7.0 g, 51.51 mmol), followed by the dropwise addition of 4-methoxybenzylamine (3.52 mL, 25.0 mmol) at room temperature. The reaction mixture is stirred at 50°C for 16 hours. Upon completion, the reaction is diluted with ethyl acetate and washed with cold water. The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. The crude product is purified by flash column chromatography, eluting the compound with ethyl acetate (10-20%) in hexanes. The desired fractions are concentrated under reduced pressure to give methyl 3-bromo-5-((4-methoxybenzyl)amino)isonicotinate (C).
[0338] To a solution of methyl 3-bromo-5-((4-methoxybenzyl)amino)isonicotinate (C, 2.8 g, 8.0 mmol) in methanol (5.0 mL) and water (5.0 mL), sodium hydroxide (0.64 g, 26.0 mmol) is added and the reaction mixture is stirred at room temperature for 6 hours. After completion, the reaction is concentrated to evaporate the methanol. The aqueous layer is cooled to 0° C. and acidified with 2 N hydrochloric acid (pH ∼4). The precipitated solid is filtered and dried to give 3-bromo-5-((4-methoxybenzyl)amino)isonicotinic acid (D).
[0339] To a solution of 3-bromo-5-((4-methoxybenzyl)amino)isonicotinic acid (D, 0.9 g, 26.0 mmol) in dimethylformamide (15 mL) is added methyl 7-(2-(2-aminoethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (E, 1.16 g, 32.0 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (1.48 g, 39.0 mmol) at 0° C. Diisopropylethylamine is added dropwise at 0° C. and the reaction mixture is stirred at room temperature for 3 hours. Upon completion, the reaction is diluted with ethyl acetate and washed with cold water. The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Purify the crude product by flash column chromatography, eluting with methanol (2-5%) in dichloromethane. Concentrate the desired fractions under reduced pressure to obtain methyl 7-(2-(2-(3-bromo-5-((4-methoxybenzyl)amino)isonicotinamido)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (F).
[0340] To a solution of methyl 7-(2-(2-(3-bromo-5-((4-methoxybenzyl)amino)isonicotinamido)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (F, 1.8 g, 26.0 mmol) in dichloromethane (10 mL) is added triflouroacetic acid (10 mL) at 0° C. and the reaction mixture is stirred at room temperature for 2 hours. Upon completion, the reaction is concentrated to give the crude product. The crude product is triturated with diethyl ether to give methyl 7-(2-(2-(3-amino-5-bromoisonicotinamido)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (G).
[0341] To a solution of methyl 7-(2-(2-(3-amino-5-bromoisonicotinamido)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (G, 1.2 g, 2.1 mmol) in tetrahydrofuran (10 mL) is added 2,2-difluoroacetic anhydride (H, 0.26 mL, 2.1 mmol) at 0° C. and the reaction mixture is stirred at room temperature for 1 hour. Upon completion, the reaction is concentrated to give the crude product. The crude product is washed and purified by trituration with diethyl ether to give methyl 7-(2-(2-(3-bromo-5-(2,2-difluoroacetamido)isonicotinamido)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (I).
[0342] A solution of methyl 7-(2-(2-(3-bromo-5-(2,2-difluoroacetamido)isonicotinamido)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (I, 1.0 g, 1.56 mmol) in acetic acid (10 mL) is heated and stirred at 110° C. for 24 hours. After completion, the acetic acid is removed under reduced pressure to give the crude product. The crude product is purified by flash column chromatography, eluting the compound with ethyl acetate (50-70%) in hexanes. The desired fractions are concentrated under reduced pressure to give methyl 7-(2-(2-(5-bromo-2-(difluoromethyl)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (J).
[0343] Example 1D. Post-Coupling Modification Method Example 1D.1
[0344] [ka]
[0345] To a solution of cyclopropanol (B, 2.5 equiv.) in tetrahydrofuran (0.6 M) is added sodium hydride (3 equiv.) and the reaction mixture is stirred for 10 minutes at 0° C. tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equiv.) is added to the reaction mixture at room temperature and heated to 120° C. for 6 hours. The reaction mixture is cooled to room temperature, diluted with water, extracted with ethyl acetate, and the ethyl acetate layer is dried over sodium sulfate, concentrated, and purified on a silica gel plug to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-cyclopropoxy-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C1).
[0346] To a solution of tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-cyclopropoxy-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C1, 1 equivalent) in dichloromethane (0.1 M) is added trifluoroacetic acid (0.1 M) at 0° C. The reaction is allowed to slowly come to room temperature and stirred for 16 hours. The reaction is concentrated under reduced pressure, washed with diethyl ether and purified by preparative HPLC to give 7-(5-chloro-2-(2-(5-cyano-6-cyclopropoxy-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C2).
[0347] Example 1D.2
[0348] [ka]
[0349] To a solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) and azetidin-3-ol hydrochloride (B, 2 equivalents) in DMF (0.16 M) is added potassium carbonate (5 equivalents) at room temperature, followed by heating at 100° C. with stirring for 16 hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the organic layer is washed with water, brine solution, dried over sodium sulfate, concentrated, and purified by flash chromatography to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-(3-hydroxyazetidin-1-yl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C).
[0350] Example 1D.3
[0351] [ka]
[0352] A solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) and cesium hydroxide (3 equivalents) in 1,4-dioxane (0.12 M) is degassed under nitrogen for 5 minutes. Tris(dibenzylideneacetone)dipalladium(0) (0.05 equivalents) and 5-(di-tert-butylphosphino)-1′,3′,5′-triphenyl-1′H-[1,4′]bipyrazole (0.03 equivalents) are added, and the mixture is heated at 90° C. for 16 hours. The reaction mixture is cooled, diluted with water, extracted with ethyl acetate, and the combined organic layers are dried over anhydrous sodium sulfate, filtered, and concentrated to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-hydroxy-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (B).
[0353] Example 1D.4
[0354] [ka]
[0355] A solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) in methanolic ammonia (20%, 0.05 M) is heated in a sealed tube at 120° C. for 16 hours. The reaction mixture is concentrated to give tert-butyl 7-(2-(2-(6-amino-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (B).
[0356] Example 1D.5
[0357] [ka]
[0358] To a solution of tert-butyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(methylamino)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) in acetic anhydride (B, 0.06 M) is added acetic acid (0.24 M) at room temperature and the mixture is heated at 120° C. for 27 hours. The reaction mixture is quenched on ice, extracted with ethyl acetate, and the organic layer is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by preparative HPLC to give 7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(N-methylacetamido)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C).
[0359] Example 1D.6
[0360] [ka]
[0361] A solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) in methanolic ammonia (20%, 0.05 M) is heated in a sealed tube at 120° C. for 16 hours. The reaction mixture is concentrated to give tert-butyl 7-(2-(2-(6-amino-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (B).
[0362] Example 1D.7
[0363] [ka]
[0364] To a solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-ethylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) in N,N-dimethylformamide (0.05 M) is added 1-methylpiperazine (B, 3 equivalents), potassium fluoride (5 equivalents) and 18-crown-6 (1 equivalent) and the mixture is heated at 90°C for 3 hours. The reaction mixture is cooled, diluted with water, extracted with ethyl acetate, and the combined organic layers are dried over anhydrous sodium sulfate, filtered, and concentrated to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(4-methylpiperazin-1-yl)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-ethylthieno[3,2-b]pyridine-3-carboxylate (C).
[0365] Example 1D.8
[0366] [ka]
[0367] To a solution of 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (A, 1 equivalent) and tert-butyl azetidin-3-yl(methyl)carbamate hydrochloride (B, 2 equivalents) in 1,4-dioxane (0.088 M) is added cesium carbonate (0.172 g, 0.530 mmol) and the reaction mixture is heated at 90° C. for 3 hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the organic layer is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give 7-(2-(2-(6-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C1).
[0368] To a solution of 7-(2-(2-(6-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C1, 1 equivalent) in dichloromethane (0.045 M) is added 2,2,2-trifluoroacetic acid (0.14 M) at 0° C. and the reaction mixture is stirred at room temperature for 16 hours. The reaction mixture is concentrated and purified by preparative HPLC to give 7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(3-(methylamino)azetidin-1-yl)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylic acid (C2).
[0369] Example 1D.9
[0370] [ka]
[0371] tert-Butyl 7-(2-(2-(6-bromo-5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent), 3-aminopyridine (B, 1.1 equivalents), Xantphos (0.2 equivalents), cesium carbonate (3 equivalents), and tris(dibenzylideneacetone)dipalladium(0) (0.2 equivalents) are suspended in 1,4-dioxane (0.047 M) in a screw-cap vial equipped with a stir bar. The reaction mixture is sparged with argon for 3 minutes, then sealed and heated in a heating block at 100° C. for 75 minutes. The reaction mixture is cooled to room temperature, dissolved in 1:1 N,N-dimethylformamide:methanol, and filtered through a syringe filter. Preparative HPLC affords tert-butyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-6-(pyridin-3-ylamino)-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C).
[0372] Example 1D.10
[0373] [ka]
[0374] To a stirred solution of oxetan-3-amine (B, 1 equiv.) is added sodium carbonate (3.5 equiv.) and 1,5-dichloropentan-3-one (A, 1 equiv.) in methanol (0.68 M) at room temperature, and the reaction mixture is heated at 75° C. for 3 h. The reaction mixture is cooled to room temperature, diluted with water, extracted with ethyl acetate, and the ethyl acetate layer is dried over sodium sulfate, concentrated, and purified on a silica gel plug to give 1-(oxetan-3-yl)piperidin-4-one (C).
[0375] To a solution of 1-(oxetan-3-yl)piperidin-4-one (C, 0.8 g, 5.16 mmol) in dichloromethane (0.5 M) was added ethylamine (2 M in tetrahydrofuran, 1.3 equivalents) and acetic acid (10 M) at room temperature. The reaction mixture was stirred for 60 minutes, and sodium triacetoxyborohydride (1.3 equivalents) was added at 0° C. and stirred for 16 hours at room temperature. The reaction was quenched with 10% aqueous sodium hydroxide solution, extracted with methanol (5%) in dichloromethane, and the organic layer was washed with sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give N-ethyl-1-(oxetan-3-yl)piperidin-4-amine (D).
[0376] To a solution of tert-butyl 7-(5-chloro-2-(3-(5-cyano-6-fluoro-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (E, 1 equivalent) in acetonitrile (0.1 M) are added N-ethyl-1-(oxetan-3-yl)piperidin-4-amine (D, 2 equivalents) and N,N-diisopropylethylamine (3 equivalents) at room temperature, and the reaction mixture is stirred at 100° C. for 30 hours. The reaction is cooled to room temperature, quenched with water, extracted with ethyl acetate, and the organic layer is washed with sodium chloride solution, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by Combi flash to give tert-butyl 7-(5-chloro-2-(3-(5-cyano-6-(ethyl(1-(oxetan-3-yl)piperidin-4-yl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (F).
[0377] Example 1D.11
[0378] [ka]
[0379] To a solution of tert-butyl (2-(difluoromethyl)pyridin-4-yl)(methyl)carbamate (A, 1 equivalent) and acetic acid (10 equivalents) in methanol (0.029 M) is added 5% rhodium on carbon (0.5 equivalents) at room temperature, and the mixture is heated at 80° C. under 80 psi for 15 hours. The reaction mixture is filtered and concentrated to give tert-butyl (2-(difluoromethyl)piperidin-4-yl)(methyl)carbamate (B).
[0380] To a solution of tert-butyl (2-(difluoromethyl)piperidin-4-yl)(methyl)carbamate (B, 1 equivalent) in THF (0.19 M) is added formaldehyde (37% solution in water, 10 equivalents), acetic acid (9 equivalents), and molecular sieves (approximately 3x by weight). The mixture is stirred for 30 minutes at room temperature, sodium triacetoxyboranuide (361 mg, 1.7 mmol) is added, and the mixture is stirred for 30 minutes. The reaction mixture is diluted with methanol, and the residue is passed through a Strata ion exchange column eluting three times with water, then three times with acetonitrile, then three times with methanol. tert-Butyl (2-(difluoromethyl)-1-methylpiperidin-4-yl)(methyl)carbamate (C) is eluted by washing the column with a solution of dichloromethane, methanol, and ammonium hydroxide (50:40:10).
[0381] tert-Butyl (2-(difluoromethyl)-1-methylpiperidin-4-yl)(methyl)carbamate (C, 1 equivalent) in trifluoroacetic acid (0.006 M) is stirred at room temperature for 30 minutes, and the reaction mixture is concentrated to give 2-(difluoromethyl)-N,1-dimethylpiperidin-4-amine (D).
[0382] A mixture of 7-(5-chloro-2-(2-(5-cyano-8-fluoro-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylic acid (E, 1 equivalent), 2-(difluoromethyl)-N,1-dimethylpiperidin-4-amine (D, 5 equivalents) and NMP (0.037 M) in DIPEA (7 equivalents) is stirred at room temperature for 30 minutes. The reaction mixture is filtered and purified by HPLC to give 7-(5-chloro-2-(2-(5-cyano-8-((2-(difluoromethyl)-1-methylpiperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylic acid (F).
[0383] Example 1D.12
[0384] [ka]
[0385] To a solution of tert-butyl 7-(5-chloro-2-(3-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) in dichloromethane (40 mL) is added trifluoroacetic acid (0.25 M) at 0° C. and stirred at room temperature for 17 hours. The mixture is concentrated in vacuo, aqueous sodium bicarbonate is added, and the mixture is washed with diethyl ether. The aqueous layer is acidified with 3N hydrogen chloride solution and stirred for 15 minutes. Filtration gives 7-(5-chloro-2-(3-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylic acid (B).
[0386] To a solution of 7-(5-chloro-2-(3-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylic acid (B, 1160 mg, 2.12 mmol) in dichloromethane (0.11 M) and methanol (0.42 M) is added trimethylsilyldiazomethane (4 equivalents) at 0°C. After stirring at 0° C. for 10 minutes, the reaction is quenched with acetic acid (3.5 M), concentrated, and purified by silica gel column chromatography to give methyl 7-(5-chloro-2-(3-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (C).
[0387] To methyl 7-(5-chloro-2-(3-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (C, 433 mg, 0.770 mmol) in N-methyl-2-pyrrolidone (0.21 M) is added 1-(2-(trifluoromethoxy)ethyl)piperazine dihydrochloride (D, 1.5 equivalents) at room temperature, and the mixture is stirred at 50° C. for 2 hours, followed by stirring at room temperature for 17 hours. The mixture is diluted with methanol, filtered, and the filtrate is purified by preparative HPLC to give methyl 7-(5-chloro-2-(3-(5-cyano-2-methyl-4-oxo-6-(4-(2-(trifluoromethoxy)ethyl)piperazin-1-yl)pyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylate (E).
[0388] Example 1D.13
[0389] [ka]
[0390] To a solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) and potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate (B, 1.4 equivalents) in a mixture of toluene and water (2:1, 0.7 M) is added cesium carbonate (2 equivalents) and the reaction mixture is degassed with argon for 15 minutes. [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.1 equivalents) is added and heated at 100° C. for 16 hours. The reaction is filtered through Celite, washed with ethyl acetate, and the filtrate is dried over anhydrous sodium sulfate, concentrated, and purified by Combiflash to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-6-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C).
[0391] To a stirred solution of tert-butyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-6-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)pyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C, 1 equivalent) in a mixture of acetonitrile and water (3:1, 0.018 M) is added Selectfluor-II (2 equivalents) at 0° C., and the mixture is stirred at room temperature for 48 hours. The reaction mixture is partitioned between water and ethyl acetate, and the organic layer is dried over sodium sulfate and concentrated to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-(2-hydroxyethyl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (D).
[0392]
[0298] To a solution of tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-(2-hydroxyethyl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (D, 1 equivalent) in dichloromethane (0.4 M) is added diethylaminosulfur trifluoride (1.5 equivalents) at 0°C and the mixture is stirred at room temperature for 3 hours. The reaction is quenched with 10% aqueous sodium hydroxide at 0° C., extracted with dichloromethane, and the organic layer is dried over anhydrous sodium sulfate and concentrated to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-(2-fluoroethyl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (E).
[0393] Example 1D.14
[0394] [ka]
[0395] tert-Butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent), PdCl2(PPh3)2 (0.18 equivalents) and (E)-4,4,5,5-tetramethyl-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)-1,3,2-dioxaborolane (B, 1.6 equivalents) are suspended in 1,4-dioxane (0.054 M) in an oven-dried microwave vial equipped with a stir bar. Aqueous potassium carbonate (2.0 M, 4 equiv.) is added, the sealed vial is sparged with argon for 5 minutes, and heated in a microwave reactor at 100° C. for 4 hours. The reaction mixture is diluted with saturated aqueous sodium bicarbonate and ethyl acetate, and the aqueous layer is extracted three times with ethyl acetate. The combined organic material is washed with brine, dried over magnesium sulfate, filtered, and purified via silica gel chromatography to give tert-butyl (E)-7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-6-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)pyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (C).
[0396] tert-Butyl (E)-7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-6-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)pyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (C, 1 eq.) is suspended in methanol (0.05 M) and tetrahydrofuran (0.05 M) and water (0.05 M) in a screw-cap vial equipped with a stir bar, and p-toluenesulfonic acid (0.35 eq.) is added in one portion while the reaction mixture is stirred at room temperature. After 30 minutes, the temperature is increased to 55° C. and stirred for an additional hour. Water (0.1 M) is added, and after 1 hour, the temperature is increased to 80° C. and heated at this temperature for 8 hours. The reaction mixture is cooled to room temperature, and the volatile solvents are then removed in vacuo. The reaction mixture is diluted with saturated aqueous sodium bicarbonate and ethyl acetate, the layers are separated, and the aqueous layer is extracted three times with ethyl acetate. The combined organic material is washed with brine, dried over magnesium sulfate, and the solids are filtered and concentrated to give tert-butyl (E)-7-(5-chloro-2-(2-(5-cyano-6-(3-hydroxyprop-1-en-1-yl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (D).
[0397] tert-Butyl (E)-7-(5-chloro-2-(2-(5-cyano-6-(3-hydroxyprop-1-en-1-yl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (D, 1 equivalent) is dissolved in dichloromethane (0.086 M) in an oven-dried screw-cap vial equipped with a stir bar. N,N-diisopropylethylamine (6 equivalents) is added slowly while the reaction mixture is stirred at 0° C. Methanesulfonyl chloride (2.6 equivalents) is then added dropwise, at which time the ice bath is removed. After 30 minutes, the reaction mixture is diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate, filtered, and the solvent removed in vacuo to give tert-butyl (E)-7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(3-((methylsulfonyl)oxy)prop-1-en-1-yl)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (E).
[0398] tert-Butyl (E)-7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(3-((methylsulfonyl)oxy)prop-1-en-1-yl)-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (E, 54.5 mg, 0.07 mmol) is dissolved in 1,2-dichloroethane (0.05 M) in a screw-cap vial equipped with a stir bar, and 4,4-difluoropiperidine (F, 3.3 equiv.) is added dropwise while the reaction mixture is stirred at 10° C. N,N-diisopropylethylamine (6.6 equiv.) is added dropwise, and after 5 min, the reaction mixture is allowed to warm to room temperature. After 15 min, the temperature is increased to 45° C., and stirring is continued for 3 h. The reaction mixture is cooled to room temperature, and the solvent is then removed in vacuo. The residue is dissolved in DMF and filtered through a syringe filter. Preparative HPLC affords the desired product, which is isolated by passing the HPLC fraction through a Strata ion exchange column and then washing with a solution of dichloromethane, methanol, and ammonium hydroxide. The solvent is removed to give tert-butyl (E)-7-(5-chloro-2-(2-(5-cyano-6-(3-(4,4-difluoropiperidin-1-yl)prop-1-en-1-yl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (G).
[0399] Example 1D.15
[0400] [ka]
[0401] A solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent), tributyl(methoxymethyl)stannane (B, 1.5 equivalents) in 1-methyl-2-pyrrolidinone (0.1 M) is degassed using argon for 10 minutes, and tetrakis(triphenylphosphine)palladium(0) (0.055 g, 0.048 mmol) is added at room temperature and heated at 130° C. for 10 hours. The reaction mixture is cooled to room temperature, diluted with water, extracted with ethyl acetate, and the ethyl acetate layer is dried over sodium sulfate, concentrated, and purified by preparative HPLC to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-(methoxymethyl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C).
[0402] Example 1D.16
[0403] [ka]
[0404] To a solution of tert-butyl 7-(5-chloro-2-(2-(6-chloro-5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (A, 1 equivalent) and (2-fluorophenyl)boronic acid (B, 1.5 equivalents) in 1,4-dioxane, 2 M aqueous potassium carbonate (3 equivalents) is added and the reaction mixture is degassed with argon gas for 10 minutes. [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.05 equivalents) is added, degassed with argon gas for 5 minutes, and the reaction mixture is heated to 90° C. for 3 hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the organic layer is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-(2-fluorophenyl)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (C).
[0405] Example 1D.17
[0406] [ka]
[0407] To a solution of 7-(5-chloro-2-(3-(5-cyano-6-((1-(2,2-difluoropropyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)thieno[3,2-b]pyridine-3-carboxylic acid (A, 1 equivalent) and oxetane-3-sulfonamide (B, 2.5 equivalents) in dichloromethane (0.07 M) is added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2 equivalents) and 4-(dimethylamino)pyridine (2.5 equivalents) at 0° C. and stirred at room temperature for 12 hours. The reaction mixture is diluted with water, extracted with dichloromethane, and the organic layer is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by preparative HPLC to give 7-(5-chloro-2-(3-(5-cyano-6-((1-(2,2-difluoropropyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(oxetan-3-ylsulfonyl)thieno[3,2-b]pyridine-3-carboxamide (C).
[0408] Example 1D.18
[0409] [ka]
[0410] To a stirred solution of 5-bromo-3-(3-(2-bromo-4-chlorophenyl)prop-2-yn-1-yl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one (6, 0.6 g, 1.28 mmol) in N,N-dimethylformamide, copper(I) cyanide (0.138 g, 1.53 mmol) is added and the reaction mixture is heated and stirred at 90° C. for 16 hours. After completion, the reaction is diluted with ethyl acetate and washed with cold water. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude compound is purified by Combi-flash using 50% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 3-(3-(2-bromo-4-chlorophenyl)prop-2-yn-1-yl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (7).
[0411] A stirred solution of 3-(3-(2-bromo-4-chlorophenyl)prop-2-yn-1-yl)-2-methyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-5-carbonitrile (7, 0.1 g, 0.24 mmol), 4-boronophthalic acid (8, 0.075 g, 0.36 mmol), and potassium carbonate (0.099 g, 0.72 mmol) in a mixture of dioxane, N,N-dimethylformamide, and water (1.2 mL, 0.6 mL, and 0.2 mL, respectively) is degassed with argon for 25 minutes. Dichlorobis(triphenylphosphine)palladium(II) is added, and the reaction mixture is heated and stirred at 90° C. for 2 hours. After completion, the volatiles are removed under reduced pressure to give a residue. The residue is diluted with water, acidified with 1N aqueous hydrochloric acid, and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give compound 9. The compound is purified by preparative HPLC to give 5'-chloro-2'-(3-(5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)-[1,1'-biphenyl]-3,4-dicarboxylic acid (9).
[0412] Example 1D.18
[0413] [ka]
[0414] To a solution of methyl 2-amino-5'-chloro-2'-(2-(5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-[1,1'-biphenyl]-3-carboxylate (3, 1.5 g, 3.06 mmol) in acetonitrile (40 mL) is added tert-butyl nitrite (0.50 g, 4.8 mmol) at room temperature. A suspension of copper(I) iodide (0.93 g, 3.06 mmol) in acetonitrile (10 mL) is added dropwise over a period of 10 minutes at room temperature. The reaction mixture is stirred at 60°C for 4 hours. Upon completion, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic layer is washed with aqueous sodium thiosulfate, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude material is purified by flash column chromatography using 0 to 40% ethyl acetate in hexanes to give methyl 5'-chloro-2'-(2-(5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-2-iodo-[1,1'-biphenyl]-3-carboxylate (4).
[0415] A solution of methyl 5'-chloro-2'-(2-(5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-2-iodo-[1,1'-biphenyl]-3-carboxylate (4, 0.57 g, 0.95 mmol) in dioxane (20 mL) is degassed using argon for 10 minutes. Tributyl(ethynyl)stannane (5, 0.6 g, 1.86 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.076 g, 0.066 mmol) are added and the reaction mixture is stirred at 90°C for 16 hours. Upon completion, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude material is purified by flash column chromatography using 0 to 40% ethyl acetate in hexanes to give methyl 5'-chloro-2'-(2-(5-cyano-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)ethoxy)-2-ethynyl-[1,1'-biphenyl]-3-carboxylate (6).
[0416]
[0310] Compounds made using one or more of the above general methods are shown in Table 1. Characterization data, where indicated, is to the right of the compounds.
[0417] [Table 1-1]
[0418] [Table 1-2]
[0419] [Table 1-3]
[0420] [Table 1-4]
[0421]
Table 1-5
[0422]
Table 1-6
[0423]
Table 1-7
[0424]
Table 1-8
[0425]
Table 1-9
[0426]
Table 1-10
[0427]
Table 1-11
[0428]
Table 1-12
[0429]
Table 1-13
[0430]
Table 1-14
[0431]
Table 1-15
[0432]
Table 1-16
[0433]
Table 1-17
[0434]
Table 1-18
[0435]
Table 1-19
[0436]
Table 1-20
[0437]
Table 1-21
[0438]
Table 1-22
[0439]
Table 1-23
[0440]
Table 1-24
[0441]
Table 1-25
[0442]
Table 1-26
[0443]
Table 1-27
[0444]
Table 1-28
[0445]
Table 1-29
[0446]
Table 1-30
[0447]
Table 1-31
[0448]
Table 1-32
[0449]
Table 1-33
[0450]
Table 1-34
[0451]
Table 1-35
[0452]
Table 1-36
[0453]
Table 1-37
[0454]
Table 1-38
[0455]
Table 1-39
[0456]
Table 1-40
[0457]
Table 1-41
[0458]
Table 1-42
[0459]
Table 1-43
[0460]
Table 1-44
[0461]
Table 1-45
[0462]
Table 1-46
[0463]
Table 1-47
[0464]
Table 1-48
[0465]
Table 1-49
[0466]
Table 1-50
[0467]
Table 1-51
[0468]
Table 1-52
[0469]
Table 1-53
[0470]
Table 1-54
[0471]
Table 1-55
[0472]
Table 1-56
[0473]
Table 1-57
[0474]
Table 1-58
[0475]
Table 1-59
[0476]
Table 1-60
[0477]
Table 1-61
[0478]
Table 1-62
[0479]
Table 1-63
[0480]
Table 1-64
[0481]
Table 1-65
[0482]
Table 1-66
[0483]
Table 1-67
[0484]
Table 1-68
[0485]
Table 1-69
[0486]
Table 1-70
[0487]
Table 1-71
[0488]
Table 1-72
[0489]
Table 1-73
[0490]
Table 1-74
[0491]
Table 1-75
[0492]
Table 1-76
[0493]
Table 1-77
[0494] Table 1-78
[0495]
Table 1-79
[0496]
Table 1-80
[0497]
Table 1-81
[0498]
Table 1-82
[0499]
Table 1-83
[0500]
Table 1-84
[0501]
Table 1-85
[0502]
Table 1-86
[0503]
Table 1-87
[0504]
Table 1-88
[0505]
Table 1-89
[0506]
Table 1-90
[0507]
Table 1-91
[0508]
Table 1-92
[0509]
Table 1-93
[0510]
Table 1-94
[0511]
Table 1-95
[0512]
Table 1-96
[0513]
Table 1-97
[0514]
Table 1-98
[0515]
Table 1-99
[0516]
Table 1-100
[0517]
Table 1-101
[0518]
Table 1-102
[0519]
Table 1-103
[0520]
Table 1-104
[0521]
Table 1-105
[0522]
Table 1-106
[0523]
Table 1-107
[0524]
Table 1-108
[0525]
Table 1-109
[0526]
Table 1-110
[0527]
Table 1-111
[0528]
Table 1-112
[0529]
Table 1-113
[0530]
Table 1-114
[0531]
Table 1-115
[0532]
Table 1-116
[0533]
Table 1-117
[0534]
Table 1-118
[0535]
Table 1-119
[0536]
Table 1-120
[0537]
Table 1-121
[0538]
Table 1-122
[0539]
Table 1-123
[0540]
Table 1-124
[0541]
Table 1-125
[0542]
Table 1-126
[0543]
Table 1-127
[0544] Table 1-128
[0545]
Table 1-129
[0546] Table 1-130
[0547]
Table 1-131
[0548] Table 1-132
[0549]
Table 1-133
[0550] Table 1-134
[0551] Table 1-135
[0552]
Table 1-136
[0553]
Table 1-137
[0554]
Table 1-138
[0555]
Table 1-139
[0556] Table 1-140
[0557]
Table 1-141
[0558] Table 1-142
[0559] Table 1-143
[0560] Table 1-144
[0561]
Table 1-145
[0562] Table 1-146
[0563]
Table 1-147
[0564]
Table 1-148
[0565]
Table 1-149
[0566]
Table 1-150
[0567]
Table 1-151
[0568]
Table 1-152
[0569]
Table 1-153
[0570] Table 1-154
[0571]
Table 1-155
[0572]
Table 1-156
[0573] Example 2.7 - General Method for the Synthesis of CF3-Thienylpyridine and Derivative Compounds The 7-CF3-thienylpyridine and derivative compounds in Table 2 can be synthesized using the methods described in Example 2. Many of the reactions described in Example 1 were used to synthesize the compounds in Table 2. For some compounds, some of the reactions described in Example 3 below can be used to prepare the compounds.
[0574] Example 2A. Method for synthesizing the left side Example 2A.1
[0575] [ka]
[0576] To a solution of diisopropylamine (17.8 mL, 0.123 mol) in dry tetrahydrofuran (200 mL) is added n-butyllithium (1.6 M, 66.5 mL, 0.113 mol) dropwise under an argon atmosphere at −78° C. The reaction mixture is warmed to −10° C. and stirred for 30 minutes. A solution of 1-bromo-3-fluoro-5-(trifluoromethyl)benzene (1, 25.0 g, 0.102 mol) in dry tetrahydrofuran (50 mL) is added at −78° C., and the mixture is stirred at −78° C. for 45 minutes. Carbon dioxide gas is purged through the reaction mixture for 15 minutes, and the temperature is gradually raised to room temperature over 2 hours. Upon completion, the reaction mixture is cooled to −78° C. and quenched with ice water. The mixture is basified with 1 N aqueous sodium hydroxide solution and washed with diethyl ether. The aqueous layer is acidified with 2N hydrochloric acid to pH 1 and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give 2-bromo-6-fluoro-4-(trifluoromethyl)benzoic acid (2).
[0577] Example 2A.2
[0578] [ka]
[0579] To a solution of 2-bromo-6-fluoro-4-(trifluoromethyl)benzamide (3, 4.5 g, crude, 15.7 mmol) in N,N-dimethylformamide (40 mL) was added potassium carbonate (6.5 g, 47.2 mmol) and (2,4-dimethoxyphenyl)methanamine (3.1 mL, 20.45 mmol) at room temperature. The reaction mixture was heated to 50° C. and stirred for 16 hours. After completion of the reaction, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography using 5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to obtain 2-bromo-6-((2,4-dimethoxybenzyl)amino)-4-(trifluoromethyl)benzamide (4).
[0580] To a solution of 2-bromo-6-((2,4-dimethoxybenzyl)amino)-4-(trifluoromethyl)benzamide (4, 1.0 g, 2.30 mmol) in dichloromethane (10 mL) is added trifluoroacetic acid (1.8 mL, 23.0 mmol), and the mixture is stirred for 30 minutes. After completion of the reaction, the reaction mixture is concentrated, and the resulting crude product is diluted with dichloromethane, washed with saturated sodium bicarbonate solution, brine solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product is purified by column chromatography using 5% methanol in dichloromethane as the eluent. The desired fractions are concentrated under reduced pressure to obtain 2-amino-6-bromo-4-(trifluoromethyl)benzamide (5).
[0581] To a solution of 2-amino-6-bromo-4-(trifluoromethyl)benzamide (5, 2.0 g, 7.06 mmol) in dichloromethane (20 mL) are added triethylamine (2.93 mL, 21 mmol) and 2-fluoroacetyl chloride (1.0 mL, 14.1 mmol) at 0° C., and the reaction mixture is stirred at the same temperature for 30 minutes. After completion of the reaction, the reaction mixture is diluted with ice water and extracted with dichloromethane. The organic layer is washed with saturated brine solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 2-bromo-6-(2-fluoroacetamido)-4-(trifluoromethyl)benzamide (6).
[0582] To a solution of 2-bromo-6-(2-fluoroacetamido)-4-(trifluoromethyl)benzamide (6, 0.600 g, 1.749 mmol) in ethanol (5 mL) is added 5% sodium hydroxide (4.0 mL). The mixture is heated to 110° C. and stirred for 30 minutes. After completion of the reaction, the reaction mixture is neutralized with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer is washed with saturated brine solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude product is purified by column chromatography using silica gel (100-200 mesh) and 0-5% methanol in dichloromethane as the eluent. The desired fractions are concentrated under reduced pressure to give 5-bromo-2-(fluoromethyl)-7-(trifluoromethyl)quinazolin-4(3H)-one (7).
[0583] Example 2A.3
[0584] [ka]
[0585] To a solution of 7-bromo-6-fluoro-2-methyl-4-oxo-3,4-dihydroquinazoline-5-carbonitrile (5, 0.200 g, 0.7 mmol) in N,N-dimethylformamide (2 mL) is added copper(I) iodide (0.159 g, 0.84 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (5a, 0.403 g, 2.1 mmol), and the reaction mixture is heated at 100° C. for 16 hours. Upon completion, the reaction mixture is cooled, water is added to the reaction mixture, and the mixture is extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give 6-fluoro-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (6).
[0586] Example 2A.4
[0587] [ka]
[0588] A suspension of copper(I) bromide (89.8 g, 620.1 mmol) and tert-butyl nitrite (63.8 mL, 620.1 mmol) in acetonitrile (2500 mL) is heated at 65° C. for 15 minutes. A solution of 2-bromo-4-fluoro-6-(trifluoromethyl)aniline (1, 100 g, 387.6 mmol) in acetonitrile is added, and the reaction mixture is heated at 65° C. for 1 hour. Upon completion, the reaction is quenched with water and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude material. The crude compound is purified by column chromatography on silica gel (100-200 mesh) using 0-5% ethyl acetate in hexane to give 1,2-dibromo-5-fluoro-3-(trifluoromethyl)benzene (2).
[0589] Example 2A.5
[0590] [ka]
[0591] To a stirred solution of 4-fluoro-1-methyl-2-(trifluoromethyl)benzene (1, 1.05 g, 5.89 mmol) in TFA (4 mL) is added sulfuric acid (1.25 mL), followed by N-bromosuccinimide (1.05 g, 5.89 mmol). The resulting mixture is capped, covered with aluminum foil to protect from light, and stirred overnight at room temperature. The reaction mixture is poured into vigorously stirred ice-water and then extracted with hexanes. The organics are washed with brine and then saturated aqueous sodium bicarbonate. The organics are dried over magnesium sulfate, filtered, concentrated on a rotary evaporator, and purified via silica gel chromatography (100% hexanes) to give 1-bromo-5-fluoro-2-methyl-3-(trifluoromethyl)benzene (2).
[0592] Example 2A.6
[0593] [ka]
[0594] To a solution of 2-bromo-4-fluoro-6-(trifluoromethyl)aniline (1, 100.0 g, 389.2 mmol) in acetonitrile (2500 mL) is added p-toluenesulfonic acid (220.9 g, 1160.1 mmol) in portions at −10° C. A solution of sodium nitrite (51.68 g, 750 mmol) and potassium iodide (157.7 g, 949.2 mmol) in water (100 mL) is added at −10° C., and the mixture is stirred at −10° C. for 45 minutes. Upon completion, the reaction mixture is quenched with water and extracted with ethyl acetate (5000 mL). The organic layer is washed with saturated aqueous sodium thiosulfate (500 mL). The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give 1-bromo-5-fluoro-2-iodo-3-(trifluoromethyl)benzene (2).
[0595] To a solution of 1-bromo-5-fluoro-2-iodo-3-(trifluoromethyl)benzene (2, 80.0 g, 217.3 mmol) in N,N-dimethylformamide (500 mL) is added copper(I) cyanide (19.4 g, 217.2 mmol) at room temperature. The reaction mixture is stirred at 90° C. for 12 hours. After completion, it is cooled to room temperature, poured into ice water, and extracted with ethyl acetate (2.0 L). The organic layer is washed with brine solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude compound is purified by flash column chromatography using 0-5% ethyl acetate in hexane to give 2-bromo-4-fluoro-6-(trifluoromethyl)benzonitrile (3).
[0596] To a solution of 2-bromo-4-fluoro-6-(trifluoromethyl)benzonitrile (3, 12.0 g, 44.9 mmol) in tetrahydrofuran (200 mL) is added borane in tetrahydrofuran (1 M, 67 mL, 67.1 mmol) dropwise at 0° C. The reaction mixture is stirred at 90° C. for 12 hours. Upon completion, the reaction mixture is poured into chilled methanol and concentrated under reduced pressure. The crude compound is purified by flash column chromatography using 0-15% ethyl acetate in hexane to give (2-bromo-4-fluoro-6-(trifluoromethyl)phenyl)methanamine (4).
[0597] To a solution of (2-bromo-4-fluoro-6-(trifluoromethyl)phenyl)methanamine (4, 6.0 g, 22.6 mmol) in methanol (100 mL) is added a solution of paraformaldehyde (6.0 g, 200.0 mmol) and sodium acetate (5.4 g, 66.0 mmol) in water (10 mL) and stirred at room temperature for 1 hour. Sodium cyanoborohydride (4.03 g, 66.1 mmol) is added portionwise at 0° C. The reaction mixture is stirred at room temperature for 12 hours. Upon completion, the reaction mixture is concentrated under reduced pressure. The crude residue is diluted with water and extracted with diethyl ether (100 mL). The crude compound is purified by flash column chromatography using 0-15% ethyl acetate in hexane to give 1-(2-bromo-4-fluoro-6-(trifluoromethyl)phenyl)-N,N-dimethylmethanamine (5).
[0598] Example 2A.7
[0599] [ka]
[0600] To a solution of 5-bromo-6-(hydroxymethyl)-2-methyl-7-(trifluoromethyl)quinazolin-4(3H)-one (A, 0.32 g, 0.94 mmol) in dichloromethane (6 mL) at 0° C., triethylamine (0.39 mL, 2.84 mmol) and methanesulfonyl chloride (0.11 mL, 1.42 mmol) are added and stirred at 0° C. for 1 hour. Upon completion, the reaction mixture is diluted with water and extracted with dichloromethane. The organic layer is washed with water, saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 5-bromo-6-(chloromethyl)-2-methyl-7-(trifluoromethyl)quinazolin-4(3H)-one (1).
[0601] To a solution of 4,4-difluoropiperidine (1a, 2.0 g, 12.7 mmol) in N,N-dimethylformamide (10.0 mL) was added potassium carbonate (1.06 g, 7.62 mmol) at room temperature, and the mixture was stirred for 20 minutes. 5-Bromo-6-(chloromethyl)-2-methyl-7-(trifluoromethyl)quinazolin-4(3H)-one (1, 0.9 g, 2.54 mmol) was then added to the reaction mixture at room temperature, and stirring was continued for 24 hours. Upon completion, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using silica gel (100-200 mesh) and 50% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 5-bromo-6-((4,4-difluoropiperidin-1-yl)methyl)-2-methyl-7-(trifluoromethyl)quinazolin-4(3H)-one (2).
[0602] Example 2A.8
[0603] [ka]
[0604] To a solution of 6-bromo-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (1, 50 mg, 0.151 mmol) in tetrahydrofuran (3 mL) and water (0.75 mL) was added 1-methyl-4-((trifluoro-λ 4(4-boranyl)methyl)piperazine, potassium salt (1a, 497 mg, 2.25 mmol), cesium carbonate (196 mg, 0.602 mmol), and XPhos chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (24 mg, 0.0301 mmol) were added, and the mixture was sparged with argon for 5 minutes. It was then sealed and heated to 80 °C for 15 hours. After completion, the mixture was concentrated under reduced pressure to give the crude product. The resulting crude product was purified by preparative HPLC to give 2-methyl-6-((4-methylpiperazin-1-yl)methyl)-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (2).
[0605] Example 2A.9
[0606] [ka]
[0607] A solution of 6-bromo-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (1, 1.00 g, 3.02 mmol), tert-butyl 4-methylenepiperidine-1-carboxylate (1a, 5.90 g, 30.1 mmol), triethylamine (1.20 mL, 9.03 mmol), and tri(o-tolyl)phosphine (0.366 g, 1.23 mmol) in acetonitrile (10.0 mL) was degassed with argon for 10 minutes. Palladium acetate(II) (0.134 g, 0.60 mmol) was then added to the reaction mixture, and degassing was continued for 5 minutes. The reaction mixture was heated at 90° C. for 24 hours. After this time, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, and concentrated to dryness under reduced pressure. The crude product is purified by silica gel (100-200 mesh) column chromatography using 30-50% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 4-((5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-6-yl)methylene)piperidine-1-carboxylate (2).
[0608] To a solution of tert-butyl 4-((5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-6-yl)methylene)piperidine-1-carboxylate (2, 0.90 g, 2.0 mmol) in methanol (20 mL) is added 10% palladium on carbon (1.35 g) at room temperature. The reaction mixture is stirred under a hydrogen atmosphere at room temperature for 2 hours. The reaction mixture is then filtered through Celite. The filtrate is washed with ethyl acetate and concentrated to dryness under reduced pressure to give the crude product. The crude product is purified by silica gel (100-200 mesh) column chromatography using 3-5% methanol in dichloromethane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 4-((5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-6-yl)methyl)piperidine-1-carboxylate (3).
[0609] Example 2A.10
[0610] [ka]
[0611] To a solution of 4-fluoro-2-(trifluoromethyl)aniline (1, 100.0 g, 558.66 mmol) in N,N-dimethylformamide (500 mL) was added N-chlorosuccinamide (78.7 g, 558.66 mmol) at room temperature. The reaction mixture was stirred for 16 hours. After this time, the mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel (100-200 mesh) column chromatography using hexane as the eluent. The desired fractions were concentrated under reduced pressure to give 2-chloro-4-fluoro-6-(trifluoromethyl)aniline (2).
[0612] To a solution of 2-chloro-4-fluoro-6-(trifluoromethyl)aniline (2, 43.0 g, 201.87 mmol) in acetonitrile (200 mL) was added p-toluenesulfonic acid monohydrate (115.0 g, 605.63 mmol) at −10° C. The reaction mixture was stirred at the same temperature for 15 min. A solution of sodium nitrite (27.85 g, 403.74 mmol) and potassium iodide (83.77 g, 504.67 mmol) in water (50 mL) was added dropwise to the reaction mixture with stirring at −10° C. for 30 min. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium thiosulfate solution, then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel (100-200 mesh) column chromatography using hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 1-chloro-5-fluoro-2-iodo-3-(trifluoromethyl)benzene (3).
[0613] To a solution of 1-chloro-5-fluoro-2-iodo-3-(trifluoromethyl)benzene (3, 30 g, 92.6 mmol) in N,N-dimethylformamide (200 mL) is added copper(I) cyanide (12.36 g, 138.88 mmol). The reaction mixture is heated at 100° C. for 16 h. After this time, the mixture is diluted with water and extracted with ethyl acetate. The organic layer is washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by silica gel (100-200 mesh) column chromatography using 3% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 2-chloro-4-fluoro-6-(trifluoromethyl)benzonitrile (4).
[0614] To a solution of 2-chloro-4-fluoro-6-(trifluoromethyl)benzonitrile (4, 15.0 g, 67.26 mmol) in dry dichloromethane (150 mL) is added dropwise diisobutylaluminum hydride (1.0 M in toluene, 134.52 mL, 134.52 mmol) at −78° C. The mixture is stirred at the same temperature for 30 minutes. The reaction mixture is then quenched with 1N aqueous hydrochloric acid solution and extracted with dichloromethane. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give 2-chloro-4-fluoro-6-(trifluoromethyl)benzaldehyde (5).
[0615] To a solution of 2-chloro-4-fluoro-6-(trifluoromethyl)benzaldehyde (5, 17.00 g, 75.22 mmol) in tetrahydrofuran (100 mL), 2-methylpropane-2-sulfinamide (5a, 13.65 g, 112.83 mmol) and titanium ethoxide (34.30 mL, 150.44 mmol) are added dropwise at room temperature. The reaction mixture is stirred at the same temperature for 16 hours. After this time, the reaction mixture is quenched with aqueous ammonium chloride solution, filtered through Celite, and washed with ethyl acetate. The filtrate is concentrated, and the crude residue is purified by Combi-flash (40 g, Redi-Sep column) using 20% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give (E)-N-(2-chloro-4-fluoro-6-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfinamide (6).
[0616] Magnesium turnings (5.0 g) are added to dry tetrahydrofuran (50 mL) followed by iodine (0.002 g), and the mixture is heated to just above room temperature. 2-(2-Bromoethyl)-1,3-dioxane (6a, 9.8 mL, 72.94 mmol) is then added, and the mixture is heated until colorless. This mixture is then added dropwise at room temperature to a solution of (E)-N-(2-chloro-4-fluoro-6-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfinamide (6, 12.00 g, 36.47 mmol) in tetrahydrofuran (50 mL). The resulting mixture is stirred at room temperature for 1 hour. The reaction mixture is then quenched with aqueous ammonium chloride and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate and concentrated. The crude residue is purified by Combi-flash (40 g, Redi-Sep column) using 30% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give N-(1-(2-chloro-4-fluoro-6-(trifluoromethyl)phenyl)-3-(1,3-dioxan-2-yl)propyl)-2-methylpropane-2-sulfinamide (7).
[0617] A solution mixture of N-(1-(2-chloro-4-fluoro-6-(trifluoromethyl)phenyl)-3-(1,3-dioxan-2-yl)propyl)-2-methylpropane-2-sulfinamide (7, 12.00 g, 26.96 mmol) in trifluroacetic acid in water (3:1, 180 mL) is stirred at room temperature for 16 hours. After this time, the reaction mixture is quenched with aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated. The solid residue is dissolved in methanol, after which sodium borohydride (8.00 g, 269.66 mmol) is added at 0° C., and the mixture is stirred at room temperature for 8 hours. After this time, the reaction mixture is quenched with ice-cold water and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give 2-(2-chloro-4-fluoro-6-(trifluoromethyl)phenyl)pyrrolidine (8).
[0618] Example 2A.11
[0619] [ka]
[0620] To a solution of 2,3-difluoro-4-(trifluoromethyl)benzoic acid (1.5 g, 22.123 mmol) in N,N-dimethylformamide (50 mL) is added N-iodosuccinimide (7.43 g, 33.185 mmol) and purged with argon for 20 minutes. Palladium acetate (1.48 g, 6.637 mmol) is then added and the reaction mixture is heated at 100° C. for 48 hours. Upon completion, the reaction mixture is cooled, diluted with water, and extracted with ethyl acetate. The combined organic layers are washed with cold water and brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 2,3-difluoro-6-iodo-4-(trifluoromethyl)benzoic acid (2).
[0621] Example 2B. Method for synthesizing the right side Example 2B.1
[0622] [ka]
[0623] To a solution of 2-bromo-4-chlorophenol (7, 50.0 g, 241.0 mmol) in aqueous sodium hydroxide (1 M) (1.0 L), tetra-n-butylammonium bromide (11.64 g, 36.15 mmol) and potassium iodide (6.00 g, 36.15 mmol) are added. 1,2-Dibromoethane (8, 165.6 g, 891.7 mmol) is added at 85° C. and stirred at the same temperature for 16 hours. Upon completion, the reaction mixture is poured into water and extracted with ethyl acetate. The combined organic layers are washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude compound is purified by flash column chromatography (using 0-5% ethyl acetate in hexane) to give 2-bromo-1-(2-bromoethoxy)-4-chlorobenzene (9).
[0624] Example 2B.2
[0625] [ka]
[0626] A stirred solution of phosphorus oxybromide (7.5 g, 26.4 mmol) and thieno[3,2-b]pyridin-7-ol (1, 2.0 g, 13.2 mmol) in 1,2-dichloroethane is heated at 90° C. for 12 hours. After completion of the reaction, the mixture is cooled to room temperature, quenched with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer is washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 7-bromothieno[3,2-b]pyridine (2).
[0627] To a stirred solution of 7-bromothieno[3,2-b]pyridine (2, 1.5 g, 7.04 mmol) in dry tetrahydrofuran (20 mL) was added freshly prepared lithium diisopropylamide (2.0 M in hexane, 8.75 mL, 17.5 mmol) at −78° C., and the mixture was stirred at the same temperature for 1 h. Hexachloroethane (2.0 mL, 8.44 mmol) was added dropwise, and the reaction mixture was allowed to warm to room temperature over 3 h. The reaction was quenched with aqueous ammonium chloride, diluted with water, and extracted with ethyl acetate. The organic layer was washed with water, saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a silica gel plug, eluting the compound with ethyl acetate (0–10%) in hexane. The desired fractions were concentrated under reduced pressure to give 7-bromo-2-chlorothieno[3,2-b]pyridine (3).
[0628] A solution of 7-bromo-2-chlorothieno[3,2-b]pyridine (3, 0.5 g, 2.02 mmol) in dry tetrahydrofuran (10 mL) and the mixture is cooled to −78° C. Lithium diisopropylamide (2 M, 1.5 mL, 3.03 mmol) is added dropwise, and the reaction mixture is stirred at −78° C. for 1 hour. Carbon dioxide gas is purged into the reaction at the same temperature for 20 minutes and stirred at −78° C. for 1 hour. The reaction mixture is slowly warmed to 0° C. and stirred for 30 minutes. Upon completion, the reaction mixture is quenched with water and washed with ethyl acetate. The ethyl acetate layer is discarded, and the aqueous layer is acidified with aqueous citric acid. It is then extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 7-bromo-2-chlorothieno[3,2-b]pyridine-3-carboxylic acid (4).
[0629] Example 2B.3
[0630] [ka]
[0631] To a stirred solution of 7-chlorothieno[3,2-b]pyridine (1, 1.5 g, 8.9 mmol) in dry tetrahydrofuran (50 mL), lithium diisopropylamide (11.7 mL, 19.5 mmol) is added dropwise at −78° C., and the mixture is stirred at the same temperature for 1 h. Iodine (2.25 g, 8.87 mmol, dissolved in tetrahydrofuran, 10 mL) is added dropwise, and the reaction mixture is allowed to warm to room temperature over 4 h. It is quenched with aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer is washed with water and saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product is purified by Combiflash (12 g, RediSep column) using 5–10% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 7-chloro-2-iodothieno[3,2-b]pyridine (2).
[0632] To a solution of 7-chloro-2-iodothieno[3,2-b]pyridine (2, 1.0 g, 3.4 mmol) in N,N-dimethylformamide (10 mL) is added N-bromosuccinamide at room temperature. The reaction mixture is heated and stirred at 70 °C for 12 h. After completion of the reaction, the mixture is diluted with water and extracted with ethyl acetate. The organic layer is washed with water and saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by Combiflash (12 g, RediSep column) using 5-10% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 3-bromo-7-chloro-2-iodothieno[3,2-b]pyridine (3).
[0633] A suspension of 3-bromo-7-chloro-2-iodothieno[3,2-b]pyridine (3, 1.0 g, 2.7 mmol) and tributylvinyltin (1.01 mL, 3.21 mmol) in 1,4-dioxane (10 mL) was degassed using argon for 10 minutes. Tetrakis(triphenylphosphine)palladium(0) (0.21 g, 0.19 mmol) was added to the reaction mixture at room temperature, and the mixture was heated at 100 °C for 1 hour. Upon completion, the reaction mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The ethyl acetate layer was dried over sodium sulfate and concentrated to dryness under reduced pressure. The crude product was purified on a silica gel plug, eluting the compound with ethyl acetate:hexane (1-10%). The desired fractions were concentrated under reduced pressure to give 3-bromo-7-chloro-2-vinylthieno[3,2-b]pyridine (4).
[0634] To a solution of 3-bromo-7-chloro-2-vinylthieno[3,2-b]pyridine (4, 0.6 g, 2.19 mmol) in dry tetrahydrofuran (20 mL), n-butyllithium (1.7 mL, 1.3 M in hexane, 2.19 mmol) is added dropwise at −78° C., and the reaction mixture is stirred at the same temperature for 2 hours. Carbon dioxide gas is purged into the reaction mixture at −78° C. for 30 minutes, and the reaction mixture is stirred at the same temperature for 1 hour. The reaction mixture is slowly warmed to 0° C. and stirred for 30 minutes. Upon completion, the reaction mixture is quenched with water and washed with ethyl acetate. The ethyl acetate layer is discarded, and the aqueous layer is acidified with aqueous citric acid and extracted with ethyl acetate. The organic layer is separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 7-chloro-2-vinylthieno[3,2-b]pyridine-3-carboxylic acid (5).
[0635] Example 2B.4
[0636] [ka]
[0637] Methyl 7-bromothieno[3,2-b]pyridine-3-carboxylate (1, 68.0 mg, 0.25 mmol) and bis(trifluoromethylsulfinyloxy)zinc (1a, 139.8 mg, 0.50 mmol) are dissolved in dimethyl sulfoxide (1.71 mL) in an oven-dried screw-cap vial equipped with a stir bar. tert-Butyl hydroperoxide (0.09 mL, 0.92 mmol) is slowly added while the mixture is vigorously stirred at 0°C. After the addition is complete, the ice bath is removed and the reaction mixture is heated to 50°C in a heating block for 2.5 hours before being cooled to room temperature. The reaction mixture is diluted with saturated aqueous sodium bicarbonate and ethyl acetate. The layers are separated and the aqueous layer is extracted three times with ethyl acetate. The combined organic material is washed with brine and dried over magnesium sulfate. The solids are filtered and the solvent removed in vacuo to give a crude residue which is purified via silica gel chromatography (5 to 40% ethyl acetate in hexanes) to give methyl 7-bromo-2-(trifluoromethyl)thieno[3,2-b]pyridine-3-carboxylate (2).
[0638] Example 2B.5
[0639] [ka]
[0640] A solution of tert-butyl 7-bromothieno[3,2-b]pyridine-3-carboxylate (1, 150.0 mg, 0.480 mmol), (3-oxo-1λ^{3},2-benzoiodoxol-1-yl)acetate (417.5 mg, 0.950 mmol), 2-(tert-butyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1a, 132.0 mg, 0.720 mmol), and tris(2,2'-bipyridyl)dichloro-ruthenium(II) hexahydrate (35.7 mg, 0.048 mmol) in hexafluoroisopropanol (1.25 mL) was stirred at room temperature and irradiated for 24 hours using a 60-watt house lamp positioned 10 cm from the vial. Upon completion, the reaction mixture is diluted with dichloromethane and silica gel is added. The solvent is evaporated. The crude silica mixture is purified by flash chromatography using silica gel (100-200 mesh) and 0-10% methanol in dichloromethane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 7-bromo-2-(tert-butyl)thieno[3,2-b]pyridine-3-carboxylate (2).
[0641] Example 2B.6
[0642] [ka]
[0643] Methyl 7-chlorothieno[3,2-b]pyridine-3-carboxylate (1, 0.2 g, 0.88 mmol) was dissolved in dichloromethane (2.2 mL) in an oven-dried screw-cap vial equipped with a stir bar. 3-Chloroperbenzoic acid (0.24 g, 1.41 mmol) was added in four portions over 2 minutes while the reaction mixture was stirred at room temperature. After 24 hours, the reaction mixture was poured onto silica gel and purified via silica gel chromatography (50-100% ethyl acetate in hexanes, then 10% methanol in ethyl acetate) to give 7-chloro-3-(methoxycarbonyl)thieno[3,2-b]pyridine 4-oxide (2).
[0644] 7-Chloro-3-(methoxycarbonyl)thieno[3,2-b]pyridine 4-oxide (2, 0.12 g, 0.47 mmol) was dissolved in dichloromethane (3.3 mL) in an oven-dried screw-cap vial equipped with a stir bar. Methanesulfonyl chloride (0.18 mL, 2.36 mmol) was added dropwise while the mixture was stirred at room temperature. After 3 hours, additional methanesulfonyl chloride (0.18 mL, 2.36 mmol) was added dropwise. After 4.5 hours, the reaction mixture was warmed to 40°C and stirred for an additional 16 hours before being cooled to room temperature. The reaction mixture was poured onto silica gel and purified via silica gel chromatography (0-50% ethyl acetate in hexanes) to give methyl 5,7-dichlorothieno[3,2-b]pyridine-3-carboxylate (3).
[0645] Zinc chloride solution (0.5 M, 0.59 mL, 0.29 mmol) is dissolved in tetrahydrofuran (1.0 mL) in an oven-dried screw-cap vial equipped with a stir bar. The reaction mixture is stirred at room temperature while a solution of bromo(cyclopropyl)magnesium (0.59 mL, 0.29 mmol) is slowly added. After 45 minutes, a solution of methyl 5,7-dichlorothieno[3,2-b]pyridine-3-carboxylate (3, 67.0 mg, 0.25 mmol) in tetrahydrofuran (1.5 mL) is slowly added. After 1 minute, Pd2(dba)3 (28.4 mg, 0.03 mmol) and dppf (30.4 mg, 0.06 mmol) are added, and the reaction mixture is subsequently heated to 60°C for 1 hour. The reaction mixture is cooled to room temperature and poured onto saturated aqueous NH4Cl. The aqueous phase is extracted three times with ethyl acetate. The combined organic material is washed with brine, dried over magnesium sulfate, filtered, and the solvent removed in vacuo to give a brown oil. Purification via silica gel chromatography (8-29% ethyl acetate in hexanes) affords methyl 7-chloro-5-cyclopropylthieno[3,2-b]pyridine-3-carboxylate (4).
[0646] Example 2B.7
[0647] [ka]
[0648] 7-Bromo-3-(methoxycarbonyl)thieno[3,2-b]pyridine 4-oxide (2, 148 mg, 0.514 mmol) is dissolved in chloroform (10 mL) and POCl (0.48 mL, 0.79 g, 5.1 mmol) is added. The vial is sealed and the mixture is stirred at 60° C. for 4 hours and then at room temperature overnight. The mixture is then concentrated, dissolved in DCM, washed with NaHCO (aq), dried (Na SO ), filtered, and concentrated. The crude product (140 mg) is dissolved in THF (9 mL) and sodium methanolate (25% in MeOH, 0.12 mL, 0.12 g, 0.52 mmol) is added. The mixture is stirred at room temperature for 2.75 hours and an additional 0.13 mL NaOMe sulphate (25% in MeOH) is added. After 30 min, an additional 0.04 mL NaOMe sLn (25% in MeOH) is added. After another 10 min, an additional 0.04 mL NaOMe sLn (25% in MeOH) is added. The mixture is then diluted with DCM and washed with water. The organic layer is dried (Na2SO4), filtered, and concentrated. Purification by column chromatography affords 23.9 mg of a 3:1 mixture of 3' and 3.
[0649] Example 2B.8
[0650] [ka]
[0651] To a solution of tert-butyl 7-bromo-5-(bromomethyl)thieno[3,2-b]pyridine-3-carboxylate (2, 200.0 mg, 0.491 mmol) in N,N-dimethylpyrrolidone (3 mL), tert-butyl N-tert-butoxycarbonylcarbamate (160.1 mg, 0.736 mmol) and potassium carbonate (203.6 mg, 1.473 mmol) are added, and the reaction mixture is stirred at room temperature for 24 h. Upon completion, the reaction mixture is diluted with dichloromethane and silica gel is added. The solvent is evaporated. The crude silica mixture is purified by Isco column chromatography using 0-10% methanol in dichloromethane as the eluent. The desired fractions are concentrated under reduced pressure to give tert-butyl 5-[[bis(tert-butoxycarbonyl)amino]methyl]-7-bromo-thieno[3,2-b]pyridine-3-carboxylate (3).
[0652] Example 2B.9
[0653] [ka]
[0654] A suspension of methyl 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylate (1, 3.50 g, 12.3 mmol) in 10 mL of formalin (37-40%) is irradiated in a microwave at 120° C. for 1 h. After 1 h, the reaction is cooled and extracted with ethyl acetate. No starting material is consumed in 1 h, and the reaction is irradiated again after three microwave workups. The reaction is monitored by LCMS; 50% starting material still remains. The reaction is cooled and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. The residue is purified by column chromatography using silica (100-200 mesh) and 0-40% ethyl acetate in hexane to give methyl 7-bromo-5-(2-hydroxyethyl)thieno[3,2-b]pyridine-3-carboxylate (2).
[0655] To a solution of methyl 7-bromo-5-(2-hydroxyethyl)thieno[3,2-b]pyridine-3-carboxylate (2, 0.32 g, 1.01 mmol) in pyridine (10 mL), acetic anhydride (0.115 mL, 1.22 mmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 16 hours. After completion of the reaction, as confirmed by thin layer chromatography and LCMS, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. The crude product is purified by combi flash (4 g, Redi Sep column) using 50% ethyl acetate in hexane as the eluent to give methyl 5-(2-acetoxyethyl)-7-bromothieno[3,2-b]pyridine-3-carboxylate (3).
[0656] Example 2B.10
[0657] [ka]
[0658] To a solution of 4-chloro-3-fluorophenol (1, 3.0 g, 20.59 mmol) in acetone (30 mL) is added iodomethane (5.2 mL, 82.00 mmol) and potassium carbonate (5.6 g, 41.00 mmol) at room temperature, and the reaction mixture is stirred at 60° C. for 12 hours. After completion of the reaction, as confirmed by thin-layer chromatography, the reaction mixture is evaporated, diluted with water, and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give 1-chloro-2-fluoro-4-methoxybenzene (2).
[0659] To a solution of 1-chloro-2-fluoro-4-methoxybenzene (2, 1.9 g, 11.84 mmol) in tetrahydrofuran (20 mL), lithium diisopropylamide (2 M in tetrahydrofuran) (11.8 mL, 23.75 mmol) is added dropwise at −78° C., and the reaction mixture is stirred at the same temperature for 1 hour. Then, triisopropyl borate (3.26 mL, 14.16 mmol) is added dropwise at −78° C. The reaction mixture is stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture is quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound. The obtained crude compound is purified by combi flash chromatography using a 12 gm Redisep column eluted with 80% ethyl acetate in hexane to give (3-chloro-2-fluoro-6-methoxyphenyl)boronic acid (3).
[0660] To a solution of (3-chloro-2-fluoro-6-methoxyphenyl)boronic acid (3, 0.35 g, 1.71 mmol) in dichloromethane (5 mL) is added boron tribromide (0.324 mL, 3.43 mmol) dropwise at 0° C., and the reaction mixture is stirred at room temperature for 1 hour. After completion of the reaction, as confirmed by thin layer chromatography, the reaction mixture is quenched with ice-cold water. The precipitated solid is filtered and washed with pentane to give (3-chloro-2-fluoro-6-hydroxyphenyl)boronic acid (4).
[0661] A suspension of tert-butyl 7-bromo-5-methylthieno[3,2-b]pyridine-3-carboxylate (4a, 0.230 g, 0.8 mmol), (3-chloro-2-fluoro-6-hydroxyphenyl)boronic acid (4, 0.30 g, 1.6 mmol), and potassium carbonate (0.334 g, 2.4 mmol) in 1,4-dioxane (2.0 mL) and water (0.5 mL) was degassed with argon gas for 10 minutes. [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane complex (0.03 g, 0.04 mmol) was added to the above suspension, and the reaction mixture was stirred at 90 °C for 3 hours. The reaction mixture was monitored by LCMS and thin-layer chromatography. Upon completion, the reaction was filtered through a Celite bed and washed with ethyl acetate. The resulting crude compound is purified through combi flash chromatography using a 4 gm redisep column by eluting with 90% ethyl acetate in hexane to give tert-butyl 7-(3-chloro-2-fluoro-6-hydroxyphenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (5).
[0662] Example 2B.11
[0663] [ka]
[0664] To a solution of 2,5-dimethylpyridine (1, 10.0 g, 93.4 mmol) in chloroform (100 mL) under an argon atmosphere is added metachloroperbenzoic acid (19.3 g, 112.1 mmol) at 0° C., and the mixture is stirred at room temperature for 16 h. Upon completion, the reaction mixture is diluted with 10% calcium hydroxide solution, the solution is filtered through celite, and the filtrate is concentrated and dried to give 2,5-dimethylpyridine 1-oxide (2).
[0665] To a solution of 2,5-dimethylpyridine 1-oxide (2, 10.0 g, 81.3 mmol) in dichloromethane (100 mL) under an argon atmosphere, trimethylsilyl cyanide (11.2 g, 89.4 mmol) was added at 0°C and stirred at room temperature for 30 min. Diethylcarbamic chloride (2a, 11.3 mL, 89.4 mmol) was added and stirring was continued at room temperature for 24 h. Upon completion, the reaction mixture was quenched with 10% potassium carbonate solution and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. The crude product was purified by column chromatography using silica (100-200 mesh) with 30-40% ethyl acetate in hexane as the eluent. The desired fractions were concentrated under reduced pressure to give 3,6-dimethylpicolinonitrile (3).
[0666] To a solution of 3,6-dimethylpicolinonitrile (3, 7.00 g, 46.9 mmol) in chloroform (70 mL) under an argon atmosphere is added metachloroperbenzoic acid (8.75 g, 56.6 mmol) at 0° C. and stirring is continued at room temperature for 16 h. Upon completion, the reaction mixture is diluted with 10% calcium hydroxide solution, filtered through celite, and the filtrate is concentrated and dried to give 2-cyano-3,6-dimethylpyridine 1-oxide (4).
[0667] A solution of 2-cyano-3,6-dimethylpyridine 1-oxide (4, 7.0 g, 46.9 mmol) in phosphoryl chloride (50 mL) was stirred at 90° C. for 4 h. Upon completion, the reaction mixture was concentrated and purified by column chromatography using silica (100-200 mesh) with 20-30% ethyl acetate in hexane as the eluent. The desired fractions were concentrated under reduced pressure to give 4-chloro-3,6-dimethylpicolinonitrile (5).
[0668] A solution of 4-chloro-3,6-dimethylpicolinonitrile (5, 4.0 g, 24.0 mmol) in ethanol (20 mL) and 10% potassium hydroxide solution (20 mL) is stirred at 100° C. for 16 h. Upon completion, the reaction mixture is cooled, acidified to pH 5 with 2 M hydrochloric acid solution, and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give 4-chloro-3,6-dimethylpicolinic acid (6).
[0669] To a solution of 4-chloro-3,6-dimethylpicolinic acid (6, 1.50 g, 8.10 mmol) in tert-butyl alcohol (9.0 mL), di-tert-butyl dicarbanate (0.75 mL, 3.56 mmol) and 4-dimethylaminopyridine (1.48 g, 12.1 mmol) are added at 0°C under an argon atmosphere and stirred at 90°C for 4 h. Upon completion, the reaction mixture is concentrated under reduced pressure. The crude compound is purified by flash column chromatography using 20-30% ethyl acetate in hexane to give tert-butyl 4-chloro-3,6-dimethylpicolinate (7).
[0670] Example 2B.12
[0671] [ka]
[0672] To a stirred solution of thieno[3,2-b]pyridin-7-ol (1, 5.0 g, 33.07 mmol) in 1,2-dichloroethane (50 mL) is added phosphorus oxybromide (143.21 g, 496.09 mmol) portionwise at room temperature, and the mixture is stirred at 70° C. for 10 h. The reaction mixture is cooled to 0° C., basified with 10% aqueous sodium hydroxide, and extracted with dichloromethane. The organic layer is washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give 7-bromothieno[3,2-b]pyridine (2).
[0673] To a stirred solution of 7-bromothieno[3,2-b]pyridine (2, 4.0 g, 18.78 mmol) in dry tetrahydrofuran (40 mL) is added dropwise lithium diisopropylamide solution (2.0 M in hexane, 26.30 mL, 53.60 mmol) at −78° C., and the mixture is stirred at the same temperature for 1 h. Carbon dioxide gas is purged into the reaction for 15 min, and the reaction mixture is allowed to warm to room temperature over 4 h. The reaction is quenched with aqueous ammonium chloride solution, diluted with water, and extracted with ethyl acetate. The organic layer is washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 7-bromothieno[3,2-b]pyridine-2-carboxylic acid (3).
[0674] Example 2B.12
[0675] [ka]
[0676] To a stirred solution of (4-methoxyphenyl)methanethiol (12.3 g, 87.77 mmol) in N,N-dimethylformamide (150 mL) was added sodium hydride (4.60 g, 119.69 mmol) in portions at 0°C. After 10 min, 1-bromo-2-fluoro-4-methylbenzene (1, 15.0 g, 79.79 mmol) was added and the reaction was stirred at room temperature for 2 h. Upon completion, the reaction was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude product was purified by Combiflash (40 g, RediSep column) using 0-5% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to give (2-bromo-5-methylphenyl)(4-methoxybenzyl)sulfane (2).
[0677] To a solution of (2-bromo-5-methylphenyl)(4-methoxybenzyl)sulfane (2, 18.0 g, 55.90 mmol) in dichloromethane (140 mL) is added dropwise a mixture of trifluoroacetic acid (20 mL) and triflic acid (5 mL) in dichloromethane (40 mL) at 0° C., and the reaction mixture is stirred at room temperature for 2 hours. Upon completion, the reaction is poured into ice water and extracted with dichloromethane. The organic layer is washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude 2-bromo-5-methylbenzenethiol (3).
[0678] To a solution of 2-bromo-5-methylbenzenethiol (3, 4.7 g, 23.27 mmol) in acetone (47.0 mL) is added potassium carbonate (16.0 g, 116.35 mmol) at room temperature, and the mixture is stirred for 10 minutes. 3-Bromo-2-oxopropanoic acid (3a, 11.6 g, 69.80 mmol) is added to the reaction mixture, and the mixture is stirred at room temperature for 5 hours. After completion, the acetone is evaporated under reduced pressure, and the residue is diluted with water and extracted with ethyl acetate. The organic layer is washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 3-((2-bromo-5-methylphenyl)thio)-2-oxopropanoic acid (4).
[0679] To a solution of 3-((2-bromo-5-methylphenyl)thio)-2-oxopropanoic acid (4, 4.0 g, 13.89 mmol) in dichloromethane (40.0 mL), sulfuric acid (10.0 mL) is added and the reaction mixture is stirred at room temperature for 5 hours. After completion, the reaction mixture is poured into ice water and extracted with dichloromethane. The organic layer is washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 7-bromo-4-methylbenzo[b]thiophene-3-carboxylic acid (5). To a solution of 7-bromo-4-methylbenzo[b]thiophene-3-carboxylic acid (5, 3.0 g, 11.11 mmol) in N,N-dimethylformamide (30.0 mL) was added potassium carbonate (4.6 g, 33.33 mmol) and iodomethane (1.4 mL, 22.22 mmol) at 0° C., and the reaction mixture was stirred at room temperature for 4 hours. Upon completion, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the crude product was purified by flash column chromatography using 5% ethyl acetate in hexane as the eluent. The desired fractions were concentrated under reduced pressure to give methyl 7-bromo-4-methylbenzo[b]thiophene-3-carboxylate (6).
[0680] Example 2B.13
[0681] [ka]
[0682] To a solution of tert-butyl 4-bromo-7-chlorobenzo[b]thiophene-3-carboxylate (1, 0.7 g, 2.01 mmol) in N,N-dimethylformamide (2 mL) was added copper(I) cyanide (0.180 g, 2.01 mmol). The reaction mixture was heated at 90 °C for 2 h. After this time, the reaction mixture was filtered through Celite and washed with ethyl acetate. The filtrate was washed with water, then brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. This was purified by column chromatography using silica gel (100-200 mesh) and 30-50% ethyl acetate in hexane as the eluent. The desired fractions were concentrated under reduced pressure to give tert-butyl 7-chloro-4-cyanobenzo[b]thiophene-3-carboxylate (2).
[0683] Example 2B.14
[0684] [ka]
[0685] A solution of 2,2-dimethyl-1,3-dioxane-4,6-dione (1, 0.41 g, 2.84 mmol) and diethoxymethoxyethane (50.0 mL) is stirred and heated in a closed vessel at 90° C. for 2 h. Methyl 3-aminothiophene-2-carboxylate hydrochloride (1a, 0.5 g, 2.58 mmol) is added portionwise at 90° C. under an argon atmosphere, and heating is continued at 90° C. for 12 h. Upon completion, the reaction is cooled to room temperature, water is added, and the mixture is extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the crude product. The crude product is triturated with diethyl ether to give methyl 3-((1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)ethyl)amino)thiophene-2-carboxylate (2).
[0686] A solution of methyl 3-((1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)ethyl)amino)thiophene-2-carboxylate (2, 0.200 g, 0.61 mmol) in N-methylpyrrolidone (15 mL) is heated at 200° C. for 30 minutes under microwave. Upon completion, the reaction is cooled to room temperature, filtered, and the crude solid is purified by preparative HPLC to give methyl 4-hydroxy-2-methylthieno[3,4-b]pyridine-7-carboxylate (3).
[0687] Example 2B.15
[0688] [ka]
[0689] To a stirred solution of 7-chloro-3-methylthieno[3,2-b]pyridine (1, 1.0 g, 5.44 mmol) in ethyl acetate (10 mL) was added 1-bromopyrrolidine-2,5-dione (1a, 1.93 g, 10.8 mmol) and azobisisobutyronitrile (0.088 g, 0.540 mmol) at room temperature. The reaction was stirred at 60 °C for 4 h. Upon completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product was purified by Combiflash (12 g, RediSep column) using 1-5% ethyl acetate in hexane as the eluent to give 3-(bromomethyl)-7-chlorothieno[3,2-b]pyridine (2).
[0690] To a solution of 3-(bromomethyl)-7-chlorothieno[3,2-b]pyridine (2, 1.50 g, 5.70 mmol) in N,N-dimethylformamide (15 mL) is added sodium cyanide (0.561 g, 11.40 mmol) and the mixture is stirred at room temperature for 3 hours. Upon completion, the reaction is quenched with ice-cold water and extracted with ethyl acetate. The organic layer is washed with cold water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give 2-(7-chlorothieno[3,2-b]pyridin-3-yl)acetonitrile (3).
[0691] To a solution of 2-(7-chlorothieno[3,2-b]pyridin-3-yl)acetonitrile (3, 1.10 g, 5.20 mmol) in a 1:1 mixture (20 mL) of ethanol and water, potassium hydroxide (2.96 g, 52.8 mmol) is added and the mixture is stirred at 60° C. for 10 hours. After completion, the reaction mixture is concentrated and extracted with diethyl ether. The aqueous layer is acidified with 1 N aqueous hydrochloric acid and extracted with ethyl acetate. The organic layer is washed with saturated brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give 2-(7-chlorothieno[3,2-b]pyridin-3-yl)acetic acid (4).
[0692] Example 2B.16
[0693] [ka]
[0694] To a solution of 1H-pyrrolo[3,2-b]pyridine (1, 2.5 g, 21 mmol) in DCM (75 mL) at 0 °C, m-CPBA (5.69 g, 25.4 mmol) is slowly added. The mixture is stirred from 0 °C to room temperature. After 16 h, the reaction is complete as judged by TLC (SiO2, 10% MeOH / DCM). The mixture is concentrated, and the residue is purified by column chromatography (SiO2, 0-20% MeOH / DCM). The product is obtained as a mixture with m-CPBA ( 1 The material thus obtained was 1H-pyrrolo[3,2-b]pyridine 4-oxide (2), isolated as a mixture of 1H-pyrrolo[3,2-b]pyridine 4-oxide (2) in a ratio of approximately 1:0.7 by H-NMR.
[0695] 1H-Pyrrolo[3,2-b]pyridine 4-oxide (2, 3.64 g) in POCl3 (30 mL, 50 g, 0.32 mol) is refluxed (oil bath, 130 °C) under argon overnight. The mixture is then carefully transferred with stirring to an Erlenmeyer flask containing crushed ice. The mixture is then basified with NaOH (aq, 12.5%) to pH approx. 8, and the precipitated material is collected by filtration. The aqueous phase is extracted (3 x EtOAc), and the combined organic layers are dried (Na2SO4), filtered, and concentrated. The precipitated and extracted materials are combined, dissolved in DCM, and washed with NaHCO3 (aq). The organic layer is dried (Na2SO4), filtered, and concentrated to give 7-chloro-1H-pyrrolo[3,2-b]pyridine (3).
[0696] The reaction was carried out in two batches (0.80 g of (3) per batch), and the two batches were combined for purification purposes. To a solution of 7-chloro-1H-pyrrolo[3,2-b]pyridine (3, 0.80 g, 5.2 mmol) in 1,4-dioxane (14 mL) and water (3.5 mL) was added (5-chloro-2-hydroxyphenyl)boronic acid (3a, 1.4 g, 8.1 mmol) and potassium carbonate (2.2 g, 16 mmol), and the mixture was degassed by bubbling argon through the mixture for 5 minutes. Pd(PPh3)4 (0.61 g, 0.53 mmol) was added, and the mixture was degassed for another 5 minutes, then placed in a preheated heating block (100 °C) and stirred for 20 hours. The mixture was then cooled to room temperature. The two batches were combined, diluted with water, and extracted with EtOAc. The organic layer was dried (Na2SO4), filtered, and concentrated. Purification by column chromatography (SiO2, 0-20% MeOH / DCM) gives 4-chloro-2-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenol (4).
[0697] To a solution of 4-chloro-2-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenol (4, 37 mg, 0.15 mmol) in DMF (0.7 mL) at 0 °C, imidazole (23 mg, 0.34 mmol) and tert-butyl-chloro-diphenyl-silane (0.05 mL, 0.05 g, 0.2 mmol) are added, and the mixture is stirred at room temperature. After 3 h, the mixture is diluted with water and EtOAc, and the aqueous phase is extracted (3 × EtOAc). The combined organic layers are dried (NaSO), filtered, and concentrated. Purification by column chromatography (SiO, 0–40% EtOAc / hexanes) gives 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-1H-pyrrolo[3,2-b]pyridine (5).
[0698] To a solution of 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-1H-pyrrolo[3,2-b]pyridine (5; 1.08 g, 2.24 mmol) in THF (20 mL) at 0 °C, N-iodosuccinimide (503 mg, 2.24 mmol) is added and the mixture is stirred for 10 min. The reaction is then diluted with EtOAc, quenched with NaSO(aq) and water, and extracted (2 × EtOAc). The combined organic layers are dried, filtered, and concentrated. Purification by column chromatography (SiO, 0–40% EtOAc / hexanes) gives 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-3-iodo-1H-pyrrolo[3,2-b]pyridine (6).
[0699] To a solution of 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-3-iodo-1H-pyrrolo[3,2-b]pyridine (6, 990 mg, 1.63 mmol) in MeCN (11 mL) at 0° C., triethylamine (0.45 mL, 0.33 g, 3.2 mmol), di-tert-butyl dicarbonate (531 mg, 2.43 mmol) and 4-dimethylaminopyridine (40 mg, 0.33 mmol) in 2 mL MeCN are added and the mixture is stirred at room temperature. After 1 h, water is added and the mixture is extracted with DCM (3×). The combined organic layers are dried (NaSO), filtered and concentrated. Purification by column chromatography (SiO2, 0-20% EtOAc / hexanes) gives tert-butyl 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-3-iodo-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (7).
[0700] To a solution of tert-butyl 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-3-iodo-1H-pyrrolo[3,2-b]pyridine-1-carboxylate (7, 1.06 g, 1.49 mmol) in methanol (11 mL) and DMF (4 mL) is added triethylamine (0.43 mL, 0.31 g, 3.1 mmol) and (PhP)PdCl (105 mg, 0.149 mmol). The mixture is then stirred at 50° C. under a CO atmosphere. After 18 h, the mixture is concentrated and purified by column chromatography (SiO, 0–50% EtOAc / hexanes) to give 1-(tert-butyl) 3-methyl 7-(2-((tert-butyldiphenylsilyl)oxy)-5-chlorophenyl)-1H-pyrrolo[3,2-b]pyridine-1,3-dicarboxylate (8).
[0701] Example 2B.17
[0702] [ka]
[0703] To a solution of 3-bromo-7-chlorothieno[3,2-b]pyridine (4, 0.30 g, 1.21 mmol) and ethyl 2-bromo-2,2-difluoroacetate (4a, 0.73 g, 3.62 mmol) in dimethyl sulfoxide (12.0 mL) is added copper powder (0.11 g, 1.81 mmol) at room temperature, and the mixture is heated at 60 °C for 16 h. Upon completion, the reaction is diluted with ethyl acetate and filtered through Celite. The filtrate is washed with water and brine solution, dried over sodium sulfate, filtered, and concentrated. The crude product is purified by flash column chromatography using silica gel (100-200 mesh) and 20-30% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give ethyl 2-(7-chlorothieno[3,2-b]pyridin-3-yl)-2,2-difluoroacetate (5).
[0704] Example 2B.18
[0705] [ka]
[0706] To a solution of N,N,N',N'-tetramethylethylenediamine (11.69 g, 100.42 mmol) in tetrahydrofuran (100 mL) is added n-butyllithium (1.3 M in hexanes, 71.1 mL, 92.43 mmol) at -78 °C, followed by dropwise addition of 6,7-dihydro-5H-cyclopenta[b]pyridine (1, 10.0 g, 84.03 mmol), and the mixture is stirred at -78 °C for 45 min. A solution of dimethyl carbonate (1a, 8.31 g, 92.43 mmol) in tetrahydrofuran (10 mL) is then added dropwise, and the mixture is allowed to warm to room temperature over 1 h. The reaction mixture is quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The combined organic layers are dried over anhydrous sodium sulfate, filtered, and concentrated. The crude material is purified by column chromatography using silica gel (100-200 mesh) and 0-25% ethyl acetate in hexane as eluent to give methyl 6,7-dihydro-5H-cyclopenta[b]pyridine-7-carboxylate (2).
[0707] To a solution of methyl 6,7-dihydro-5H-cyclopenta[b]pyridine-7-carboxylate (2, 2.5 g, 14.12 mmol) in dichloromethane (30 mL) was added 3-chloroperbenzoic acid (4.85 g, 28.24 mL) at 0 °C, and the mixture was stirred at the same temperature for 30 min. After completion, the reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL) and extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography using silica gel (100-200 mesh) and 0-10% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to give 7-(methoxycarbonyl)-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (3).
[0708] To a solution of 7-(methoxycarbonyl)-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (3, 1.5 g, 7.77 mmol) in acetonitrile (25 mL) was added lithium bromide (0.67 g, 7.77 mmol) and phosphorus bromide (22.3 g, 77.72 mmol), and the reaction mixture was heated at 80° C. for 24 h. Upon completion, the reaction mixture was cooled to 0° C., quenched with saturated sodium bicarbonate solution (50 mL), and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography using silica gel (100-200 mesh) and 0-25% ethyl acetate in hexane to give methyl 4-bromo-6,7-dihydro-5H-cyclopenta[b]pyridine-7-carboxylate (4).
[0709] Example 2B.19
[0710] [ka]
[0711] To a solution of 7-bromothieno[3,2-b]pyridine-3-carbaldehyde (1, 36 mg, 0.148 mmol) in DCM (1 mL) in an oven-dried screw-cap vial equipped with a stir bar, ethoxyethanetrifluoroborane (0.02 mL, 0.163 mmol) was slowly added to the mixture at room temperature with constant stirring. 1,2-bis((trimethylsilyl)oxy)cyclobut-1-ene (1a, 0.06 mL, 0.222 mmol) was then added dropwise, and the clear yellow mixture was allowed to stir at room temperature for 40 minutes. Water (0.030 mL) was added, followed by ethoxyethanetrifluoroborane (0.27 mL, 2.22 mmol), and the reaction was stirred overnight at room temperature. Since no conversion to the pinacol rearrangement product was observed, water and DCM were added, and the aqueous layer was extracted three times with dichloromethane. The combined organic material is washed with brine and dried over magnesium sulfate. The solids are filtered and the solvent is removed in vacuo to give a crude yellow residue. The aqueous layer is concentrated in vacuo. Both the aqueous and organic layers are combined, dissolved in TFA (3.5 mL, 0.1480 mmol), placed in a vial, which is sealed, and stirred in a heating block at 70° C. for 3 hours. The reaction is cooled to room temperature, and the solvent is removed in vacuo. Preparative HPLC (water with 0.1% TFA) gives the product, 2-(7-bromothieno[3,2-b]pyridin-3-yl)-3-hydroxycyclopent-2-en-1-one (2).
[0712] Example 2B.20
[0713] [ka]
[0714] To a stirred solution of methyl 7-chlorothieno[3,2-b]pyridine-3-carboxylate (1, 15.0 g, 65.88 mmol) in methanol, tetrahydrofuran, and water (2:1:1, 225 mL) is added lithium hydroxide (13.82 g, 329.43 mmol) at 0° C., and the reaction mixture is stirred at room temperature for 16 h. After completion, the solvent is concentrated under reduced pressure, and the aqueous layer is acidified to pH 3 with 1 N aqueous hydrochloric acid. The resulting solid precipitate is filtered and washed with n-pentane to give 7-chlorothieno[3,2-b]pyridine-3-carboxylic acid (2).
[0715] To a solution of 7-chlorothieno[3,2-b]pyridine-3-carboxylic acid (2, 12.20 g, 57.10 mmol) in N,N-dimethylformamide (50 mL), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (32.5 g, 85.65 mmol) is added and the reaction mixture is stirred for 10 minutes. The reaction mixture is then cooled to 0°C, and N,N-diisopropylethylamine (29.841 mL, 171.316 mmol) and ammonium chloride (15.2 g, 285.52 mmol) are added. The reaction mixture is warmed to room temperature and stirred for 16 hours. Upon completion, the reaction is quenched with ice-cold water and extracted with ethyl acetate. The organic layer is washed with cold water, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product is triturated with pentane and dried to give 7-chlorothieno[3,2-b]pyridine-3-carboxamide (3).
[0716] To a solution of 7-chlorothieno[3,2-b]pyridine-3-carboxamide (3, 10.0 g, 51.37 mmol) in N,N-dimethylformamide (100 mL) at 0 °C, phosphorus oxytrichloride (48.0 mL, 513.76 mmol) is added. The reaction is warmed to room temperature and stirred for 16 h. Upon completion, the reaction mixture is concentrated to dryness under reduced pressure. The reaction mixture is basified to pH 8 with saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic layer is washed with brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product is purified by Combiflash (40 g, RediSep column) using 0-20% ethyl acetate in hexanes as the eluent. The desired fractions are concentrated under reduced pressure to give 7-chlorothieno[3,2-b]pyridine-3-carbonitrile (4).
[0717] To a solution of 7-chlorothieno[3,2-b]pyridine-3-carbonitrile (4, 8.0 g, 41.10 mmol) and (5-chloro-2-hydroxyphenyl)boronic acid (4a, 14.1 g, 82.20 mmol) in 1,4-dioxane (120.0 mL), a 2 M solution of potassium carbonate (14.2 g, 102.7 mmol) was added, and the reaction mixture was degassed with argon gas for 10 minutes. [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (3.0 g, 4.11 mmol) was then added to the reaction mixture, and the reaction mixture was stirred at 110 °C for 2 hours. Upon completion, the reaction mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product is purified by column chromatography using silica gel (100-200 mesh) and 0-50% ethyl acetate in hexane as the eluent. The desired fractions are concentrated under reduced pressure to give 7-(5-chloro-2-hydroxyphenyl)thieno[3,2-b]pyridine-3-carbonitrile (5).
[0718] To a solution of 7-(5-chloro-2-hydroxyphenyl)thieno[3,2-b]pyridine-3-carbonitrile (5, 5.1 g, 17.78 mmol) in N,N-dimethylformamide (50.0 mL) is added sodium azide (5.8 g, 88.93 mmol) at room temperature, and the reaction mixture is heated to 110° C. for 36 hours. After completion, the reaction mixture is concentrated to dryness under reduced pressure. The resulting crude product is triturated with n-pentane to give 2-(3-(1H-tetrazol-5-yl)thieno[3,2-b]pyridin-7-yl)-4-chlorophenol (6).
[0719] Example 2C. General Coupling Methods
[0720] [ka]
[0721] To a solution of 2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (6, 0.20 g, 0.79 mmol) in N,N-dimethylformamide (5 mL) is added potassium carbonate (0.33 g, 2.37 mmol) at room temperature. After 10 minutes, 2-bromo-1-(2-bromoethoxy)-4-chloro-benzene (9, 0.25 g, 0.79 mmol) is added and stirred at room temperature for 16 hours. Upon completion, the reaction mixture is poured into water and extracted with ethyl acetate. The combined organic layers are washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product, which is purified by flash column chromatography (using 10-70% ethyl acetate in hexanes) to give 3-(2-(2-bromo-4-chloro-phenoxy)ethyl)-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (10).
[0722] Example 2D. Post-Coupling Modification Method Example 2D.1
[0723] [ka]
[0724] A solution of 3-(2-(2-bromo-4-chlorophenoxy)ethyl)-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (10, 1.8 g, 3.71 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (11, 1.13 g, 4.45 mmol), and potassium acetate (0.73 g, 7.42 mmol) in 1,4-dioxane (35 mL) was degassed with argon gas for 10 minutes. 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride (0.217 g, 0.296 mmol) was added, and the reaction mixture was degassed for an additional 10 minutes. The reaction mixture is heated and stirred at 90° C. for 6 hours. Upon completion, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude compound is purified by flash column chromatography using 40% ethyl acetate in hexane as the eluent to give 3-(2-(4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (12).
[0725] To a solution of methyl 3-bromo-2-iodobenzoate (13, 2.0 g, 5.88 mmol) in N,N-dimethylformamide (20 mL) is added copper(I) cyanide (0.58 g, 6.47 mmol) and heated at 60° C. for 4 h. Upon completion, the reaction is diluted with water (100 mL) and extracted with ethyl acetate. The combined organic layers are washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude compound is purified by flash column chromatography (using 0-10% ethyl acetate in hexanes) to give methyl 3-bromo-2-cyanobenzoate (14).
[0726] To a solution of 3-(2-(4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)-2-methyl-4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazoline-5-carbonitrile (12, 0.40 g, 0.75 mmol) and methyl 3-bromo-2-cyanobenzoate (14, 0.215 g, 0.90 mmol) in 1,4-dioxane (8 mL) and water (2 mL) is added potassium carbonate (0.313 g, 2.25 mmol) at room temperature. The reaction is degassed by purging argon gas through the reaction for 10 minutes. Add 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (0.055 g, 0.075 mmol) under an argon atmosphere, heat, and stir the reaction mixture at 90 °C for 3 h. Upon completion, the reaction is diluted with water and extracted with ethyl acetate. The combined organic layers are washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude compound is purified by flash column chromatography (using 0-50% ethyl acetate in hexanes) to give methyl 5'-chloro-2-cyano-2'-(2-(5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)-[1,1'-biphenyl]-3-carboxylate (15).
[0727] Example 2D.2
[0728] [ka]
[0729] To a stirred solution of methyl 5-chloro-7-[5-chloro-2-[2-[5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3-yl]ethoxy]phenyl]thieno[3,2-b]pyridine-3-carboxylate (0.050 g, 0.079 mmol) in N-methyl-2-pyrrolidone and water (9:1, 2 mL) in a microwave vial, zinc cyanide (0.011 g, 0.095 mmol) and zinc dust (0.030 mg, 0.034 mmol) are added and the mixture is degassed with argon for 30 minutes. After adding 1,1'-bis(diphenylphosphino)ferrocene (0.0131 g, 0.023 mmol) and tris(dibenzylideneacetone)dipalladium(0) (10.8 mg, 0.012 mmol), the vial was sealed and then placed in a preheated heating block at 80 °C for 30 min. After completion of the reaction, the reaction mixture was loaded onto an Isco silica column. Purification by column chromatography eluting with 0 to 5% methanol / dichloromethane gave methyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)-5-cyanothieno[3,2-b]pyridine-3-carboxylate (2).
[0730] To a solution of methyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)-5-cyanothieno[3,2-b]pyridine-3-carboxylate (2, 25.0 mg, 0.040 mmol) in 1,2-dichloroethane (2 mL) is added trimethyltin hydroxide (0.029 g, 0.160 mmol) at room temperature. The reaction mixture is heated at 90° C. for 16 hours. After completion of the reaction, the organic solvent is evaporated and the crude is diluted with 50% dimethyl sulfoxide / methanol. The crude product is purified by preparative HPLC to give 5-carbamoyl-7-(5-chloro-2-(2-(5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylic acid (Cpd. No. 445F).
[0731] Example 2D.3
[0732] [ka]
[0733] To a solution of methyl 7-(2-(2-(5-bromo-6-iodo-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)-5-chlorophenyl)thieno[3,2-b]pyridine-3-carboxylate (5, 0.20 g, 0.256 mmol) in N,N-dimethylformamide is added copper(I) cyanide (0.069 g, 0.770 mmol) and stirred at 85° C. for 2 hours. After completion, the reaction mixture is cooled to room temperature and poured into ice water. The precipitate that forms is collected by filtration and dried. The solid is dissolved in 10% methanol in dichloromethane and passed through a bed of Celite. The filtrate is concentrated under reduced pressure to give methyl 7-(5-chloro-2-(2-(5,6-dicyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)thieno[3,2-b]pyridine-3-carboxylate (6).
[0734] Example 2D.3
[0735] [ka]
[0736] To a solution of tert-butyl 7-(2-(2-(6-bromo-5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (1, 0.20 g, 0.273 mmol) in N-methyl-2-pyrrolidone (5.0 mL) is added 1-methylpiperazine (1a, 0.06 mL, 0.546 mmol) and the reaction mixture is degassed with argon for 10 minutes. Copper(I) iodide (0.005 g, 0.027 mmol) and 1,10-phenanthroline (0.009 g, 0.054 mmol) are then added and the reaction mixture is heated at 150° C. for 6 hours. After completion, the reaction mixture is diluted with water and extracted with ethyl acetate. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound, which is purified by column chromatography using silica gel (100-200 mesh) and 3-4% methanol in dichloromethane to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-2-methyl-6-(4-methylpiperazin-1-yl)-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (2).
[0737] Example 2D.4
[0738] [ka]
[0739] To a solution of tert-butyl 7-(2-(2-(6-bromo-5-cyano-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)-5-chlorophenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (1, 50 mg, 0.0681 mmol) and 3-fluoro-2-((tributylstannyl)methyl)pyridine (1a, 190 mg, 0.476 mmol) in N,N-dimethylformamide (2 mL) is added copper(II) oxide (11 mg, 0.136 mmol) at room temperature. The reaction mixture is purged with argon gas for 5 minutes, bis(triphenylphosphine)palladium(II) dichloride (9.6 mg, 0.0136 mmol) is added, and the vessel is then sealed and microwaved at 150° C. for 1 hour. Upon completion, the reaction mixture is then loaded directly onto an Isco packed column. Purification is carried out by column chromatography using 5 to 80% ethyl acetate in hexanes as the eluent, with the product eluting at approximately 60% ethyl acetate / hexanes. The desired fractions are concentrated under reduced pressure to give tert-butyl 7-(5-chloro-2-(2-(5-cyano-6-((3-fluoropyridin-2-yl)methyl)-2-methyl-4-oxo-7-(trifluoromethyl)quinazolin-3(4H)-yl)ethoxy)phenyl)-5-methylthieno[3,2-b]pyridine-3-carboxylate (2).
[0740]
[0404] Compounds made using one or more of the above general methods are shown in Table 2. Characterization data, where indicated, is to the right of the compounds.
[0741] [Table 2-1]
[0742] [Table 2-2]
[0743] [Table 2-3]
[0744]
Table 2-4
[0745]
Table 2-5
[0746]
Table 2-6
[0747]
Table 2-7
[0748]
Table 2-8
[0749]
Table 2-9
[0750]
Table 2-10
[0751]
Table 2-11
[0752]
Table 2-12
[0753]
Table 2-13
[0754]
Table 2-14
[0755]
Table 2-15
[0756]
Table 2-16
[0757]
Table 2-17
[0758]
Table 2-18
[0759]
Table 2-19
[0760]
Table 2-20
[0761]
Table 2-21
[0762]
Table 2-22
[0763]
Table 2-23
[0764]
Table 2-24
[0765]
Table 2-25
[0766]
Table 2-26
[0767]
Table 2-27
[0768]
Table 2-28
[0769]
Table 2-29
[0770]
Table 2-30
[0771]
Table 2-31
[0772]
Table 2-32
[0773]
Table 2-33
[0774]
Table 2-34
[0775]
Table 2-35
[0776]
Table 2-36
[0777]
Table 2-37
[0778]
Table 2-38
[0779]
Table 2-39
[0780]
Table 2-40
[0781]
Table 2-41
[0782]
Table 2-42
[0783]
Table 2-43
[0784]
Table 2-44
[0785]
Table 2-45
[0786]
Table 2-46
[0787]
Table 2-47
[0788]
Table 2-48
[0789]
Table 2-49
[0790]
Table 2-50
[0791]
Table 2-51
[0792]
Table 2-52
[0793]
Table 2-53
[0794]
Table 2-54
[0795]
Table 2-55
[0796]
Table 2-56
[0797]
Table 2-57
[0798]
Table 2-58
[0799]
Table 2-59
[0800]
Table 2-60
[0801]
Table 2-61
[0802]
Table 2-62
[0803]
Table 2-63
[0804]
Table 2-64
[0805]
Table 2-65
[0806]
Table 2-66
[0807]
Table 2-67
[0808]
Table 2-68
[0809]
Table 2-69
[0810]
Table 2-70
[0811]
Table 2-71
[0812]
Table 2-72
[0813]
Table 2-73
[0814]
Table 2-74
[0815] Example 3 General methods for synthesizing other compounds The compounds in Table 3 may be synthesized using the methods described in Example 3. Many of the reactions described in Examples 1 and 2 were also used to synthesize the compounds in Table 3.
[0816] Example 3A How to composite the left side Example 3A.1
[0817] [ka]
[0818] 3-Amino-6-chloropicolinamide (1, 3.00 g, 16.6 mmol) is dissolved in 1,1,1-triethoxyethane (45 mL, 16.6 mmol) in a flame-dried round-bottom flask equipped with a stir bar. The reaction mixture is heated to 110° C. for 90 minutes, then cooled to 10° C. and diluted with cold ether. The solid is filtered and washed several times with cold ether. The solid is dried in vacuo to give 6-chloro-2-methylpyrido[3,2-d]pyrimidin-4(3H)-one (2).
[0819] 6-Chloro-2-methylpyrido[3,2-d]pyrimidin-4(3H)-one (2, 1.00 g, 5.1 mmol) is dissolved in DMSO (30 mL) in a round-bottom flask equipped with a stir bar. The reaction mixture is stirred at 10° C. while bis(trifluoromethylsulfonyl)zinc (4.23 g, 12.8 mmol) is added in one portion. tert-Butyl hydroperoxide (3.53 mL, 19.2 mmol) is then added dropwise via an addition funnel. After 5 minutes, the reaction mixture is warmed to room temperature, and after another 5 minutes, it is warmed to 50° C. for 6.5 hours. The reaction mixture is cooled to room temperature, and then the reaction mixture is diluted with saturated sodium bicarbonate and ethyl acetate. The layers are separated, and the aqueous phase is extracted three times with ethyl acetate. The combined ...
Claims
1. Compound of Formula III: [Case 1] or a pharma- ceutically acceptable salt thereof, During the ceremony: L 1 is -(CH 2 ) -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -CH((C 1 ~C 8 ) alkyl) (CH 2 )-, -CH((C 1 ~C 8 ) alkyl) (CH 2 ) 2 -, -(CH 2 ) 2 -O-, -CH 2 CH=CH-, -CH 2 C≡C-, or -CH 2 (cyclopropyl)-; L 2 is a bond; Ring C is a 5-10 membered heteroaryl, wherein said 5-10 membered heteroaryl is a monocyclic or bicyclic group containing hydrogen atoms and 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and containing at least one aromatic ring; R 1 is H, (C 1 ~C 8 ) alkyl, or (C 1 ~C 8 ) haloalkyl; R 2 are independently halo, CN, (C 1 ~C 8 ) alkyl, or (C 1 ~C 8 ) haloalkyl; R 3 are independently OH, halo, CN, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) haloalkyl, (C 1 ~C 6 ) Alkoxy, C≡CH, NHR 7 , N.R. 7 R 7 , CO 2 H, [(C 1 ~C 3 ) alkylene](C 1 ~C 3 ) alkoxy, (C 3 ~C 5 ) cycloalkyl, =O. =S, SR 7 , or S.O. 2 R7; R 5 are independently H, (C 1 ~C 3 ) alkyl, (C 1 ~C 3 ) haloalkyl, (C 3 ~C 5 ) cycloalkyl or heterocyclyl selected from the group consisting of oxetane, thiazolyl, pyrazolyl, imidazolyl, pyridinyl and pyrimidinyl; R 7 are independently H, or (C 1 ~C 8 ) alkyl; R 8 CO 2 H, CO 2 R 7 ,C(O)N(H)SO 2 R 5 ,C(O)N(H)R 5 , or P(O)(OR 5 ) OH; R 9 is H, (C 1 ~C 8 ) alkyl, (C 1 ~C 8 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, or heterocyclyl, where said heterocyclyl is a 3-7 membered monocyclic or bicyclic radical containing carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; m is 1 or 2; n is 0, 1, 2, or 3; p is 0, 1, or 2; where any alkyl, alkylene, cycloalkyl, heterocyclyl, or heteroaryl is selected from the group consisting of OH, CN, SO 2 CH3, halogen, NH 2 , NH(C 1 ~C 4 ) alkyl, N[(C 1 ~C 4 ) alkyl] 2 , (C 1 ~C 8 ) alkyl, (C 1 ~C 8 ) haloalkyl, O(C 1 ~C 8 ) alkyl, O(C 1 ~C 8 ) haloalkyl, (C 2 ~C 8 )alkenyl, and C(O)-(C(O)-(C(O))-alkyl) optionally substituted with one, two or three groups selected from OH, CN, NH 2 and N[(C 1 -C 4 )alkyl] 2 . 1 ~C 8 ) alkyl, A compound or a pharma- ceutically acceptable salt thereof.
2. Ring C [chemical 2] 2. The compound or salt of claim 1,
3. R 1 But (C 1 ~C 8 3. The compound or salt of claim 1 or 2, wherein:
4. R 2 is independently CN, or (C 1 ~C 8 4. The compound or salt according to claim 1, wherein R is 1 or 2.
5. The compound or salt according to claim 1, wherein R is 1 or 2.
5. m is 1, and R 25. The compound or salt according to claim 1, wherein is CN.
6. R 5 But (C 1 ~C 3 6. The compound or salt according to claim 1, wherein R is 1 or 2.
7. The compound or salt according to claim 1, wherein R is 1 or 2.
7. R 8 But CO 2 7. The compound or salt of claim 1, wherein R is H.
8. R 8 is C(O)N(H)SO 2 R 5 7. The compound or salt according to any one of claims 1 to 6,
9. R 9 9. The compound or salt of any one of claims 1 to 8, wherein is (C3-C6)cycloalkyl.
10. R 9 is a heterocyclyl selected from the group consisting of oxirane, oxetane, azetidinyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, thietanyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxothiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.
11. 11. A compound or salt according to any one of claims 1 to 10, wherein p=0 or 1.
12. formula: [C3] or a pharma- ceutically acceptable salt thereof.
13. formula: [C4] A compound having the formula:
14. formula: [C5] A pharma- ceutically acceptable salt of a compound having the formula:
15. formula: [C6] or a pharma- ceutically acceptable salt thereof.
16. formula: [C7] A compound having the formula:
17. formula: [C8] A pharma- ceutically acceptable salt of a compound having the formula:
18. formula: [C9] or a pharma- ceutically acceptable salt thereof.
19. formula: [C10] A compound having the formula:
20. formula: [C11] A pharma- ceutically acceptable salt of a compound having the formula:
21. (a) a compound or salt according to any one of claims 1 to 20; and (b) a pharma- ceutically acceptable carrier, diluent, or excipient; 23. A pharmaceutical composition comprising:
22. 22. The pharmaceutical composition of claim 21 for use in treating cancer.
23. 23. The pharmaceutical composition of claim 22, wherein the cancer is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, B cell lymphoma, T cell lymphoma, hairy cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, pancreatic cancer, melanoma, brain cancer, CNS cancer, renal cancer, prostate cancer, ovarian cancer, or breast cancer.
24. The pharmaceutical composition of claim 23, wherein the cancer is a metastatic cancer.
25. The pharmaceutical composition of claim 23, wherein the cancer is breast cancer, prostate cancer, or lung cancer.
26. The pharmaceutical composition of claim 25, wherein the cancer is breast cancer.
27. 27. The pharmaceutical composition of claim 26, wherein the breast cancer is hormone receptor positive breast cancer.
Citation Information
Patent Citations
3-hydroquinazolin-4-one derivatives for use as stearoyl-CoA desaturase inhibitors
JP2010523674A
Use of bicyclic heterocyclic derivatives and GPR119 modulators
JP2011520969A
Substituted 3-benzylquinoxalin-4(3H)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
WO2014179237A1
